


CANCER INCIDENCE & MORTALITY DATA SRI LANKA 2018



NATIONAL CANCER CONTROL PROGRAMME
MINISTRY OF HEALTH

National Cancer Incidence and Mortality Data

Sri Lanka

2018



National Cancer Control Programme,
555/5, Public Health Complex,
Elvitigala Mawatha,
Narahenpita, Colombo 5,
Sri Lanka.

20th Publication - National Cancer Incidence and Mortality Data Sri Lanka: 2018

Published in November 2021

ISBN 978-624-5719-16-7

Compiled by

Strategic Information Management (SIM) Unit,
National Cancer Control Programme,
Ministry of Health

Published by



National Cancer Control Programme,
Ministry of Health,
555/5, Public Health Complex,
Elvitigala Mawatha,
Narahenpita, Colombo 05,
Sri Lanka.

Contact No +94 112368627, Fax +94 112368627

Email - nccpsl@yahoo.com

Web - www.nccp.health.gov.lk



National Cancer Control Programme, Sri Lanka.

Printed by: P & G Printers (Pvt) Ltd,
Colombo 10, Sri Lanka.
Tel - 011 2447722
www.pandgprinters.com

Table of contents

| | Page No. |
|---|----------|
| Table of Contents | iii |
| List of Tables | iv |
| List of Figures | v |
| Message from the Director General of Health Services | vii |
| Message from Deputy Director General (Non-Communicable Diseases) | ix |
| Foreword | xi |
| Contributors | xiii |
| Acknowledgements | xiv |
| Executive Summary | 1 |
| Cancer Incidence and Mortality Data Sri Lanka – 2018 | 5 |
| 1. Introduction | 5 |
| 2. Methodology | 5 |
| Cancer Incidence Data of Sri Lanka – 2018 | 11 |
| Crude incidence rates of leading cancers in Sri Lanka in 2018 | 18 |
| Leading cancers of Sri Lanka according to age group in 2018 | 19 |
| Clinical staging at the point of diagnosis of Breast, Cervix and Lip, Tongue and Mouth cancers in Sri Lanka, 2018 | 79 |
| Cancer incidence by districts among males in Sri Lanka, 2018 | 99 |
| Cancer incidence by districts among females in Sri Lanka, 2018 | 104 |
| Cancer Mortality Data of Sri Lanka | 109 |
| Annex | 112 |
| List of References | 115 |

List of Tables

| Table No. | Description | Page No. |
|-----------|---|----------|
| Table 1: | Distribution of government cancer treatment centers in year 2018 | 6 |
| Table 2: | Distribution of pathology laboratories which sent details of newly diagnosed patients in year 2018 | 7 |
| Table 3: | Distribution of OMF Units which sent details of newly diagnosed cancer patients in year 2018 | 8 |
| Table 4: | Distribution of Medical Record Departments which have sent the details of newly diagnosed cancer patients for year 2018 | 8 |
| Table 5: | Estimated mid – year population by district in Sri Lanka 2018 | 10 |
| Table 6: | Cancer Incidence by sex in Sri Lanka, 2005- 2018 | 12 |
| Table 7: | Cancer Incidence by 5-year age groups and sex in Sri Lanka 2018 | 15 |
| Table 8: | Leading cancer site by sex in Sri Lanka – 2018 | 16 |
| Table 9: | Number of cancers by five – year age groups and ICD 10 site, among males in Sri Lanka in 2018 | 24 |
| Table 10: | Number of cancers by five-year age groups and ICD 10 site, among females in Sri Lanka 2018 | 28 |
| Table 11: | Number of cancers by five-year age group and ICD 10 site categories among males in Sri Lanka 2018 | 32 |
| Table 12: | Number of cancers by five-year age group and ICD 10 site categories among females in Sri Lanka 2018 | 33 |
| Table 13: | Age specific incidence rate, Crude incidence rate, Age standardized incidence rate per 100,000 population and Cumulative risk of cancers by five-year age group and ICD 10 site categories among males in Sri Lanka, 2018 | 34 |
| Table 14: | Age specific incidence rate, Crude incidence rate, Age standardized incidence rate per 100,000 population and Cumulative risk of cancers by five-year age group and ICD 10 site categories among females in Sri Lanka, 2018 | 35 |
| Table 15: | Lip, tongue and mouth cancer incidence data in Sri Lanka, 2018 | 36 |
| Table 16: | Pharyngeal cancer incidence data in Sri Lanka, 2018 | 39 |
| Table 17: | Oesophageal cancer incidence data in Sri Lanka, 2018 | 41 |
| Table 18: | Stomach cancer incidence data in Sri Lanka, 2018 | 43 |
| Table 19: | Colon and rectal cancer incidence data in Sri Lanka, 2018 | 45 |
| Table 20: | Laryngeal cancer incidence data in Sri Lanka, 2018 | 49 |
| Table 21: | Trachea, bronchus and lung cancer incidence data in Sri Lanka, 2018 | 50 |
| Table 22: | Skin cancer incidence data in Sri Lanka, 2018 | 53 |
| Table 23: | Breast cancer incidence data in Sri Lanka, 2018 | 56 |
| Table 24: | Cervix Uteri cancer incidence data in Sri Lanka, 2018 | 59 |
| Table 25: | Uterine cancer incidence data in Sri Lanka, 2018 | 61 |
| Table 26: | Ovary cancer incidence data in Sri Lanka, 2018 | 64 |
| Table 27: | Prostate cancer incidence data in Sri Lanka, 2018 | 67 |
| Table 28: | Urinary bladder cancer incidence data in Sri Lanka, 2018 | 69 |
| Table 29: | Thyroid gland cancer incidence data in Sri Lanka, 2018 | 71 |
| Table 30: | Lymphoma incidence data in Sri Lanka, 2018 | 73 |
| Table 31: | Leukemia incidence data in Sri Lanka, 2018 | 76 |
| Table 32: | Basis of diagnosis of cancer patients in Sri Lanka, 2018 | 80 |
| Table 33: | Childhood and adolescent cancer incidence data (0-19 years) in Sri Lanka, 2018 according to International Classification of Childhood Cancer third edition (ICCC-3) by sex | 82 |
| Table 34: | Overall cancer incidence by province & district in Sri Lanka, 2018 | 88 |
| Table 35: | Leading cancer incidence data by district in Sri Lanka, 2018 | 89 |
| Table 36: | Deaths due to cancers among males & females in hospitals in Sri Lanka, 2012-2018 | 109 |
| Table 37: | Deaths due to cancers in hospitals, crude hospital annual death rates due to cancers and proportionate mortality ratio for cancers out of all hospital deaths in Sri Lanka, 2005-2018 | 110 |
| Table 38: | Hospitalizations, hospital deaths and case fatality rate due to cancers in year 2018 by RDHS divisions in Sri Lanka | 111 |

List of Figures

| Figure No. | Description | Page No. |
|------------|---|----------|
| Figure 1: | Population pyramid of Sri Lanka in 2018 by 5-year age groups | 11 |
| Figure 2 : | Crude Cancer Incidence Rates of Sri Lanka, 2005-2018 | 13 |
| Figure 3: | Age Standardized Cancer Incidence Rates of Sri Lanka, 2005-2018 | 13 |
| Figure 4: | Cancer Incidence Rates of Sri Lanka in 2018 | 14 |
| Figure 5: | Age Specific Cancer Incidence Rates in Sri Lanka 2018 | 15 |
| Figure 6: | Proportion of leading cancers in males in Sri Lanka - 2018 | 17 |
| Figure 7: | Proportion of leading cancers in females in Sri Lanka - 2018 | 17 |
| Figure 8: | Crude incidence rates of leading cancers in males in Sri Lanka - 2018 | 18 |
| Figure 9: | Crude incidence rates of leading cancers in females in Sri Lanka - 2018 | 18 |
| Figure 10: | Leading cancers by 0-14 year age group among males in Sri Lanka in 2018 | 19 |
| Figure 11: | Leading cancers by 0-14 year age group among females in Sri Lanka in 2018 | 19 |
| Figure 12: | Leading cancers by 15 -34 year age group among males in Sri Lanka in 2018 | 20 |
| Figure 13: | Leading cancers by 15 -34 year age group among females in Sri Lanka in 2018 | 20 |
| Figure 14: | Leading cancers by 35 - 49 year age group among males in Sri Lanka in 2018 | 21 |
| Figure 15: | Leading cancers by 35 - 49 year age group among females in Sri Lanka in 2018 | 21 |
| Figure 16: | Leading cancers by 50 - 64 year age group among males in Sri Lanka in 2018 | 22 |
| Figure 17: | Leading cancers by 50 - 64 year age group among females in Sri Lanka in 2018 | 22 |
| Figure 18: | Leading cancers by 65 years & above age group among males in Sri Lanka in 2018 | 23 |
| Figure 19: | Leading cancers by 65 years & above age group among females in Sri Lanka in 2018 | 23 |
| Figure 20: | Age specific rates of Lip, Tongue & Mouth cancer in Sri Lanka in 2018 | 38 |
| Figure 21: | Age standardized incidence rates of Lip, Tongue & Mouth cancer in Sri Lanka, 2005 - 2018 | 38 |
| Figure 22: | Age specific rates of Pharyngeal cancer in Sri Lanka in 2018 | 40 |
| Figure 23: | Age standardized incidence rates of Pharyngeal cancer in Sri Lanka, 2012 - 2018 | 40 |
| Figure 24: | Age specific incidence rates of Oesophageal cancer in Sri Lanka in 2018 | 42 |
| Figure 25: | Age standardized incidence rates of Oesophageal cancer in Sri Lanka, 2005 - 2018 | 42 |
| Figure 26: | Age specific incidence rates of Stomach cancer in Sri Lanka in 2018 | 44 |
| Figure 27: | Age standardized incidence rates of Stomach cancer in Sri Lanka, 2005 - 2018 | 44 |
| Figure 28: | Age specific incidence rates of Colon and Rectal cancer in Sri Lanka in 2018 | 47 |
| Figure 29: | Age standardized incidence rates of Colon and Rectal cancer in Sri Lanka, 2005 – 2018 | 47 |
| Figure 30: | Age specific incidence rates of Laryngeal cancer in Sri Lanka in 2018 | 49 |
| Figure 31: | Age standardized incidence rates of Laryngeal cancer in Sri Lanka, 2005 - 2018 | 49 |
| Figure 32: | Age specific incidence rates of Trachea, Bronchus and Lung cancer in Sri Lanka in 2018 | 52 |
| Figure 33: | Age standardized incidence rates of Trachea, Bronchus and Lung cancer in Sri Lanka, 2005 - 2018 | 52 |
| Figure 34: | Age specific incidence rates of Skin cancer in Sri Lanka in 2018 | 55 |
| Figure 35: | Age standardized incidence rates of Skin cancer in Sri Lanka, 2005 - 2018 | 55 |
| Figure 36: | Age specific incidence rates of Breast cancer in Sri Lanka in 2018 | 58 |
| Figure 37: | Age standardized incidence rates of Breast cancer in Sri Lanka, 2005 - 2018 | 58 |
| Figure 38: | Age specific incidence rates of Cervical cancer in Sri Lanka in 2018 | 60 |
| Figure 39: | Age standardized incidence rates of Cervical cancer in Sri Lanka, 2005 - 2018 | 60 |
| Figure 40: | Age specific incidence rates of Uterine cancer in Sri Lanka in 2018 | 63 |
| Figure 41: | Age standardized incidence rates of Uterine cancer in Sri Lanka, 2005 - 2018 | 63 |
| Figure 42: | Age specific incidence rates of Ovarian cancer in Sri Lanka in 2018 | 66 |

| Figure No. | Description | Page No. |
|------------|---|----------|
| Figure 43: | Age standardized incidence rates of Ovarian cancer in Sri Lanka, 2005 - 2018 | 66 |
| Figure 44: | Age specific incidence rates of Prostate cancer in Sri Lanka in 2018 | 68 |
| Figure 45: | Age standardized incidence rates of Prostate cancer in Sri Lanka, 2005 - 2018 | 68 |
| Figure 46: | Age specific incidence rates of Urinary Bladder cancer in Sri Lanka in 2018 | 70 |
| Figure 47: | Age standardized incidence rates of Urinary Bladder cancer in Sri Lanka, 2005 - 2018 | 70 |
| Figure 48: | Age specific incidence rates of Thyroid gland cancer in Sri Lanka in 2018 | 72 |
| Figure 49: | Age standardized incidence rates of Thyroid gland cancer in Sri Lanka, 2005 - 2018 | 72 |
| Figure 50: | Age specific incidence rates of Lymphoma in Sri Lanka in 2018 | 75 |
| Figure 51: | Age standardized incidence rates of Lymphoma in Sri Lanka, 2011 - 2018 | 75 |
| Figure 52: | Age specific incidence rates of Leukaemia in Sri Lanka in 2018 | 78 |
| Figure 53: | Age standardized incidence rates of Leukaemia in Sri Lanka, 2011 - 2018 | 78 |
| Figure 54: | Clinical stage at diagnosis of Breast cancers in Sri Lanka, 2018 | 79 |
| Figure 55: | Clinical stage at diagnosis of Cervical cancers in Sri Lanka, 2018 | 79 |
| Figure 56: | Clinical stage at diagnosis of Lip, Tongue and Mouth cancers in Sri Lanka, 2018 | 79 |
| Figure 57: | Basis of diagnosis of cancers in Sri Lanka, 2018 | 80 |
| Figure 58: | Percentage of newly detected cancer patients who received different types of treatment in Sri Lanka, 2018 | 81 |
| Figure 59: | Cancer incidence by districts among males in Sri Lanka, 2018 | 99 |
| Figure 60: | Cancer incidence by districts among females in Sri Lanka, 2018 | 104 |

Message from the Director General of Health Services



I would like to send this message for the publication named 'National Cancer Incidence and Mortality Data Sri Lanka – 2018', published by the National Cancer Control Programme (NCCP) of Ministry of Health.

Cancer related data generated through the National Cancer Registry Programme provides most comprehensive information on burden of cancers in Sri Lanka. Therefore, it is an essential resource material for planning, implementing, monitoring and evaluation of cancer prevention and control programmes.

I appreciate the partnership of WHO Country office to clear the backlog of cancer incidence data ensuring publication of cancer registry data. The contribution of other stakeholder including hospital administrators, Oncology units, Oro-maxillo facial units and the pathology laboratories (histopathology, haematology, oral pathology) for their contributions. The coordination and hard work of National Cancer Control Programme is highly appreciated.

Dr. Asela Gunawardena

Director General of Health Services

Message from the Deputy Director General (Non-Communicable Diseases)



I am happy to send this message to the 20th edition of 'Cancer Incidence & Mortality Data, Sri Lanka - 2018' published by the National Cancer Control Programme (NCCP).

Comprehensive information on burden of Non-Communicable Diseases is essential optimizing Non-Communicable Disease Control programme in the country. Since Cancer is a leading non-communicable disease, the information generated from National Cancer Registry Programme provides valuable information for directing and future planning of cancer control programme in the country.

The partnership of WHO Country office was extremely beneficial to clear the backlog of cancer incidence data enabling National Cancer Control Programme to release this publication. I hope National Cancer Control Programme will take sustainable measures to ensure timely publication of cancer incidence data.

The efforts taken by the Director and entire staff of National Cancer Control Programme to clear the backlog and releasing the report are highly appreciated.

Dr. Champika Wickramasingha

MBBS, MSc, MD (Community Medicine)

Deputy Director General (Non-Communicable Diseases)

Foreword



National Cancer Control Programme (NCCP) of Ministry of Health would like to release 20th edition of 'Cancer Incidence & Mortality Data, Sri Lanka - 2018'. The contributions received from the stakeholders from the points of diagnosis (histopathology, haematology, oral pathology laboratories) points of treatment (specialized cancer treatment units, other units treating cancer patients) and points of death (divisional death registrar officers). In addition, cancer related mortality data published by the Registrar General Department and Department of Census & Statistics are incorporated for the publication to generate a comprehensive picture of cancer mortality data.

World Health Organization (WHO) country office, Colombo has provided technical support for cancer surveillance throughout the period. Especially WHO country office for providing partnership to clear the backlog is highly appreciated. Partnership given by Dr. Nalika Gunawardana, National Professional Officer (NPO), WHO country office is highly appreciated.

The National Cancer Control Programme would like to express special thank for all government cancer treatment centers, all government pathology laboratories, all government Oral and Maxillo- Facial surgery units and private sector hospitals for providing necessary data.

I acknowledge the contribution given by the Multi Tech Solution (Pvt) Ltd to complete this endeavor. In addition to that contribution from Cancer Care Association is appreciated.

I would like to thank the untiring effort of National Cancer Control Programme team for generating this publication and mitigating measures to clear the backlog of publishing cancer incidence data of subsequent years.

Dr. Janaki Vidanapathirana
MBBS, MSc, MD (Community Medicine)
Director, National Cancer Control Programme

Contributors

Data coding

| | | |
|----------------------------|---------------------------|-----------------------|
| Dr. K. G. Nirmala Jayanthi | Dr. Dulanjali Laxamana | Ms. Sachini Sashikala |
| Dr. Thanuja Wickramatunga | Mrs. Pubudika Amarasingha | |
| Dr. Imalka Suriyapperuma | Ms. Chammi Balasooriya | |
| Dr. Tevini Vitharana | Mrs. Chamila Peiris | |
| Dr. Chathurika Jayamani | Mrs. Sunethra Kasthuri | |

Data entry & duplicate checking at the centre

| | |
|----------------------|-------------------------|
| Mrs. Nimesha Prasadi | Mrs. Nayomi Weerasingha |
|----------------------|-------------------------|

Duplicate checking & data verification

| | | |
|---------------------------|---------------------------|---------------------------|
| Dr. Suraj Perera | Dr. Chathurika Jayamani | Dr. K.G. Nirmala Jayanthi |
| Dr. Nirma Alapitiarachchi | Dr. Thanuja Wickramatunga | Mrs. Chamila Peiris |
| Dr. Tevini Vitharana | Dr. Chulaka Jayaweera | Ms. Sachini Sashikala |

Statistical analysis and report writing

| | | |
|----------------------------|---------------------------|------------------|
| Dr. Malawige Amila Suranga | Dr. K.G. Nirmala Jayanthi | Dr. Suraj Perera |
|----------------------------|---------------------------|------------------|

Infographics

Dr. Chathurika Jayamani

GIS Maps

Dr. A.H.N. Maduranga & Ms. Priyadarshani Somasekaran of Anti Malaria Campaign

Support staff

Mr. Saman Kumara Mahalekam Mrs. Deepa Pathmanjali
Mrs. Thushari Dammika

Overall Coordination

Dr. Suraj Perera,
Consultant Community Physician,
Strategic Information Management Unit, National Cancer Control Programme

Acknowledgement

National Advisory Committee on Prevention & Control of Cancers

Technical Advisory Committee on Cancer Registration & Research

All the government cancer treatment centers

All pathology laboratories, Oral and Maxillo- Facial surgery unit

Private hospitals

Professional Colleges – College of Oncologists, College of Pathologists, College of Haematologists

Association of Oral Pathology & Oral Medicine

World Health Organization - Country Office, Sri Lanka

Multi Tech Solutions (Pvt) Ltd

Cancer Care Association – Sri Lanka

Executive summary

Cancer Incidence and Mortality Data, Sri Lanka- 2018 is the 20th volume of the series of publication on cancer surveillance data, Sri Lanka. National Cancer Registry Sri Lanka is based on the newly reported cancers in the year 2018. The newly detected cancers through the cancer treatment centers, pathology laboratories, Oral and Maxillo Facial (OMF) surgery units in the country were considered for this publication. All the data were entered into the 'Can Reg 5' data base. Quality checks were conducted and duplicate entries were eliminated. Analysis was done by Can Reg 5 and SPSS software. For Cancer mortality data, mortality data published at the Annual Health Bulletin – 2018 were analyzed.

In the year 2018, a total number of 30,853 patients were newly diagnosed with cancer, giving crude incidence rate (CR) of 142.4 per 100,000 population. Crude incidence rate of males was 142.2/100,000 and Crude incidence rate of females was 142.6/100,000 population. The highest 5- year age specific incidence rates were reported among males and females of 70- 74-year age group (Males 1076.5/100 000 and females 668.1 /100 000). When age standardized rates (ASR) were considered, the overall ASR was 125.8/100 000 and the ASR for males and females were 133.6/100 000 and 121.1/100 000.

Lip, tongue and mouth cancers (n=2411, CR= 23.0/100 000), Trachea, bronchus and lung cancers (n=1303, CR= 12.4/100 000), Colon and rectal cancers (n= 1161, CR= 11.1/100 000) and oesophageal cancers (n=1136, CR = 10.8/100 000) were the highest incident cancers among males. Crude rates of leading male cancers, there were slight reduction of crude incidence rate in comparison to the similar figure in year 2017 except Lip, tongue and mouth cancer (20.0/ 100,000 to 21.2 /100,000) and prostate cancer (9.9/ 100,000 to 10.2 /100,000). Out of all male cancers, 16 % were lip, tongue and mouth cancers.

Breast (n= 3778, CR= 33.8/100 000), Thyroid (n=1896, CR= 17.0/100 000), Colon and Rectum cancers (n= 1169, CR= 10.5/100 000) and Cervix uteri cancers (n=1073, CR=9.6/100 000) were the highest incident cancers among females. Except lip, tongue and mouth cancers, crude rates of all other leading cancers among females there were slight reduction of crude incidence rate in comparison to the similar figure in year 2017. Out of all female cancers 24% were breast cancers.

Cumulative rate of developing cancer between the age group of 0-74 years males is 16.8% and females is 14.1%. It means that among 1 in 5.9 males and 1 in 7.0 females have risk of developing cancer during their life time.

Staging information was available for 30% breast cancers, 21% cervical cancers and 11% lip tongue and mouth cancers. Among those with staging information 38% breast cancers, 39% cervical cancers and 60% lip, tongue and mouth cancers were diagnosed at the advanced stages (Stage III and IV).

Out of all cancers 90.7 % were diagnosed microscopically and histopathology details were available for 89.5% cancers. There were 767 cases of childhood cancers (age between 0-19 Years) and 20.6 % were leukaemias.

Highest number of cancers were reported from Colombo district (n=3833, CR=157.2), Kurunegala district (n=1891, CR=110.6), Kandy district (n=1654, CR=112.7), Gampaha district (n=1414, CR= 58.7) and Kalutara district (n=981, CR=76.6). A total of 5789 deaths were occurred due to cancers at government hospital settings in year 2017 according to Annual Health Bulletin, 2018.

Cancer Incidence, 2018


New cases **30853**



14917




15936




Crude cancer incidence rates of Sri Lanka

2005 -2018




Number of cases and Crude Incidence Rates of leading cancer sites by sex in Sri Lanka, 2018

(CR per 100 000 population)



ASR of five most common male cancers from 2005 - 2018



ASR of five most common female cancers from 2005 - 2018

Childhood cancers


(0-19 years)



767
Cases



Number of Cases of Childhood Cancers from 2011 to 2018



Percentage Composition of Childhood Cancers - 2018

Cancer Incidence & Mortality Data Sri Lanka – 2018


1. Introduction

Cancer surveillance (Cancer registration) is a process of systematic, continuous collection, storage, analysis, interpretation and dissemination of epidemiological information on cancers occurring in a country or a specific geographic area. Information generated from the cancer registration is essential for planning, implementation, monitoring and evaluation of cancer control activities of the country.

The National Cancer Control Programme (NCCP) of the Ministry of Health coordinates surveillance of cancers in Sri Lanka with the active participation of other stakeholders for cancer surveillance including cancer treatment centres, pathology laboratories, Oral and Maxillo Facial (OMF) units, professional colleges, WHO country office etc. The process of surveillance of cancers is technically guided by the International Agency for Research on Cancer (IARC) of WHO and WHO IARC Regional Hub for Cancer Registration, Mumbai India. In addition, technical help is received from Department of Epidemiology, Bio statistics and Cancer Registry, WIA Cancer Institute, Chennai India.

The information based on surveillance of cancers is published as a publication named 'Cancer Incidence Data Sri Lanka'. Up to now 19 volumes have been published (Annex I). This publication is the 20th volume of Cancer Incidence Data Sri Lanka.

2. Methodology



Steps of cancer surveillance

The methodology of each step of cancer surveillance (Figure 1) is described below.

2.1 Collection of cancer incidence data

Cancer incidence data were collected from cancer treatment centres, pathology laboratories and Oral & Maxillo-Facial (OMF) units throughout the country.

2.1.1 Newly registered cancer patients at the cancer treatment centres

In the year 2018, there were 19 government cancer treatment centres involved in data collection (Table i). Relevant data were extracted from cancer patients' clinic records using 'National Cancer Surveillance Form – H 1256'. Data were extracted by the medical officers, nursing officers and development officers attached to the cancer treatment centres, trained pre-intern medical graduates temporarily recruited through WHO Biennium funds and by the cancer registry staff of NCCP.

Table 1: Distribution of government cancer treatment centres in year 2018

| Category of hospital | Name of the hospital |
|-------------------------------------|--|
| National Hospitals | Apeksha Hospital - Maharagama (National Cancer Institute) |
| Teaching Hospitals | Kandy, Karapitiya, Anuradhapura, Batticaloa |
| Provincial General Hospitals | Badulla, Kurunegala, Ratnapura |
| District General Hospital | Gampaha, NuwaraEliya, Hambanthota, Vavuniya, Polonnaruwa, Monaragala, Trincomalee, Ampara, Chilaw, Kegalle |
| Base Hospital | Telippalai (Jaffna) |

2.1.2 Newly detected cancers at the pathology laboratories

The information on newly detected cancers at the pathology laboratories were received monthly through the 'Cancer Return Form - 1' (H-1290). A total of 60 Histopathology laboratories (20,756 diagnosed patients), twelve Haematology laboratories (377 diagnosed patients) and one oral pathology laboratory (488 diagnosed patients) have passively sent relevant data for the year 2018 (Table 2).

Table 2: Distribution of pathology laboratories which sent details of newly diagnosed cancer patients in year 2018

| Category of hospital | Type of Pathology laboratory | | |
|--|--|---|---|
| | Histopathology | Haematology | Oral Pathology |
| National Hospital | National Hospital of Sri Lanka National Hospital of Kandy | | |
| Teaching Hospitals | De Soysa Hospital for Women, Castle Hospital for Women, Lady Ridgeway Hospital, National Eye Hospital, Colombo South, Colombo North, National Hospital for Respiratory Diseases-Welisara Karapitiya, Rathnapura Anuradhapura, Mahamodara Peradeniya, SBCH, Batticaloa Jaffna | Castle Street Hospital (CSHW) Colombo South, Rathnapura | |
| Provincial Hospitals General | Kurunegala, Badulla | Kurunegala | |
| District Hospitals General | Awissawella Gampaha, Negombo, Kalutara, Matara, Hambanthota, Kegalle, Chilaw, Polonnaruwa, Nawalapitiya, Nuwaraeliya, Matale, Monaragala, Ampara, Trincomalee, Vavuniya | Gampaha, Kalutara, Hambanthota, Chilaw | |
| Base Hospital | Homagama, Mulleriyawa, Wathupitiwala, Kethumathi, Panadura, Balapitiya, Elpitiya, Tangalle, Embilipitiya, Balangoda, Kuliyaipitiya, Horana, Nikaweratiya, Puttlam, Gampola Dambulla, Diyathalawa, Mahiyanganaya, Karawanella, Thambuththegama | Wathupitiwala, Embilipitiya, Kuliyaipitiya, Puttlam | |
| University Units | Faculty of Medicine – Colombo, Ruhuna, Jayawardanapura, Ragama | Ragama | Faculty of Dental Sciences – Peradeniya |
| Other Hospitals | Army Hospital | | |
| Private sector | Delmons Hospital-Colombo | | |

2.1.3 Newly diagnosed cancers at the Oral & Maxillo – Facial (OMF) Surgery Units

Data on newly confirmed cancer patients at the Oral & Maxillo-Facial (OMF) surgery units were received annually through the Annual Notification Form of Oral Cancer (H -1294). A total of 26 OMF units have sent relevant data for year 2018 (Table iii).

Table 3: Distribution of OMF Units which sent details of newly diagnosed cancer patients in year 2018

| Category of hospital | Name of the hospital |
|------------------------------|---|
| National Hospital | Dental Institute, Colombo |
| Teaching Hospitals | Colombo South, Colombo North, Karapitiya, Kandy, Anuradhapura, Jaffna |
| Provincial General Hospitals | Kurunegala, Ratnapura |
| District General Hospitals | Gampaha, Kalutara, Polonnaruwa, Avissawella, Hambanthota, Negombo, NuwaraEliya, Trincomalee, Ampara, Matara, Embilipitiya |
| Base Hospital | Kuliyapitiya, Panadura, Chilaw |
| University Units | – |

2.1.4 Population Based Cancer Registry – Colombo district

Two additional data sources were identified for capturing additional cancer incidence data from Colombo district when commencing the Population Based Cancer Registry and those data sources were also incorporated as data generating centres for national cancer registry.

a. Details from Medical Record Departments of Colombo district & adjacent districts

The information on cancer patients treated at the secondary and tertiary care hospitals in the government sector, private sector and armed services in the Colombo district and selected hospitals in the adjacent districts were collected through the 'Cancer Return Form -2' (H-1291). A total of 22 Medical Record Departments have sent the details in year 2018 (Table iv).

Table 4: Distribution of Medical Record Departments which have sent the details of newly diagnosed cancer patients for year 2018

| Category of hospital | Name of the hospital |
|----------------------------|---|
| National Hospital | National hospital, Dental Institute Colombo, National Hospital for Respiratory Diseases |
| Teaching Hospitals | Colombo South, Colombo North, Eye hospital, LRH, DMH, CSHW |
| District General Hospitals | Avissawella, Gampaha, Mulleriyawa |
| Base Hospital | Panadura, Horana |
| Private sector hospitals | Asiri central, Asiri medical, Asiri surgical, Durdans, Lanka |
| Armed services hospitals | Army hospital, navy hospital, police hospital |

a. Details from Divisional Death Registration of the Colombo district

Details of all cancer related deaths registered by the Divisional Death Registrars of the Colombo district were received through the Cancer Return Form – 3. A total of 40 divisional death registrars have sent relevant details for the year 2018.

2.2 Coding of cancer incidence data

According to the instructions of International Classification of Disease for Oncology 3rd edition (ICD-O 3), cancer incidence data were coded according to the site (Topography) and the histology (Morphology) of cancer. The cancer registry staff of the NCCP coded the cancer incidence data.

2.3 Entering of cancer incidence data to the database

Cancer incidence data were entered into the CanReg5 database by the trained data entry operators attached to the NCCP and also by a third party of data entry operators in a private company through a WHO funded project. These activities were closely supervised by the cancer registry staff and was regularly involved in refresher training to the data entry operators to ensure accuracy and quality of data.

2.4 Duplicate checking & verification of data

While entering and confirming the data to the CanReg5 database, duplicate checking was conducted using 'Person search' option of the CanReg 5 database. In addition to the duplicate checking done through CanReg 5, further duplicate checking had to be conducted during the data verification stage as well to identify all possible duplicates.

The additional methods used were;

- i. Use of Linkpro software
- ii. Use of Excel software – Sorted according to the descending or ascending order of selected variables

After removing possible duplicates, consistency checking and verification was conducted using 'IARCcrg' tool & MS Excel.

Mismatches according to;

Age/Incidence and birthdates

Age /Site /Histology

Site /Histology

Sex/Site

Sex/Histology

Behaviour /Site

Behaviour / Histology

Grade /Histology Basis of Diagnosis /Histology were corrected.

After these procedures, preliminary analysis was conducted using CanReg 5 & SPSS to detect further mismatches. Data sources up to the patient clinic files were rechecked in the instances where mismatches were noted by the cancer registry staff of the NCCP. After identifying errors or misclassifications, necessary corrections were done before finalizing the data for analysis.

2.5 Analysis of cancer incidence data & dissemination of information

Analysis section of the CanReg 5 package, SPSS and MS Excel software were used to analyze cancer incidence data. The standard cancer registry tables described at the CI 5 were generated through CanReg 5 database.

Population estimates used for incidence and mortality rate calculation are given in table 5

Table 5: Estimated mid – year population by district in Sri Lanka 2018

| District | Male | Female | Total |
|--------------|-------------------|-------------------|-------------------|
| Colombo | 1,196,628 | 1,242,171 | 2,438,799 |
| Gampaha | 1,167,491 | 1,241,756 | 2,409,247 |
| Kalutara | 619,734 | 661,008 | 1,280,742 |
| Kandy | 699,968 | 768,066 | 1,468,034 |
| Matale | 250,473 | 268,930 | 519,403 |
| NuwaraEliya | 365,008 | 398,201 | 763,209 |
| Galle | 539,002 | 585,017 | 1,124,019 |
| Matara | 410,820 | 446,898 | 857,718 |
| Hambanthota | 321,643 | 333,027 | 654,670 |
| Jaffna | 287,885 | 325,198 | 613,083 |
| Mannar | 54,899 | 54,312 | 109,211 |
| Vavuniya | 92,194 | 95,116 | 187,310 |
| Mullaitivu | 48,152 | 48,325 | 96,477 |
| Kilinochchi | 62,143 | 64,308 | 126,451 |
| Batticaloa | 271,255 | 298,541 | 569,796 |
| Ampara | 348,266 | 371,196 | 719,462 |
| Trincomalee | 207,704 | 212,797 | 420,501 |
| Kurunegala | 821,412 | 889,120 | 1,710,532 |
| Puttalam | 399,223 | 425,681 | 824,904 |
| Anuradhapura | 453,766 | 475,773 | 929,539 |
| Polonnaruwa | 215,717 | 220,581 | 436,298 |
| Badulla | 419,684 | 453,423 | 873,107 |
| Monaragala | 243,942 | 246,905 | 490,847 |
| Ratnapura | 573,180 | 589,427 | 1,162,607 |
| Kegalle | 421,273 | 462,272 | 883,545 |
| Total | 10,491,462 | 11,178,049 | 21,669,511 |

Source – Department of Census & Statistics

Cancer Incidence Data of Sri Lanka – 2018




Figure 1: Population pyramid of Sri Lanka in 2018 by 5-year age groups

Table 6: Cancer Incidence by sex in Sri Lanka, 2005- 2018

| Year | Sex | Number | % | CR | ASR |
|------|--------------|---------------|------|--------------|--------------|
| 2005 | Male | 6,058 | 45.3 | 62.3 | 68.1 |
| | Female | 7,314 | 54.7 | 73.4 | 73.4 |
| | Total | 13,372 | | 67.9 | 70.6 |
| 2006 | Male | 6,205 | 44.1 | 62.7 | 69.2 |
| | Female | 7,875 | 55.9 | 79.0 | 79.5 |
| | Total | 14,080 | | 70.9 | 74.2 |
| 2007 | Male | 6,356 | 46.6 | 63.8 | 70.9 |
| | Female | 7,279 | 53.4 | 72.2 | 72.8 |
| | Total | 13,635 | | 68.0 | 71.6 |
| 2008 | Male | 7,695 | 46.6 | 76.5 | 85.5 |
| | Female | 8,816 | 53.4 | 86.6 | 88.0 |
| | Total | 16,511 | | 81.6 | 86.4 |
| 2009 | Male | 7,858 | 46.5 | 77.4 | 86.4 |
| | Female | 9,030 | 53.5 | 87.7 | 89.1 |
| | Total | 16,888 | | 82.6 | 87.5 |
| 2010 | Male | 7,993 | 47.1 | 78.0 | 87.4 |
| | Female | 8,970 | 52.9 | 86.2 | 87.7 |
| | Total | 16,963 | | 82.1 | 87.3 |
| 2011 | Male | 8,370 | 47.9 | 80.6 | 90.4 |
| | Female | 9,112 | 52.1 | 86.7 | 88.7 |
| | Total | 17,482 | | 83.7 | 89.2 |
| 2012 | Male | 11,363 | 49.1 | 115.3 | 107.8 |
| | Female | 11,773 | 50.9 | 112.1 | 95.5 |
| | Total | 23,136 | | 113.6 | 100.1 |
| 2013 | Male | 11,364 | 48.3 | 114.0 | 106.3 |
| | Female | 12,167 | 51.7 | 114.6 | 97.4 |
| | Total | 23,531 | | 114.3 | 100.7 |
| 2014 | Male | 12,021 | 47.6 | 119.5 | 112.0 |
| | Female | 13,250 | 52.4 | 123.6 | 105.3 |
| | Total | 25,271 | | 121.6 | 107.3 |
| 2015 | Male | 13,921 | 48.1 | 137.1 | 128.6 |
| | Female | 15,046 | 51.9 | 139.1 | 118.8 |
| | Total | 28,967 | | 138.1 | 122.0 |
| 2016 | Male | 16,533 | 48.4 | 161.1 | 151.2 |
| | Female | 17,646 | 51.6 | 161.3 | 137.4 |
| | Total | 34,179 | | 161.2 | 142.0 |
| 2017 | Male | 15,458 | 48.1 | 148.9 | 140.2 |
| | Female | 16,712 | 51.9 | 151.1 | 128.8 |
| | Total | 32,170 | | 150.0 | 132.7 |
| 2018 | Male | 14,917 | 48.3 | 142.2 | 134.0 |
| | Female | 15,936 | 51.7 | 142.6 | 121.3 |
| | Total | 30,853 | | 142.4 | 125.8 |




Figure 2: Crude Cancer Incidence Rates of Sri Lanka, 2005-2018




Figure 3: Age Standardized Cancer Incidence Rates of Sri Lanka, 2005-2018



Figure 4: Cancer Incidence Rates of Sri Lanka, 2018

Table 7: Cancer Incidence by 5-year age groups and sex in Sri Lanka, 2018

| Age Group | Male | | | Female | | | Total | | |
|--------------|--------------|-------------------|--------------|--------------|-------------------|--------------|--------------|-------------------|--------------|
| | Cases | Population | Incidence | Cases | Population | Incidence | Cases | Population | Incidence |
| Unknown | 42 | | | 34 | | | 76 | | |
| 00-04 | 141 | 937,293 | 15.0 | 121 | 921,745 | 13.1 | 262 | 1859038 | 14.1 |
| 05-09 | 72 | 939,958 | 7.7 | 62 | 922,462 | 6.7 | 134 | 1862420 | 7.2 |
| 10-14 | 75 | 883,358 | 8.5 | 68 | 864,182 | 7.9 | 143 | 1747539 | 8.2 |
| 15-19 | 90 | 873,437 | 10.3 | 137 | 878,330 | 15.6 | 227 | 1751767 | 13.0 |
| 20-24 | 97 | 789,990 | 12.3 | 206 | 841,617 | 24.5 | 303 | 1631608 | 18.6 |
| 25-29 | 167 | 791,392 | 21.1 | 290 | 861,761 | 33.7 | 457 | 1653153 | 27.6 |
| 30-34 | 189 | 848,074 | 22.3 | 492 | 896,854 | 54.9 | 681 | 1744928 | 39.0 |
| 35-39 | 318 | 729,981 | 43.6 | 786 | 769,359 | 102.2 | 1104 | 1499340 | 73.6 |
| 40-44 | 490 | 703,860 | 69.6 | 1000 | 742,081 | 134.8 | 1490 | 1445940 | 103.0 |
| 45-49 | 781 | 657,760 | 118.7 | 1383 | 710,369 | 194.7 | 2164 | 1368129 | 158.2 |
| 50-54 | 1453 | 618,446 | 234.9 | 1762 | 678,745 | 259.6 | 3215 | 1297191 | 247.8 |
| 55-59 | 1955 | 532,718 | 367.0 | 1917 | 598,954 | 320.1 | 3872 | 1131672 | 342.1 |
| 60-64 | 2323 | 452,223 | 513.7 | 2251 | 523,275 | 430.2 | 4574 | 975498 | 468.9 |
| 65-69 | 2536 | 301,384 | 841.5 | 2076 | 371,085 | 559.4 | 4612 | 672470 | 685.8 |
| 70-74 | 2079 | 193,134 | 1076.5 | 1635 | 244,730 | 668.1 | 3714 | 437864 | 848.2 |
| 75+ | 2109 | 238,453 | 884.5 | 1716 | 352,500 | 486.8 | 3825 | 590953 | 647.3 |
| Total | 14917 | 10,491,462 | 142.2 | 15936 | 11,178,049 | 142.6 | 30853 | 21,669,511 | 142.4 |


**Figure 5: Age Specific Cancer Incidence Rates in Sri Lanka, 2018**

Table 8: Leading cancer site by sex in Sri Lanka, 2018

| Male | | | | | Female | | | | |
|---------------|----------------------------|-------|-------|-------|--------------|--------------------------|-------|-------|-------|
| ICD 10 | Site | No | CR | ASR | ICD 10 | Site | No | CR | ASR |
| C00-C06 | Lip, tongue & mouth | 2411 | 23.0 | 21.3 | C50 | Breast | 3778 | 33.8 | 28.7 |
| C33-C34 | Trachea, bronchus and lung | 1303 | 12.4 | 11.7 | C73 | Thyroid | 1896 | 17.0 | 15.0 |
| C18-C20 | Colon and rectum | 1161 | 11.1 | 10.4 | C18-20 | Colon and rectum | 1169 | 10.5 | 8.7 |
| C15 | Oesophagus | 1136 | 10.8 | 10.1 | C53 | Cervix | 1073 | 9.6 | 8.0 |
| C61 | Prostate | 1112 | 10.6 | 10.3 | C54-55 | Uterus | 1020 | 9.1 | 7.6 |
| C09-C14 | Pharynx | 777 | 7.40 | 6.8 | C56 | Ovary | 938 | 8.4 | 7.2 |
| C32 | Larynx | 712 | 6.80 | 6.3 | C15 | Oesophagus | 815 | 7.3 | 5.9 |
| C67 | Bladder | 573 | 5.50 | 5.2 | C00-06 | Lip, tongue & mouth | 611 | 5.5 | 4.4 |
| C81-C85 & C96 | Lymphoma | 551 | 5.2 | 5.0 | C33-34 | Trachea, bronchus & lung | 456 | 4.1 | 3.4 |
| C16 | Stomach | 415 | 3.9 | 3.7 | C81-85 & C96 | Lymphoma | 447 | 4.0 | 3.5 |
| | All sites | 14917 | 142.2 | 134.0 | | All sites | 15936 | 142.6 | 121.3 |




Figure 6: Proportion of leading cancers in males in Sri Lanka, 2018




Figure 7: Proportion of leading cancers in females in Sri Lanka, 2018

Crude incidence rates of leading cancers in Sri Lanka in 2018




Figure 8: Crude incidence rates of leading cancers in males in Sri Lanka, 2018




Figure 9: Crude incidence rates of leading cancers in females in Sri Lanka, 2018

Leading cancers of Sri Lanka according to age group in 2018




Figure 10: Leading cancers by 0-14 year age group among males in Sri Lanka, 2018




Figure 11: Leading cancers by 0-14 year age group among females in Sri Lanka, 2018




Figure 12: Leading cancers by 15 -34 year age group among males in Sri Lanka, 2018




Figure 13: Leading cancers by 15 -34 year age group among females in Sri Lanka, 2018




Figure 14: Leading cancers by 35 – 49 year age group among males in Sri Lanka, 2018




Figure 15: Leading cancers by 35 – 49 year age group among females in Sri Lanka, 2018




Figure 16: Leading cancers by 50 – 64 year age group among males in Sri Lanka, 2018




Figure 17: Leading cancers by 50 – 64 year age group among females in Sri Lanka, 2018




Figure 18: Leading cancers by 65 years & above age group among males in Sri Lanka, 2018




Figure 19: Leading cancers by 65 years & above age group among females in Sri Lanka, 2018

Table 9: Number of cancers by five – year age groups and ICD 10 site, among males in Sri Lanka in 2018

| ICD 10 site | 00-04 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75+ | unknown | Total |
|---|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-----|---------|-------|
| C00 Lip | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 3 | 9 | 22 | 32 | 38 | 48 | 38 | 31 | 26 | 0 | 252 |
| C01 Base of tongue | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 12 | 7 | 24 | 37 | 25 | 26 | 19 | 21 | 0 | 174 |
| C02 Other and unspecified parts of tongue | 0 | 0 | 0 | 0 | 0 | 5 | 6 | 16 | 27 | 61 | 101 | 103 | 91 | 97 | 63 | 47 | 4 | 621 |
| C03 Gum | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 8 | 12 | 10 | 23 | 19 | 19 | 14 | 1 | 110 |
| C04 Floor of mouth | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 1 | 17 | 29 | 28 | 31 | 33 | 13 | 14 | 0 | 171 |
| C05 Palate | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 9 | 9 | 19 | 39 | 59 | 34 | 40 | 27 | 28 | 0 | 265 |
| C06 Other and unspecified parts of mouth | 2 | 1 | 0 | 0 | 1 | 1 | 8 | 16 | 34 | 57 | 107 | 117 | 115 | 128 | 122 | 107 | 2 | 818 |
| C07 Parotid gland | 0 | 0 | 2 | 0 | 0 | 1 | 1 | 2 | 2 | 2 | 7 | 8 | 7 | 9 | 7 | 4 | 0 | 52 |
| C08 Other and unspecified major salivary glands | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 | 5 | 5 | 5 | 3 | 1 | 4 | 3 | 2 | 0 | 30 |
| C09 Tonsils | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 4 | 4 | 16 | 21 | 31 | 17 | 21 | 19 | 14 | 3 | 152 |
| C10 Oropharynx | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 5 | 7 | 27 | 30 | 29 | 19 | 22 | 9 | 0 | 150 |
| C11 Nasopharynx | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 2 | 2 | 1 | 1 | 8 | 9 | 2 | 1 | 3 | 0 | 33 |
| C12 Piriformis sinus | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 9 | 6 | 23 | 31 | 39 | 33 | 31 | 27 | 0 | 201 |
| C13 Hypopharynx | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 3 | 6 | 11 | 16 | 25 | 23 | 13 | 15 | 0 | 113 |
| C14 Other and ill-defined sites in the lip, oral cavity and pharynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 6 | 14 | 16 | 20 | 28 | 21 | 7 | 13 | 1 | 128 |
| C15 Oesophagus | 0 | 0 | 0 | 2 | 0 | 1 | 3 | 4 | 22 | 58 | 132 | 181 | 209 | 225 | 154 | 143 | 2 | 1136 |
| C16 Stomach | 0 | 0 | 0 | 0 | 0 | 4 | 2 | 5 | 8 | 17 | 47 | 74 | 78 | 69 | 63 | 47 | 1 | 415 |
| C17 Small intestine | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 5 | 2 | 10 | 7 | 12 | 10 | 10 | 6 | 1 | 67 |
| C18 Colon | 0 | 0 | 0 | 0 | 2 | 5 | 10 | 20 | 18 | 24 | 53 | 74 | 90 | 90 | 64 | 78 | 2 | 530 |
| C19 Rectosigmoid junction | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 4 | 9 | 16 | 21 | 15 | 14 | 14 | 0 | 95 |
| C20 Rectum | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 8 | 13 | 19 | 39 | 69 | 75 | 100 | 98 | 111 | 1 | 536 |
| C21 Anus and anal canal | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 1 | 2 | 9 | 10 | 10 | 15 | 14 | 14 | 0 | 79 |
| C22 Liver and intrahepatic bile ducts | 12 | 2 | 1 | 1 | 0 | 0 | 2 | 2 | 13 | 20 | 22 | 36 | 78 | 65 | 71 | 51 | 3 | 379 |
| C23 Gallbladder | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 2 | 3 | 1 | 5 | 8 | 2 | 4 | 0 | 29 |
| C24 Other and unspecified parts of biliary tract | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 3 | 2 | 3 | 5 | 4 | 11 | 10 | 7 | 13 | 0 | 60 |
| C25 Pancreas | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 1 | 4 | 7 | 7 | 12 | 11 | 18 | 14 | 13 | 0 | 91 |
| C26 Other and ill-defined digestive organs | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 5 | 6 | 6 | 4 | 5 | 2 | 0 | 33 |

Table 9 continued ...

| ICD 10 site | 00-04 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75+ | unknown | Total |
|--|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-----|---------|-------|
| C30 Nasal cavity and middle ear | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2 | 2 | 2 | 6 | 1 | 7 | 1 | 6 | 0 | 29 |
| C31 Accessory sinuses | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 3 | 5 | 12 | 3 | 8 | 2 | 4 | 0 | 38 |
| C32 Larynx | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 4 | 15 | 26 | 83 | 116 | 138 | 128 | 97 | 102 | 1 | 712 |
| C33 Trachea | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 2 | 3 | 1 | 1 | 0 | 0 | 10 |
| C34 Bronchus and lung | 1 | 0 | 1 | 0 | 2 | 2 | 5 | 14 | 21 | 37 | 109 | 201 | 222 | 278 | 216 | 179 | 5 | 1293 |
| C37 Thymus | 0 | 0 | 0 | 1 | 1 | 4 | 2 | 1 | 3 | 2 | 3 | 1 | 5 | 5 | 0 | 0 | 1 | 29 |
| C38 Heart, mediastinum and pleura | 3 | 0 | 0 | 2 | 2 | 1 | 1 | 2 | 0 | 4 | 1 | 9 | 5 | 6 | 5 | 3 | 0 | 44 |
| C39 Other and ill-defined sites in the respiratory system and intrathoracic organs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 3 | 9 | 9 | 4 | 2 | 0 | 31 |
| C40 Bone and articular cartilage of limbs | 1 | 2 | 9 | 12 | 2 | 6 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 3 | 1 | 2 | 0 | 43 |
| C41 Bone and articular cartilage of other and unspecified sites | 1 | 0 | 3 | 3 | 1 | 3 | 2 | 1 | 2 | 2 | 2 | 3 | 2 | 3 | 7 | 1 | 0 | 36 |
| C43 Melanoma of skin | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 5 | 5 | 5 | 8 | 6 | 7 | 0 | 38 |
| C44 Other malignant neoplasms of skin | 0 | 0 | 0 | 1 | 1 | 1 | 3 | 10 | 19 | 22 | 40 | 46 | 53 | 39 | 49 | 62 | 0 | 346 |
| C45 Mesothelioma | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 0 | 0 | 4 |
| C47 Peripheral nerves and autonomic nervous system | 6 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 10 |
| C48 Retroperitoneum and peritoneum | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 2 | 2 | 3 | 0 | 15 |
| C49 Other connective and soft tissue | 4 | 4 | 5 | 5 | 3 | 4 | 8 | 8 | 7 | 6 | 9 | 12 | 19 | 20 | 10 | 11 | 0 | 135 |
| C50 Breast | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 8 | 6 | 17 | 20 | 17 | 25 | 18 | 20 | 0 | 136 |
| C60 Penis | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 7 | 1 | 6 | 22 | 13 | 30 | 19 | 12 | 34 | 0 | 145 |
| C61 Prostate | 1 | 1 | 0 | 0 | 2 | 0 | 2 | 2 | 7 | 12 | 22 | 49 | 152 | 238 | 261 | 359 | 4 | 1112 |
| C62 Testis | 3 | 0 | 1 | 3 | 4 | 14 | 8 | 2 | 6 | 2 | 1 | 3 | 1 | 2 | 3 | 4 | 0 | 57 |
| C63 Other and unspecified male genital organs | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 6 |
| C64 Kidney | 11 | 4 | 0 | 1 | 1 | 0 | 3 | 10 | 10 | 20 | 21 | 28 | 53 | 57 | 39 | 22 | 0 | 280 |
| C65 Renal pelvis | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 3 |
| C66 Ureter | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 3 | 3 | 0 | 0 | 9 |
| C67 Bladder | 0 | 0 | 0 | 0 | 1 | 4 | 3 | 6 | 7 | 20 | 41 | 53 | 95 | 121 | 99 | 122 | 1 | 573 |
| C68 Other and unspecified urinary organs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 1 | 0 | 0 | 5 |

Table 9 continued ...

| ICD 10 site | 00-04 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75+ | unknown | Total |
|---|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-----|---------|-------|
| C69 Eye and adnexa | 29 | 8 | 1 | 1 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 5 | 4 | 3 | 0 | 54 |
| C70 Meninges | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 0 | 13 |
| C71 Brain | 7 | 8 | 7 | 4 | 11 | 14 | 5 | 17 | 12 | 13 | 25 | 19 | 15 | 14 | 14 | 6 | 0 | 191 |
| C72 Spinal cord, cranial nerves and other parts of central nervous system | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 2 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 12 |
| C73 Thyroid gland | 0 | 0 | 4 | 10 | 12 | 31 | 44 | 46 | 50 | 45 | 31 | 41 | 33 | 35 | 20 | 13 | 0 | 415 |
| C74 Adrenal gland | 4 | 5 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 2 | 0 | 1 | 1 | 0 | 0 | 1 | 17 |
| C75 Other endocrine glands and related structures | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 4 |
| C76 Other and ill-defined sites | 4 | 0 | 0 | 0 | 1 | 0 | 1 | 4 | 2 | 1 | 10 | 9 | 11 | 15 | 9 | 19 | 1 | 87 |
| C77 Secondary and unspecified malignant neoplasm of lymph nodes | 0 | 0 | 1 | 4 | 1 | 1 | 0 | 2 | 4 | 3 | 7 | 10 | 13 | 7 | 6 | 6 | 0 | 65 |
| C80 Unknown primary | 3 | 1 | 6 | 5 | 5 | 10 | 11 | 18 | 27 | 64 | 105 | 141 | 176 | 194 | 142 | 140 | 1 | 1049 |
| C81 Hodgkin disease | 0 | 4 | 7 | 11 | 12 | 18 | 4 | 6 | 7 | 3 | 9 | 5 | 5 | 4 | 5 | 5 | 0 | 105 |
| C82 Follicular (nodular) non 31odgkin lymphoma | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 6 | 6 | 3 | 10 | 8 | 4 | 3 | 3 | 0 | 47 |
| C83 Diffuse non 31odgkin lymphoma | 2 | 4 | 1 | 1 | 1 | 3 | 1 | 3 | 4 | 5 | 7 | 8 | 8 | 14 | 11 | 8 | 0 | 81 |
| C84 Peripheral and cutaneous T cell lymphoma | 0 | 0 | 3 | 0 | 3 | 2 | 2 | 1 | 1 | 1 | 2 | 1 | 3 | 3 | 0 | 1 | 0 | 23 |
| C85 Other and unspecified types of non-hodgkin lymphoma | 1 | 2 | 3 | 9 | 11 | 4 | 8 | 8 | 16 | 12 | 27 | 42 | 37 | 36 | 37 | 39 | 0 | 292 |
| C88 Immunoproliferative diseases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| C90 Multiple myeloma and malignant plasma cell neoplasms | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 10 | 15 | 19 | 20 | 23 | 32 | 38 | 25 | 0 | 184 |
| C91 Lymphoid leukemia | 19 | 9 | 6 | 3 | 2 | 1 | 5 | 1 | 3 | 2 | 3 | 4 | 10 | 3 | 5 | 5 | 0 | 81 |
| C92 Myeloid leukemia | 7 | 3 | 2 | 3 | 2 | 6 | 3 | 12 | 6 | 14 | 17 | 17 | 15 | 23 | 13 | 25 | 2 | 170 |
| C93 Monocytic leukemia | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 5 |
| C94 Other leukemias of specified cell type | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 2 | 0 | 5 |
| C95 Leukemia of unspecified cell type | 13 | 10 | 9 | 3 | 5 | 5 | 2 | 2 | 2 | 4 | 2 | 5 | 3 | 4 | 1 | 8 | 0 | 78 |

Table 9 continued ...

| ICD 10 site | 00-04 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75+ | unknown | Total |
|---|------------|-----------|-----------|-----------|-----------|------------|------------|------------|------------|------------|-------------|-------------|-------------|-------------|-------------|-------------|-----------|--------------|
| C96 Other and unspecified malignant neoplasms of lymphoid, haemopoietic and related tissue | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| D45 Polycythaemia vera | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 3 | 0 | 0 | 3 | 0 | 0 | 3 | 1 | 14 |
| D46 Myelodysplastic syndromes | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 3 | 1 | 0 | 4 | 6 | 10 | 11 | 2 | 40 |
| D47 Uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 7 | 3 | 2 | 4 | 1 | 1 | 22 |
| Total | 141 | 72 | 75 | 90 | 97 | 167 | 189 | 318 | 490 | 781 | 1453 | 1955 | 2323 | 2536 | 2079 | 2109 | 42 | 14917 |

Table 10: Number of cancers by five-year age groups and ICD 10 site, among females in Sri Lanka 2018

| ICD 10 site | 00-04 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75+ | unknown | Total |
|---|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-----|---------|-------|
| C00 Lip | 0 | 1 | 0 | 0 | 0 | 3 | 1 | 2 | 1 | 4 | 5 | 11 | 11 | 9 | 8 | 13 | 0 | 69 |
| C01 Base of tongue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 3 | 3 | 2 | 5 | 6 | 1 | 0 | 22 |
| C02 Other and unspecified parts of tongue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 2 | 5 | 14 | 14 | 27 | 20 | 17 | 14 | 0 | 117 |
| C03 Gum | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 5 | 4 | 4 | 6 | 7 | 12 | 1 | 41 |
| C04 Floor of mouth | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 5 | 5 | 5 | 6 | 4 | 4 | 0 | 32 |
| C05 Palate | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 3 | 2 | 7 | 8 | 6 | 7 | 3 | 9 | 0 | 50 |
| C06 Other and unspecified parts of mouth | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 5 | 14 | 19 | 32 | 39 | 48 | 50 | 67 | 0 | 280 |
| C07 Parotid gland | 0 | 0 | 1 | 2 | 1 | 2 | 1 | 3 | 3 | 2 | 6 | 6 | 3 | 1 | 1 | 3 | 0 | 35 |
| C08 Other and unspecified major salivary glands | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 2 | 3 | 1 | 2 | 0 | 11 |
| C09 Tonsils | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 4 | 2 | 2 | 2 | 2 | 3 | 0 | 17 |
| C10 Oropharynx | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 1 | 3 | 1 | 3 | 2 | 0 | 14 |
| C11 Nasopharynx | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 3 | 1 | 1 | 1 | 0 | 12 |
| C12 Piriformis sinus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 1 | 3 | 2 | 5 | 5 | 2 | 6 | 0 | 27 |
| C13 Hypopharynx | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 4 | 2 | 9 | 6 | 0 | 10 | 0 | 34 |
| C14 Other and ill-defines sites in the lip, oral cavity and pharynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 4 | 0 | 4 | 1 | 4 | 0 | 16 |
| C15 Oesophagus | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 6 | 16 | 27 | 61 | 91 | 124 | 135 | 155 | 191 | 6 | 815 |
| C16 Stomach | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 2 | 2 | 14 | 15 | 22 | 20 | 30 | 32 | 33 | 1 | 176 |
| C17 Small Intestine | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 4 | 4 | 10 | 5 | 5 | 5 | 5 | 0 | 40 |
| C18 Colon | 0 | 0 | 0 | 4 | 2 | 7 | 10 | 21 | 25 | 29 | 74 | 68 | 94 | 96 | 63 | 96 | 1 | 590 |
| C19 Rectosigmoid junction | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 2 | 9 | 10 | 14 | 17 | 16 | 7 | 13 | 0 | 91 |
| C20 Rectum | 0 | 0 | 0 | 0 | 4 | 2 | 10 | 12 | 17 | 25 | 49 | 66 | 69 | 75 | 75 | 82 | 2 | 488 |
| C21 Anus and anal canal | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 6 | 6 | 9 | 12 | 16 | 9 | 12 | 1 | 74 |
| C22 Liver and intrahepatic bile ducts | 4 | 0 | 0 | 1 | 0 | 3 | 3 | 4 | 5 | 5 | 10 | 17 | 15 | 15 | 20 | 25 | 1 | 128 |
| C23 Gallbladder | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 4 | 6 | 9 | 7 | 6 | 8 | 15 | 5 | 0 | 64 |
| C24 Other and unspecified parts of biliary tract | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 5 | 10 | 9 | 9 | 4 | 8 | 7 | 0 | 55 |

Table 10 continued ...

| ICD 10 site | 00-04 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75+ | unknown | Total |
|--|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-----|---------|-------|
| C25 Pancreas | 1 | 0 | 1 | 0 | 0 | 0 | 3 | 1 | 6 | 2 | 3 | 9 | 13 | 13 | 14 | 14 | 0 | 80 |
| C26 Other and ill-defined digestive organs | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 0 | 2 | 7 | 3 | 2 | 1 | 1 | 7 | 0 | 27 |
| C30 Nasal cavity and middle ear | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 1 | 0 | 0 | 2 | 2 | 1 | 2 | 2 | 0 | 13 |
| C31 Accessory sinuses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 4 | 2 | 3 | 0 | 13 |
| C32 Larynx | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 6 | 3 | 2 | 4 | 6 | 10 | 12 | 14 | 23 | 0 | 81 |
| C34 Bronchus and lung | 0 | 0 | 0 | 0 | 1 | 7 | 9 | 11 | 24 | 37 | 41 | 51 | 86 | 84 | 57 | 48 | 0 | 456 |
| C37 Thymus | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 3 | 4 | 5 | 2 | 3 | 3 | 0 | 24 |
| C38 Heart, mediastinum and pleura | 2 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 3 | 1 | 4 | 1 | 6 | 1 | 2 | 4 | 0 | 27 |
| C39 Other and ill-defined sites in the respiratory system and intrathoracic organs | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 4 | 2 | 0 | 0 | 0 | 8 |
| C40 Bone and articular cartilage of limbs | 4 | 2 | 5 | 7 | 0 | 1 | 0 | 3 | 2 | 1 | 2 | 3 | 2 | 1 | 5 | 1 | 0 | 39 |
| C41 Bone and articular cartilage of other and unspecified sites | 3 | 1 | 3 | 7 | 1 | 2 | 0 | 2 | 6 | 1 | 2 | 8 | 3 | 2 | 2 | 2 | 0 | 45 |
| C43 Melanoma of skin | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 2 | 5 | 3 | 7 | 6 | 12 | 0 | 38 |
| C44 Other malignant neoplasms of skin | 0 | 1 | 1 | 0 | 2 | 4 | 4 | 14 | 8 | 18 | 20 | 26 | 26 | 35 | 46 | 67 | 0 | 272 |
| C45 Mesothelioma | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| C47 Peripheral nerves and autonomic nervous system | 3 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 3 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 12 |
| C48 Retroperitoneum and peritoneum | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 1 | 1 | 4 | 4 | 4 | 4 | 3 | 0 | 28 |
| C49 Other connective and soft tissue | 20 | 7 | 3 | 4 | 3 | 2 | 8 | 5 | 13 | 11 | 13 | 7 | 25 | 16 | 5 | 15 | 0 | 157 |
| C50 Breast | 0 | 0 | 0 | 5 | 12 | 31 | 92 | 193 | 326 | 506 | 515 | 510 | 508 | 463 | 337 | 274 | 6 | 3778 |
| C51 Vulva | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 5 | 17 | 13 | 14 | 8 | 0 | 61 |
| C52 Vagina | 3 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 3 | 5 | 9 | 9 | 20 | 10 | 6 | 16 | 0 | 83 |
| C53 Cervix uteri | 0 | 0 | 0 | 1 | 3 | 2 | 7 | 39 | 68 | 108 | 146 | 155 | 187 | 140 | 104 | 111 | 2 | 1073 |
| C54 Corpus uteri | 0 | 0 | 0 | 0 | 1 | 2 | 7 | 13 | 19 | 26 | 67 | 83 | 116 | 108 | 55 | 46 | 2 | 545 |
| C55 Uterus unspecified | 0 | 1 | 0 | 0 | 1 | 2 | 7 | 11 | 17 | 28 | 49 | 76 | 106 | 81 | 50 | 46 | 0 | 475 |

Table 10 continued ...

| ICD 10 site | 00-04 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75+ | unknown | Total |
|---|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-----|---------|-------|
| C56 Ovary | 1 | 2 | 10 | 10 | 17 | 23 | 26 | 38 | 51 | 72 | 129 | 139 | 146 | 136 | 75 | 62 | 1 | 938 |
| C57 Other and unspecified female genital organs | 1 | 0 | 0 | 1 | 0 | 1 | 3 | 1 | 4 | 10 | 12 | 11 | 16 | 15 | 11 | 4 | 0 | 90 |
| C58 Placenta | 0 | 0 | 0 | 0 | 4 | 6 | 1 | 1 | 2 | 2 | 2 | 0 | 0 | 1 | 0 | 1 | 0 | 20 |
| C64 Kidney | 12 | 7 | 1 | 0 | 1 | 0 | 2 | 5 | 9 | 7 | 15 | 11 | 12 | 15 | 19 | 11 | 1 | 128 |
| C65 Renal pelvis | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 0 | 5 |
| C66 Ureter | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 1 | 5 | 0 | 0 | 9 |
| C67 Bladder | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 0 | 8 | 4 | 16 | 27 | 23 | 20 | 33 | 0 | 137 |
| C68 Other and unspecified urinary organs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 3 |
| C69 Eye and adnexa | 23 | 9 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 3 | 2 | 0 | 3 | 0 | 46 |
| C70 Meninges | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 4 | 3 | 6 | 1 | 2 | 1 | 4 | 1 | 1 | 0 | 25 |
| C71 Brain | 7 | 5 | 5 | 6 | 3 | 6 | 14 | 11 | 12 | 17 | 7 | 16 | 16 | 15 | 9 | 5 | 0 | 154 |
| C72 Spinal cord, cranial nerves and other parts of central nervous system | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 2 | 0 | 1 | 0 | 0 | 7 |
| C73 Thyroid gland | 2 | 0 | 9 | 48 | 116 | 148 | 224 | 276 | 239 | 225 | 204 | 133 | 121 | 79 | 39 | 31 | 2 | 1896 |
| C74 Adrenal gland | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 7 |
| C75 Other endocrine glands and related structures | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 8 |
| C76 Other and ill-defined sites | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 4 | 3 | 4 | 2 | 13 | 5 | 10 | 7 | 12 | 0 | 63 |
| C77 Secondary and unspecified malignant neoplasm of lymph nodes | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 2 | 2 | 2 | 6 | 6 | 5 | 4 | 0 | 30 |
| C80 Unknown primary | 0 | 0 | 2 | 4 | 6 | 5 | 11 | 21 | 40 | 47 | 78 | 94 | 117 | 110 | 103 | 116 | 1 | 755 |
| C81 Hodgkin disease | 0 | 0 | 2 | 8 | 10 | 7 | 12 | 3 | 3 | 1 | 2 | 0 | 9 | 7 | 6 | 2 | 0 | 72 |
| C82 Follicular (nodular) non 35odgkin lymphoma | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 3 | 3 | 1 | 4 | 6 | 3 | 3 | 5 | 0 | 30 |
| C83 Diffuse non 35odgkin lymphoma | 1 | 4 | 2 | 1 | 1 | 0 | 2 | 3 | 4 | 4 | 7 | 7 | 19 | 6 | 11 | 5 | 0 | 77 |

Table 10 continued ...

| ICD 10 site | 00-04 | 05-09 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 | 75+ | unknown | Total |
|--|------------|-----------|-----------|------------|------------|------------|------------|------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-----------|--------------|
| C84 Peripheral and cutaneous T cell lymphoma | 0 | 0 | 2 | 2 | 1 | 1 | 2 | 3 | 0 | 1 | 1 | 1 | 2 | 2 | 0 | 3 | 0 | 21 |
| C85 Other and unspecified types of non-hodgkin lymphoma | 0 | 1 | 2 | 8 | 5 | 6 | 3 | 9 | 5 | 22 | 26 | 31 | 32 | 33 | 26 | 36 | 0 | 245 |
| C88 Immunoproliferative diseases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 1 | 1 | 0 | 5 |
| C90 Multiple myeloma and malignant plasma cell neoplasms | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 5 | 2 | 7 | 15 | 21 | 27 | 40 | 33 | 20 | 1 | 172 |
| C91 Lymphoid leukemia | 13 | 9 | 6 | 4 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 6 | 5 | 12 | 5 | 5 | 2 | 71 |
| C92 Myeloid leukemia | 5 | 1 | 4 | 5 | 3 | 7 | 6 | 9 | 14 | 11 | 13 | 17 | 22 | 17 | 14 | 15 | 1 | 164 |
| C93 Monocytic leukemia | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 1 | 0 | 3 | 0 | 2 | 1 | 2 | 0 | 0 | 13 |
| C94 Other leukemias of specified cell type | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 4 |
| C95 Leukemia of unspecified cell type | 9 | 6 | 3 | 4 | 2 | 0 | 2 | 0 | 2 | 5 | 3 | 4 | 3 | 6 | 2 | 3 | 0 | 54 |
| C96 Other and unspecified malignant neoplasms of lymphoid, haemopoietic and related tissue | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| D45 Polycythaemia vera | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 3 |
| D46 Myelodysplastic syndromes | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 2 | 2 | 3 | 4 | 3 | 5 | 2 | 23 |
| D47 Uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 4 | 4 | 0 | 8 | 4 | 0 | 23 |
| Total | 121 | 62 | 68 | 137 | 206 | 290 | 492 | 786 | 1000 | 1383 | 1762 | 1917 | 2251 | 2076 | 1635 | 1716 | 34 | 15936 |

Table 11 : Number of cancers by five-year age group and ICD 10 site categories among males in Sri Lanka 2018

Cancer Registry (2018)

Cancer Incidence Data 2018

Cases by age group (Period) - Male

| SITE | ALL AGE GROUPS UNK | Cases by age group (Period) - Male | | | | | | | | | | | 75+ | ICD (10M) | | | | | |
|------------------------------|--------------------|------------------------------------|-----|-------|-------|-------|-------|-------|-------|-------|-------|-------|------|-----------|-------|-------|-------------|-------|---------|
| | | 0-4 | 5-9 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | | | 55-59 | 60-64 | 65-69 | 70-74 | (%) |
| Lip | 252 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 9 | 22 | 32 | 38 | 48 | 38 | 31 | 26 | C00 | | |
| Tongue | 795 | 4 | 1 | 1 | 1 | 5 | 7 | 17 | 39 | 68 | 125 | 140 | 116 | 123 | 82 | 68 | C01.02 | | |
| Mouth | 1364 | 3 | 3 | 1 | 2 | 1 | 8 | 31 | 46 | 101 | 187 | 214 | 203 | 220 | 181 | 163 | C03.06 | | |
| Salivary glands | 82 | 0 | 0 | 0 | 0 | 0 | 2 | 4 | 7 | 7 | 10 | 11 | 8 | 13 | 10 | 6 | C07.08 | | |
| Tonsil | 152 | 0 | 0 | 2 | 1 | 1 | 2 | 4 | 4 | 16 | 21 | 31 | 17 | 21 | 19 | 14 | C09 | | |
| Other oropharynx | 150 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 4 | 16 | 21 | 31 | 17 | 21 | 19 | 14 | C10 | | |
| Nasopharynx | 33 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 1 | 1 | 8 | 9 | 2 | 1 | 3 | C11 | | |
| Hypopharynx | 314 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 12 | 12 | 34 | 47 | 64 | 56 | 44 | C12-13 | | |
| Pharynx unspecified | 128 | 1 | 1 | 1 | 1 | 1 | 2 | 6 | 14 | 16 | 16 | 20 | 28 | 21 | 7 | 13 | C14 | | |
| Oesophagus | 1136 | 2 | 1 | 1 | 2 | 1 | 3 | 4 | 22 | 58 | 132 | 181 | 209 | 225 | 154 | 143 | C15 | | |
| Stomach | 415 | 1 | 1 | 1 | 1 | 4 | 2 | 5 | 8 | 17 | 47 | 74 | 78 | 69 | 63 | 47 | C16 | | |
| Small intestine | 67 | 1 | 1 | 1 | 1 | 4 | 4 | 5 | 2 | 10 | 7 | 12 | 10 | 10 | 6 | 6 | C17 | | |
| Colon | 530 | 2 | 1 | 1 | 2 | 5 | 10 | 20 | 18 | 24 | 53 | 74 | 90 | 90 | 64 | 78 | C18 | | |
| Rectum | 631 | 1 | 1 | 1 | 1 | 2 | 2 | 10 | 13 | 23 | 48 | 85 | 96 | 115 | 112 | 125 | C19-20 | | |
| Anus | 79 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 9 | 10 | 10 | 15 | 14 | 14 | C21 | | |
| Liver | 379 | 3 | 2 | 1 | 1 | 1 | 2 | 2 | 13 | 20 | 22 | 36 | 78 | 65 | 71 | 51 | C22 | | |
| Gallbladder etc. | 89 | 0 | 0 | 0 | 0 | 0 | 3 | 4 | 3 | 5 | 8 | 5 | 16 | 18 | 9 | 17 | C23-24 | | |
| Pancreas | 91 | 0 | 0 | 0 | 0 | 1 | 3 | 1 | 4 | 7 | 7 | 12 | 11 | 18 | 14 | 13 | C25 | | |
| Nose, sinuses etc. | 67 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 2 | 5 | 7 | 18 | 4 | 15 | 3 | 10 | C30-31 | | |
| Larynx | 712 | 1 | 1 | 1 | 1 | 2 | 1 | 4 | 15 | 26 | 83 | 116 | 138 | 128 | 97 | 102 | C32 | | |
| Trachea, bronchus and lung | 1908 | 5 | 1 | 1 | 1 | 2 | 2 | 3 | 14 | 21 | 39 | 110 | 201 | 225 | 279 | 217 | C33-34 | | |
| Other thoracic organs | 75 | 1 | 3 | 3 | 3 | 3 | 3 | 3 | 6 | 4 | 10 | 10 | 10 | 11 | 5 | 3 | C37-38 | | |
| Bone | 79 | 0 | 2 | 12 | 15 | 3 | 9 | 3 | 2 | 3 | 4 | 2 | 6 | 8 | 3 | 3 | C40-41 | | |
| Melanoma of skin | 38 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | C43 | | |
| Other skin | 346 | 0 | 0 | 0 | 0 | 0 | 3 | 10 | 19 | 22 | 40 | 46 | 53 | 39 | 49 | 62 | C44 | | |
| Mesothelioma | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C45 | | |
| Kaposi sarcoma | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C46 | | |
| Connective and soft tissue | 145 | 0 | 10 | 4 | 5 | 6 | 3 | 4 | 8 | 7 | 6 | 10 | 12 | 19 | 21 | 11 | C47, C49 | | |
| Breast | 136 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 8 | 6 | 17 | 20 | 17 | 25 | 18 | C50 | | |
| Penis | 145 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 6 | 2 | 1 | 13 | 30 | 19 | 12 | 34 | C60 | | |
| Prostate | 1112 | 4 | 1 | 1 | 2 | 2 | 2 | 7 | 12 | 22 | 49 | 152 | 238 | 261 | 359 | 7.6 | C61 | | |
| Testis | 57 | 0 | 1 | 1 | 3 | 4 | 14 | 8 | 2 | 6 | 2 | 1 | 3 | 1 | 2 | 4 | C62 | | |
| Other male genital organs | 6 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | C63 | | |
| Kidney | 280 | 0 | 11 | 4 | 1 | 1 | 1 | 3 | 10 | 10 | 20 | 21 | 28 | 53 | 57 | 39 | C64 | | |
| Renal pelvis | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C65 | | |
| Ureter | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C66 | | |
| Bladder | 573 | 7 | 1 | 1 | 1 | 1 | 4 | 3 | 6 | 7 | 20 | 41 | 53 | 95 | 121 | 99 | C67 | | |
| Other urinary organs | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C68 | | |
| Eye | 54 | 0 | 29 | 8 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 9 | 5 | 5 | 4 | 3 | C69 | | |
| Brain, nervous system | 216 | 0 | 8 | 9 | 8 | 4 | 12 | 15 | 7 | 20 | 15 | 26 | 22 | 16 | 16 | 17 | C70-72 | | |
| Thyroid | 415 | 0 | 4 | 4 | 10 | 12 | 31 | 44 | 46 | 50 | 45 | 31 | 41 | 33 | 35 | 20 | C73 | | |
| Adrenal gland | 17 | 1 | 4 | 5 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | C74 | | |
| Other endocrine | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C75 | | |
| Hodgkin disease | 105 | 0 | 4 | 7 | 11 | 12 | 18 | 4 | 6 | 7 | 3 | 9 | 5 | 4 | 5 | 5 | C81 | | |
| Non-Hodgkin lymphoma | 444 | 0 | 5 | 6 | 7 | 10 | 16 | 10 | 11 | 13 | 28 | 24 | 39 | 61 | 56 | 51 | C82-85, C96 | | |
| Immunoproliferative diseases | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | C88 | | |
| Multiple myeloma | 184 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 10 | 15 | 19 | 20 | 21 | 32 | 38 | C90 | | |
| Lymphoid leukaemia | 81 | 0 | 19 | 9 | 6 | 3 | 2 | 1 | 5 | 1 | 3 | 2 | 3 | 4 | 10 | 3 | C91 | | |
| Myeloid leukaemia | 180 | 2 | 7 | 3 | 2 | 3 | 2 | 6 | 4 | 12 | 6 | 15 | 17 | 18 | 16 | 24 | C92-94 | | |
| Leukaemia unspecified | 78 | 0 | 13 | 10 | 9 | 3 | 5 | 5 | 2 | 2 | 2 | 4 | 2 | 3 | 4 | 1 | C95 | | |
| Myeloproliferative disorders | 36 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | MPD | | |
| Myelodysplastic syndromes | 40 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | MDS | | |
| Other and unspecified | 1282 | 2 | 8 | 3 | 8 | 9 | 7 | 12 | 13 | 26 | 38 | 71 | 128 | 169 | 216 | 232 | 168 | O&U | |
| All sites | 14917 | 42 | 141 | 72 | 75 | 90 | 97 | 167 | 190 | 318 | 490 | 781 | 1452 | 1955 | 2323 | 2536 | 2079 | 2109 | ALL |
| All sites but C44 | 14571 | 42 | 141 | 72 | 75 | 89 | 96 | 166 | 187 | 308 | 471 | 759 | 1412 | 1909 | 2270 | 2497 | 2050 | 2047 | ALLJC44 |

Table built Tue Oct 12 12:03:18 IST 2021 by CanReg5.

Table 12: Number of cancers by five-year age group and ICD 10 site categories among females in Sri Lanka 2018

Cancer Registry (2018)

Cancer Incidence Data 2018

Cases by age group (Period) - Female

| SITE | ALL AGE AGES LINK | 0 | 5 | 10 | 15 | 20 | 25 | 30 | 35 | 40 | 45 | 50 | 55 | 60 | 65 | 70 | 75+ | (%) | ICD (I/line) | |
|------------------------------|-------------------|---|-----|----|----|-----|-----|-----|-----|-----|------|------|------|------|------|------|------|--------|--------------|-------------------|
| Lip | 69 | | 1 | | | | 3 | 1 | 2 | 1 | 4 | 5 | 11 | 11 | 9 | 8 | 13 | 0.4 | C00 | |
| Tongue | 139 | | | | | | | | 5 | 2 | 6 | 17 | 17 | 20 | 25 | 23 | 15 | 0.9 | C01-02 | |
| Mouth | 403 | | | 1 | 1 | 2 | | 1 | 8 | 9 | 18 | 36 | 49 | 54 | 67 | 64 | 92 | 2.6 | C03-06 | |
| Salivary glands | 46 | | | | | | | | 2 | 4 | 2 | 6 | 8 | 5 | 4 | 5 | 5 | 0.3 | C07-08 | |
| Tonsil | 17 | | | | | | | | 2 | 2 | 2 | 4 | 2 | 2 | 2 | 2 | 3 | 0.1 | C09 | |
| Other oropharynx | 14 | | | | | | | | 1 | 1 | 1 | 2 | 2 | 3 | 1 | 2 | 2 | 0.1 | C10 | |
| Nasopharynx | 12 | | | | 2 | | | | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 0.1 | C11 | |
| Hypopharynx | 61 | | | | | | | 1 | 3 | 1 | 2 | 7 | 4 | 14 | 11 | 2 | 16 | 0.4 | C12-13 | |
| Pharynx unspecified | 16 | | | | | | | | 1 | 1 | 2 | 2 | 4 | 4 | 4 | 1 | 4 | 0.1 | C14 | |
| Oesophagus | 815 | | | | | | 1 | 2 | 6 | 16 | 27 | 61 | 91 | 124 | 135 | 155 | 191 | 5.2 | C15 | |
| Stomach | 176 | | | | | | 2 | 3 | 2 | 3 | 4 | 15 | 22 | 20 | 30 | 32 | 33 | 1.1 | C16 | |
| Small intestine | 40 | | | | | | | | 1 | 3 | 4 | 4 | 10 | 5 | 5 | 5 | 5 | 0.3 | C17 | |
| Colon | 590 | | | | 4 | 2 | 7 | 10 | 21 | 25 | 29 | 74 | 68 | 94 | 96 | 63 | 96 | 3.8 | C18 | |
| Rectum | 579 | | | | | 5 | 3 | 11 | 12 | 19 | 34 | 59 | 80 | 86 | 91 | 82 | 95 | 3.7 | C19-20 | |
| Anus | 74 | | | | | | | | 1 | 2 | 6 | 6 | 9 | 12 | 16 | 9 | 12 | 0.5 | C21 | |
| Uterus | 128 | | 4 | | | | 3 | 3 | 4 | 5 | 5 | 10 | 17 | 15 | 15 | 20 | 25 | 0.8 | C22 | |
| Gallbladder etc. | 119 | | | | | | | 1 | 5 | 5 | 11 | 19 | 16 | 15 | 12 | 23 | 12 | 0.8 | C23-24 | |
| Pancreas | 80 | | | | | | | 3 | 1 | 6 | 2 | 3 | 9 | 13 | 13 | 14 | 14 | 0.5 | C25 | |
| Nose, sinuses etc. | 26 | | | | | | | | 2 | 1 | 2 | 1 | 3 | 3 | 3 | 4 | 3 | 0.2 | C30-31 | |
| Larynx | 81 | | | | | | | | 1 | 6 | 3 | 2 | 4 | 6 | 10 | 12 | 14 | 0.5 | C32 | |
| Trachea, bronchus and lung | 456 | | | | | | 1 | 7 | 9 | 11 | 25 | 37 | 41 | 51 | 86 | 84 | 56 | 2.9 | C33-34 | |
| Other thoracic organs | 51 | | 2 | 1 | 1 | | | 1 | 3 | 3 | 5 | 7 | 5 | 11 | 3 | 5 | 7 | 0.3 | C37-38 | |
| Bone | 84 | | 7 | 3 | 8 | 14 | 1 | 3 | 5 | 8 | 2 | 4 | 11 | 5 | 3 | 7 | 3 | 0.5 | C40-41 | |
| Melanoma of skin | 38 | | | | | | | 2 | 4 | 8 | 18 | 20 | 26 | 26 | 35 | 46 | 67 | 0.2 | C43 | |
| Other skin | 272 | | | | | | | | | | | | | | | | | 1.7 | C44 | |
| Mesothelioma | 3 | | | | | | | | 2 | | 1 | | | | | | | 0.0 | C45 | |
| Kaposi sarcoma | 0 | | | | | | | | | | | | | | | | | 0.0 | C46 | |
| Connective and soft tissue | 169 | | 7 | 3 | 4 | 3 | 3 | 9 | 6 | 16 | 11 | 14 | 7 | 26 | 16 | 5 | 16 | 1.1 | C47-C49 | |
| Breast | 3778 | | | | | 5 | 12 | 31 | 92 | 193 | 326 | 506 | 515 | 510 | 508 | 463 | 337 | 24.1 | C50 | |
| Vulva | 61 | | | | | | | | | 2 | 2 | 2 | 5 | 17 | 13 | 14 | 8 | 0.4 | C51 | |
| Vagina | 83 | | | | | | | | | 3 | 5 | 9 | 9 | 20 | 10 | 6 | 16 | 0.5 | C52 | |
| Cervix uteri | 1073 | | | | 1 | 3 | 2 | 7 | 39 | 68 | 108 | 146 | 155 | 187 | 140 | 104 | 111 | 6.9 | C53 | |
| Corpus uteri | 545 | | | | | | 1 | 2 | 7 | 13 | 19 | 26 | 67 | 83 | 116 | 108 | 55 | 3.5 | C54 | |
| Uterus unspecified | 475 | | | | | | 2 | 7 | 11 | 17 | 28 | 49 | 76 | 106 | 81 | 50 | 46 | 3.0 | C55 | |
| Ovary | 938 | | 1 | 2 | 10 | 17 | 23 | 26 | 38 | 51 | 72 | 120 | 139 | 146 | 136 | 75 | 62 | 6.0 | C56 | |
| Other female genital organs | 90 | | | | | | 1 | 3 | 1 | 4 | 10 | 12 | 11 | 16 | 15 | 11 | 4 | 0.6 | C57 | |
| Placenta | 20 | | | | | | | 1 | 1 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 0.1 | C58 | |
| Kidney | 128 | | 7 | 1 | | | | 2 | 5 | 9 | 7 | 15 | 11 | 12 | 15 | 19 | 11 | 0.8 | C64 | |
| Renal pelvis | 5 | | | | | | | | | | | | | 1 | 1 | 1 | 2 | 0.0 | C65 | |
| Ureter | 9 | | | | | | | | | | | | | | | 1 | 5 | 0.1 | C66 | |
| Bladder | 137 | | | | | | | | | | 8 | 4 | 16 | 27 | 23 | 20 | 33 | 0.9 | C67 | |
| Other urinary organs | 3 | | | | | | | | 3 | 3 | | | | 1 | | 1 | 1 | 0.0 | C68 | |
| Eye | 46 | | 2 | | | | | | 1 | 1 | 1 | 2 | 1 | 3 | 2 | 2 | 3 | 0.3 | C69 | |
| Brain, nervous system | 180 | | 6 | 5 | 6 | 3 | 6 | 16 | 15 | 24 | 9 | 19 | 19 | 19 | 19 | 31 | 7.2 | C70-72 | | |
| Thyroid | 1896 | | 2 | 9 | 48 | 116 | 148 | 224 | 276 | 239 | 225 | 204 | 193 | 121 | 79 | 39 | 31 | 12.1 | C73 | |
| Adrenal gland | 7 | | 1 | | | | | | | | | | | 1 | 1 | 1 | 1 | 0.0 | C74 | |
| Other endocrine | 8 | | | | | | | | | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 0.0 | C75 | |
| Hodgkin disease | 72 | | | 2 | 8 | 10 | 7 | 12 | 3 | 3 | 1 | 2 | 1 | 9 | 7 | 6 | 2 | 0.5 | C81 | |
| Non-Hodgkin lymphoma | 373 | | 2 | 5 | 11 | 7 | 7 | 9 | 16 | 12 | 30 | 35 | 43 | 59 | 44 | 39 | 49 | 2.4 | C82-85,C86 | |
| Immunoproliferative diseases | 5 | | | | | | | | | | | | | 1 | 2 | 1 | 1 | 0.0 | C88 | |
| Multiple myeloma | 172 | | | | | | | 1 | 5 | 2 | 7 | 15 | 21 | 27 | 40 | 33 | 20 | 1.1 | C90 | |
| Lymphoid leukaemia | 71 | | 2 | | 4 | | | 1 | 1 | 1 | 2 | 2 | 6 | 5 | 12 | 5 | 3 | 0.5 | C91 | |
| Myeloid leukaemia | 181 | | 7 | 1 | 4 | 5 | 4 | 7 | 6 | 11 | 15 | 12 | 16 | 17 | 23 | 19 | 16 | 1.2 | C92-94 | |
| Leukaemia unspecified | 54 | | 0 | 9 | 6 | 3 | 4 | 2 | 2 | 5 | 3 | 4 | 3 | 6 | 2 | 3 | 3 | 0.3 | C95 | |
| Myeloproliferative disorders | 26 | | | | | | | | | | | | | | | | | 0.2 | MPD | |
| Myelodysplastic syndromes | 23 | | | | | | | | | | | | | | | | | 0.1 | MDS | |
| Other and unspecified | 913 | | 3 | 2 | 4 | 6 | 7 | 5 | 11 | 30 | 47 | 56 | 91 | 116 | 138 | 133 | 121 | 5.8 | Other | |
| All sites | 15936 | | 121 | 62 | 68 | 137 | 206 | 290 | 492 | 786 | 1001 | 1383 | 1762 | 1917 | 2251 | 2076 | 1634 | 1716 | 100.0 | ALL sites |
| All sites but C44 | 15664 | | 121 | 61 | 67 | 137 | 204 | 286 | 488 | 772 | 993 | 1365 | 1742 | 1891 | 2225 | 2041 | 1588 | 1649 | 100.0 | ALL sites but C44 |

Table built Tue Oct 12 12:03:18 IST 2021 by CanReg5.

Table 14: Age specific incidence rate, Crude incidence rate, Age standardized incidence rate per 100,000 population and Cumulative risk of cancers by five-year age group and ICD 10 site categories among females in Sri Lanka, 2018

Cancer Registry (2018)

2018

Incidence per 100,000 by age group (Period) - Female

| SITE | ALL AGES | AGES (LYRS) | | | | | | | | | | CRUDE RATE | CUM CUM (%) | ASR (1000) | ICD | | | | | |
|------------------------------|----------|-------------|------|-------|-------|-------|-------|-------|-------|-------|-------|------------|-------------|------------|-------|-------|-------|-------|-------|---------|
| | | 0-4 | 5-9 | 10-14 | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | | | | | 50-54 | 55-59 | 60-64 | 65-69 | 70-74 |
| Lip | 69 | - | - | - | - | - | - | 0.3 | 0.1 | 0.3 | 0.1 | 0.6 | 0.7 | 1.8 | 2.1 | 2.4 | 3.3 | 3.7 | 0.5 | C00 |
| Tongue | 139 | - | - | - | - | - | - | - | - | 0.6 | 0.3 | 0.8 | 2.5 | 2.8 | 5.5 | 6.7 | 9.4 | 4.3 | 1.2 | C01-02 |
| Mouth | 403 | - | - | 0.1 | 0.1 | 0.2 | 0.1 | 0.2 | 0.1 | 1.0 | 1.2 | 2.5 | 5.3 | 8.2 | 10.3 | 18.1 | 26.2 | 26.1 | 3.6 | C03-06 |
| Salivary glands | 46 | - | - | - | - | - | - | - | - | 0.5 | 0.4 | 0.3 | 0.9 | 1.3 | 1.0 | 1.1 | 0.8 | 1.4 | 0.4 | C07-08 |
| Tonsil | 17 | - | - | - | - | - | - | - | - | 0.3 | - | - | 0.6 | 0.3 | 0.4 | 0.5 | 0.8 | 0.9 | 0.2 | C09 |
| Other oropharynx | 14 | - | - | - | - | - | - | - | - | 0.1 | - | - | 0.3 | 0.2 | 0.6 | 0.3 | 1.2 | 0.6 | 0.1 | C10 |
| Nasopharynx | 12 | - | - | - | - | - | - | - | - | 0.1 | - | - | 0.3 | 0.2 | 0.6 | 0.3 | 0.4 | 0.3 | 0.1 | C11 |
| Hypopharynx | 61 | - | - | - | - | - | - | - | - | 0.4 | 0.1 | 0.3 | 1.0 | 0.7 | 2.7 | 3.0 | 0.8 | 4.5 | 0.5 | C12-13 |
| Pharynx unspecified | 16 | - | - | - | - | - | - | - | - | 0.1 | - | 0.3 | 0.7 | - | - | 1.1 | 0.4 | 1.1 | 0.1 | C14 |
| Oesophagus | 815 | 6 | - | - | - | - | - | 0.1 | 0.2 | 0.8 | 2.2 | 3.8 | 9.0 | 15.2 | 23.7 | 36.4 | 63.3 | 54.2 | 7.9 | C15 |
| Stomach | 176 | 1 | - | - | - | - | - | 0.2 | 0.3 | 0.3 | 0.3 | 2.0 | 2.2 | 3.7 | 3.8 | 8.1 | 13.1 | 9.4 | 1.6 | C16 |
| Small intestine | 40 | - | - | - | - | - | - | - | - | 0.1 | 0.4 | 0.6 | 0.6 | 1.7 | 1.0 | 1.3 | 2.0 | 0.9 | 0.4 | C17 |
| Colon | 590 | 1 | - | - | 0.5 | 0.2 | 0.8 | 1.1 | 2.7 | 3.4 | 4.1 | 10.9 | 11.4 | 18.0 | 25.9 | 25.7 | 27.2 | 5.3 | 0.3 | C18 |
| Rectum | 579 | 2 | - | - | - | 0.6 | 0.3 | 1.2 | 1.6 | 2.6 | 4.8 | 8.7 | 13.4 | 16.4 | 24.5 | 35.5 | 27.0 | 5.7 | 3.7 | C19-20 |
| Anus | 74 | 1 | - | - | - | - | - | - | - | 0.1 | 0.3 | 0.8 | 0.9 | 1.5 | 2.4 | 4.3 | 3.7 | 3.4 | 0.2 | C21 |
| Liver | 128 | 1 | - | - | 0.1 | - | - | 0.3 | 0.3 | 0.3 | 0.7 | 1.5 | 2.8 | 2.9 | 4.0 | 8.2 | 7.1 | 1.1 | 0.8 | C22 |
| Gallbladder etc. | 119 | 0 | - | - | - | - | - | - | - | 0.1 | 0.6 | 0.7 | 1.5 | 2.8 | 2.7 | 2.9 | 3.2 | 3.4 | 1.1 | C23-24 |
| Pancreas | 80 | 0 | - | - | - | - | - | - | - | 0.3 | 0.1 | 0.8 | 0.3 | 0.4 | 1.5 | 2.5 | 3.5 | 3.7 | 0.7 | C25 |
| Nose, sinuses etc. | 26 | 0 | - | - | - | - | - | - | - | 0.2 | - | 0.3 | 0.1 | - | 0.5 | 0.5 | 1.3 | 1.6 | 0.2 | C26-31 |
| Larynx | 81 | 0 | - | - | - | - | - | - | - | 0.1 | 0.8 | 0.4 | 0.3 | 0.6 | 1.0 | 1.6 | 3.2 | 5.7 | 0.7 | C32 |
| Trachea, bronchus and lung | 456 | 0 | - | - | - | 0.1 | 0.8 | 1.0 | 1.4 | 3.2 | 5.2 | 6.0 | 8.5 | 16.4 | 22.6 | 29.3 | 19.6 | 4.1 | 2.0 | C33-34 |
| Other thoracic organs | 51 | 0 | - | - | - | - | - | - | - | 0.4 | 0.7 | 1.0 | 0.8 | 2.1 | 0.8 | 2.0 | 2.0 | 2.0 | 0.5 | C35-38 |
| Bone | 84 | 0 | 0.8 | 0.3 | 0.9 | 1.6 | 0.1 | 0.3 | - | 0.6 | 1.1 | 0.3 | 0.6 | 1.8 | 1.0 | 0.8 | 2.9 | 0.9 | 0.8 | C40-41 |
| Melanoma of skin | 38 | 0 | - | - | - | - | - | - | - | 0.4 | 1.8 | 1.1 | 0.4 | 0.5 | 0.8 | 1.9 | 2.5 | 3.4 | 0.3 | C42 |
| Other skin | 272 | 0 | - | - | - | 0.2 | 0.5 | 0.4 | - | 0.4 | 1.8 | 1.1 | 2.3 | 2.9 | 4.3 | 5.0 | 9.4 | 18.8 | 2.4 | C43 |
| Mesothelioma | 3 | 0 | - | - | - | - | - | - | - | 0.3 | - | - | - | - | - | - | - | - | 0.0 | C45 |
| Kaposi sarcoma | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.0 | C46 |
| Connective and soft tissue | 169 | 0 | 2.5 | 0.8 | 0.3 | 0.5 | 0.4 | 0.3 | 1.0 | 0.8 | 2.2 | 1.5 | 2.1 | 1.2 | 5.0 | 4.3 | 2.0 | 4.5 | 1.5 | C47-C49 |
| Breast | 3778 | 6 | - | - | 0.6 | 1.4 | 3.6 | 10.3 | 25.1 | 43.9 | 71.2 | 75.9 | 85.1 | 97.1 | 124.8 | 137.7 | 77.7 | 33.8 | 24.1 | C50 |
| Vulva | 61 | 0 | - | - | - | - | - | - | - | 0.3 | 0.3 | 0.8 | 3.2 | 3.5 | 3.2 | 3.5 | 2.5 | 2.3 | 0.5 | C51 |
| Vagina | 83 | 0 | - | - | - | - | - | - | - | 0.4 | 0.7 | 1.3 | 1.5 | 3.8 | 2.7 | 2.5 | 4.5 | 2.5 | 0.7 | C52 |
| Cervix uteri | 1073 | 2 | - | - | 0.1 | 0.4 | 0.2 | 0.8 | 1.1 | 9.2 | 15.2 | 21.5 | 25.9 | 35.7 | 37.7 | 42.5 | 31.5 | 9.6 | 6.9 | C53 |
| Corpus uteri | 545 | 2 | - | - | - | 0.1 | 0.2 | 0.8 | 1.7 | 2.6 | 3.7 | 9.9 | 13.0 | 20.2 | 29.1 | 32.5 | 19.0 | 4.9 | 3.5 | C54 |
| Uterus unspecified | 475 | 0 | - | - | - | - | - | - | - | 1.4 | 2.3 | 3.9 | 7.2 | 12.7 | 20.3 | 31.8 | 30.4 | 4.2 | 3.0 | C55 |
| Ovary | 949 | 1 | 0.1 | 0.2 | 1.2 | 1.1 | 2.0 | 2.7 | 2.9 | 4.9 | 10.1 | 19.0 | 23.2 | 27.9 | 36.6 | 50.0 | 17.0 | 8.4 | 6.0 | C56 |
| Other female genital organs | 90 | 0 | - | - | - | - | - | - | - | 0.1 | 0.3 | 0.1 | 0.5 | 1.4 | 1.8 | 3.1 | 4.5 | 1.1 | 0.8 | C57 |
| Placenta | 20 | 0 | - | - | - | - | - | - | - | 0.5 | 0.7 | 0.1 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.2 | C58 |
| Kidney | 128 | 1 | 1.3 | 0.8 | 0.1 | - | - | - | - | 0.2 | 0.6 | 1.2 | 1.0 | 2.2 | 1.8 | 2.3 | 4.0 | 7.8 | 1.1 | C59 |
| Renal pelvis | 5 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.0 | C60 |
| Ureter | 5 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.0 | C61 |
| Bladder | 737 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.1 | C62 |
| Other urinary organs | 3 | 0 | - | - | - | - | - | - | - | 0.3 | 0.4 | - | - | 2.7 | 5.2 | 6.2 | 8.2 | 9.4 | 7.2 | C63 |
| Eye | 46 | 0 | 2.5 | 1.0 | 0.2 | - | - | - | - | 0.1 | 0.3 | 0.2 | 0.6 | 0.5 | 0.2 | 0.6 | 0.5 | 0.9 | 0.4 | C64 |
| Brain, nervous system | 766 | 0 | 0.8 | 0.7 | 0.6 | 0.7 | 0.4 | 0.7 | 1.8 | 7.9 | 2.0 | 3.4 | 7.3 | 3.2 | 3.6 | 5.7 | 4.5 | 7.7 | 17.0 | C65-72 |
| Thyroid | 1896 | 2 | 0.2 | - | 1.0 | 5.5 | 13.8 | 17.2 | 25.0 | 35.9 | 32.2 | 31.7 | 30.1 | 32.2 | 33.1 | 21.3 | 15.9 | 8.8 | 0.1 | C73 |
| Adrenal gland | 1 | 0 | 0.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.1 | C74 |
| Other endocrine | 8 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.1 | C75 |
| Hodgkin disease | 72 | 0 | - | - | 0.2 | 0.9 | 1.2 | 0.8 | 1.3 | 0.4 | 0.4 | 0.1 | 0.3 | 0.2 | 1.7 | 1.9 | 2.5 | 0.6 | 0.6 | C76 |
| Non-Hodgkin lymphoma | 373 | 0 | 0.2 | 0.5 | 0.6 | 1.3 | 0.8 | 0.8 | 1.0 | 2.1 | 1.6 | 4.2 | 5.2 | 7.2 | 11.9 | 15.9 | 13.9 | 3.3 | 2.4 | C77 |
| Immunoproliferative diseases | 5 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.0 | C78 |
| Multiple myeloma | 172 | 1 | - | - | - | - | - | - | - | 0.1 | 0.6 | 0.3 | 1.0 | 2.2 | 3.5 | 5.2 | 10.8 | 13.5 | 1.5 | C79 |
| Lymphoid leukaemia | 71 | 2 | 1.4 | 1.0 | 0.7 | 0.5 | - | - | - | 0.1 | 0.1 | 0.3 | 0.3 | 1.0 | 1.0 | 3.2 | 2.0 | 0.9 | 0.6 | C80 |
| Myeloid leukaemia | 181 | 1 | 0.8 | 0.1 | 0.5 | 0.6 | 0.5 | 0.8 | 0.7 | 1.4 | 2.0 | 1.7 | 2.4 | 2.8 | 4.8 | 5.1 | 6.5 | 4.3 | 1.6 | C81-94 |
| Leukaemia unspecified | 54 | 0 | 1.0 | 0.7 | 0.3 | 0.5 | 0.2 | - | - | 0.3 | 0.7 | 0.4 | 0.7 | 0.6 | 1.6 | 0.8 | 0.9 | 0.5 | 0.3 | C95 |
| Myeloid leukaemia disorders | 26 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.2 | C96 |
| Myelodysplastic syndromes | 23 | 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.2 | C97 |
| Other and unspecified | 913 | 1 | 0.3 | 0.2 | 0.5 | 0.7 | 0.8 | 0.6 | 1.2 | 3.9 | 6.3 | 7.9 | 19.4 | 19.4 | 26.4 | 35.8 | 49.4 | 8.2 | 5.8 | C98-100 |
| All sites | 15936 | 34 | 13.1 | 6.7 | 7.9 | 15.6 | 24.5 | 33.7 | 54.9 | 102.2 | 134.8 | 194.7 | 259.6 | 320.1 | 430.2 | 559.4 | 668.1 | 142.6 | 8.01 | C00-100 |
| All sites but C44 | 15664 | 34 | 13.1 | 6.6 | 7.8 | 15.6 | 24.2 | 33.2 | 54.4 | 100.3 | 133.7 | 192.2 | 256.7 | 315.7 | 425.2 | 550.0 | 649.3 | 140.1 | 8.01 | C00-100 |

Table built Wed Jun 23 09:58:21 IST 2021 by CanReg5.

Reference population: World Standard Population

Table 15: Lip, tongue and mouth cancer incidence data in Sri Lanka, 2018

| Group | Number | % | ASR | Cum. Rate |
|--------|--------|------|------|-----------|
| Male | 2411 | 16.2 | 21.3 | 2.7 |
| Female | 611 | 3.8 | 4.4 | 0.6 |

ASR - Age Standardized Incidence Rate per 100,000 world population

Cum.Rate-Cumulative Rate (0-74 years) per 100 population

| ICD 10 code and site | | Male | Female |
|----------------------|--|-------------|------------|
| C00.0 | External upper lip | 175 | 39 |
| C00.1 | External lower lip | 31 | 11 |
| C00.2 | External lip, unspecified | 3 | 1 |
| C00.3 | Mucosa of upper lip | 0 | 1 |
| C00.4 | Mucosa of lower lip | 6 | 0 |
| C00.6 | Commissure of lip | 24 | 15 |
| C00.8 | Overlapping lesion of lip | 3 | 0 |
| C00.9 | Lip, NOS | 10 | 2 |
| C01.9 | Base of tongue, NOS | 174 | 22 |
| C02.0 | Dorsal surface of tongue | 29 | 4 |
| C02.1 | Border of tongue | 179 | 28 |
| C02.2 | Ventral surface of tongue | 27 | 4 |
| C02.3 | Anterior 2/3 of tongue, | 11 | 3 |
| C02.4 | Lingual tonsil | 2 | 0 |
| C02.8 | Overlapping lesion of tongue | 6 | 1 |
| C02.9 | Tongue, NOS | 367 | 77 |
| C03.0 | Upper gum | 26 | 9 |
| C03.1 | Lower gum | 30 | 9 |
| C03.9 | Gum, NOS | 54 | 23 |
| C04.0 | Anterior floor of mouth | 10 | 1 |
| C04.1 | Lateral floor of mouth | 16 | 5 |
| C04.8 | Overlapping lesion of mouth | 3 | 0 |
| C04.9 | Floor of mouth, NOS | 142 | 26 |
| C05.0 | Hard palate | 14 | 11 |
| C05.1 | Soft palate, NOS | 155 | 13 |
| C05.2 | Uvula | 16 | 2 |
| C05.8 | Overlapping lesion of palate | 4 | 2 |
| C05.9 | Palate, NOS | 76 | 22 |
| C06.0 | Cheek mucosa | 546 | 196 |
| C06.1 | Vestibule of mouth | 34 | 13 |
| C06.2 | Retromolar area | 77 | 15 |
| C06.8 | Overlapping lesion of other/unspecified parts of mouth | 18 | 7 |
| C06.9 | Mouth, NOS | 143 | 49 |
| Total | | 2411 | 611 |

| ICD O Code and histology | | Male | Female |
|--------------------------|------------------------|------|--------|
| 8000 | Neoplasm, malignant | 132 | 39 |
| 8001 | Tumor cells, malignant | 2 | 1 |
| 8010 | Carcinoma, NOS | 21 | 8 |
| 8022 | Pleomorphic carcinoma | 3 | 1 |

Table 15 continued ...

| ICD O Code and histology | | Male | Female |
|--------------------------|--|-------------|------------|
| 8032 | Spindle cell carcinoma, NOS | 4 | 2 |
| 8050 | Papillary carcinoma, NOS | 1 | 1 |
| 8051 | Verrucous carcinoma, NOS | 59 | 11 |
| 8070 | Squamous cell carcinoma, NOS | 1955 | 474 |
| 8071 | Squamous cell carcinoma, keratinizing | 108 | 18 |
| 8072 | Squamous cell carcinoma, large cell, non keratinizing, NOS | 3 | 0 |
| 8073 | Squamous cell carcinoma, small cell, nonkeratinizing | 1 | 0 |
| 8074 | Squamous cell carcinoma, spindle cell | 1 | 2 |
| 8076 | Squamous cell carcinoma, microinvasive | 54 | 11 |
| 8083 | Basaloid squamous cell carcinoma | 17 | 0 |
| 8098 | Adenoid basal carcinoma | 0 | 1 |
| 8140 | Adenocarcinoma, NOS | 8 | 4 |
| 8200 | Adenoid cystic carcinoma | 12 | 11 |
| 8210 | Adenocarcinoma in adenomatous polyp | 1 | 0 |
| 8290 | Oxyphilic adenocarcinoma | 1 | 0 |
| 8430 | Mucoepidermoid carcinoma | 13 | 18 |
| 8490 | Signet ring cell carcinoma | 0 | 1 |
| 8503 | Intraductal papillary adenocarcinoma with invasion | 1 | 0 |
| 8525 | Polymorphous low grade adenocarcinoma | 2 | 1 |
| 8550 | Acinar cell carcinoma | 3 | 3 |
| 8560 | Adenosquamous carcinoma | 1 | 0 |
| 8562 | Epithelial-myoepithelial carcinoma | 3 | 0 |
| 8720 | Malignant melanoma, NOS (except juvenile melanoma) | 0 | 2 |
| 8801 | Spindle cell sarcoma | 1 | 0 |
| 8890 | Leiomyosarcoma, NOS | 0 | 1 |
| 8894 | Angiomyosarcoma | 0 | 1 |
| 8910 | Embryonal rhabdomyosarcoma, NOS | 1 | 0 |
| 8980 | Carcinosarcoma, NOS | 1 | 0 |
| 9120 | Haemangio sarcoma | 1 | 0 |
| 9580 | Granular cell tumor, malignant | 1 | 0 |
| Total | | 2411 | 611 |




Figure 20: Age specific rates of Lip, Tongue & Mouth cancer in Sri Lanka, 2018




Figure 21: Age standardized incidence rates of Lip, Tongue & Mouth cancer in Sri Lanka, 2005 - 2018

Table 16: Pharyngeal cancer incidence data in Sri Lanka, 2018

| Group | Number | % | ASR | Cum. Rate |
|--------|--------|-----|-----|-----------|
| Male | 777 | 5.2 | 6.8 | 0.9 |
| Female | 120 | 0.8 | 0.9 | 0.1 |

ASR - Age Standardized Incidence Rate per 100,000 world population
 Cum.Rate- Cumulative Rate (0-74 years) per 100 population

| ICD 10 code & site | Male | Female |
|--|------------|------------|
| C09.0 Tonsillar fossa | 3 | 1 |
| C09.1 Tonsillar pillar | 4 | 0 |
| C09.9 Tonsil, NOS | 145 | 16 |
| C10.0 Vallecula | 84 | 6 |
| C10.1 Anterior surface of epiglottis | 14 | 2 |
| C10.2 Lateral wall of oropharynx | 10 | 1 |
| C10.3 Posterior wall of oropharynx | 8 | 1 |
| C10.4 Branchial cleft | 0 | 1 |
| C10.8 Overlapping lesion of oropharynx | 1 | 0 |
| C10.9 Oropharynx, NOS | 33 | 3 |
| C11.0 Superior wall of nasopharynx | 1 | 0 |
| C11.1 Posterior wall of nasopharynx | 1 | 4 |
| C11.2 Lateral wall of nasopharynx | 1 | 0 |
| C11.8 Overlapping lesion of nasopharynx | 3 | 1 |
| C11.9 Nasopharynx, NOS | 27 | 7 |
| C12.9 Pyriform sinus | 201 | 27 |
| C13.0 Postcricoid region | 30 | 21 |
| C13.1 Aryepiglottic fold | 43 | 5 |
| C13.2 Posterior wall of hypopharynx | 12 | 1 |
| C13.8 Overlapping lesion of hypopharynx | 0 | 1 |
| C13.9 Laryngopharynx, Hypopharynx NOS | 28 | 6 |
| C14.0 Pharynx, NOS | 103 | 16 |
| C14.8 Overlapping lesion of lip, oral cavity,pharynx | 25 | 0 |
| Total | 777 | 120 |

| ICD O code and histology | Male | Female |
|---|------|--------|
| 8000 Neoplasm, malignant | 46 | 8 |
| 8001 Tumor cells, malignant | 1 | 0 |
| 8004 Malignant tumor, spindle cell type | 2 | 0 |
| 8010 Carcinoma, NOS | 28 | 9 |
| 8050 Papillary carcinoma, NOS | 0 | 1 |
| 8052 Papillary squamous cell carcinoma | 1 | 0 |
| 8070 Squamous cell carcinoma, NOS | 647 | 90 |
| 8071 Squamous cell carcinoma, keratanizing | 25 | 3 |
| 8072 Squamous cell carcinoma, large | 5 | 2 |
| 8076 Squamous cell carcinoma, microinvasive | 11 | 3 |
| 8083 Basaloid squamous cell carcinoma | 6 | 1 |
| 8140 Adenocarcinoma, NOS | 3 | 1 |
| 8200 Adenoid cystic carcinoma | 0 | 1 |

Table 16 continued

| ICD O code and histology | | Male | Female |
|--------------------------|--------------------|------------|------------|
| 8802 | Giant cell sarcoma | 1 | 0 |
| 9370 | Chordoma, NOS | 0 | 1 |
| Total | | 777 | 120 |




Figure 22: Age specific rates of Pharyngeal cancer in Sri Lanka, 2018




Figure 23: Age standardized incidence rates of Pharyngeal cancer in Sri Lanka, 2012 - 2018

Table 17: Oesophageal cancer incidence data in Sri Lanka, 2018

| Group | Number | % | ASR | Cum.Rate |
|--------|--------|-----|------|----------|
| Male | 1136 | 7.6 | 10.1 | 1.3 |
| Female | 815 | 5.1 | 5.9 | 0.8 |

ASR - Age Standardized Incidence Rate per 100,000 world population

Cum.Rate -Cumulative Rate (0-74 years) per 100 population

| ICD 10 code and site | Male | Female |
|--|-------------|------------|
| C15.0 Cervical oesophagus | 4 | 1 |
| C 15.1 Thoracic part of oesophagus | 4 | 3 |
| C 15.2 Abdominal part of oesophagus | 6 | 3 |
| C15.3 Upper third of oesophagus | 26 | 14 |
| C15.4 Middle third of oesophagus | 93 | 64 |
| C15.5 Lower third of oesophagus | 298 | 233 |
| C15.8 Overlapping lesion of oesophagus | 25 | 28 |
| C15.9 Oesophagus, NOS | 680 | 469 |
| Total | 1136 | 815 |

| ICD O Code & histology | Male | Female |
|---|-------------|------------|
| 8000 Neoplasm, malignant | 110 | 71 |
| 8001 Tumor cells, malignant | 6 | 4 |
| 8010 Carcinoma, NOS | 53 | 36 |
| 8014 Large cell carcinoma with rhabdoid phenotype | 1 | 0 |
| 8032 Spindle cell carcinoma, NOS | 1 | 1 |
| 8041 Small cell carcinoma, NOS | 1 | 0 |
| 8070 Squamous cell carcinoma, NOS | 702 | 607 |
| 8071 Squamous cell carcinoma, keratinizing, NOS | 18 | 9 |
| 8072 Squamous cell carcinoma, large | 1 | 1 |
| 8073 Squamous cell carcinoma, small cell, nonkeratinizing | 2 | 0 |
| 8076 Squamous cell carcinoma, microinvasive | 19 | 20 |
| 8082 Lymphoepithelial carcinoma | 1 | 0 |
| 8083 Basaloid squamous cell carcinoma | 3 | 4 |
| 8140 Adenocarcinoma, NOS | 185 | 50 |
| 8144 Adenocarcinoma, intestinal type | 7 | 1 |
| 8145 Carcinoma, diffuse type | 2 | 1 |
| 8246 Neuroendocrine carcinoma, NOS | 2 | 3 |
| 8380 Endometrioid adenocarcinoma, NOS | 0 | 1 |
| 8480 Mucinous adenocarcinoma | 4 | 0 |
| 8481 Mucin-producing adenocarcinoma | 2 | 0 |
| 8490 Signet ring cell carcinoma | 11 | 1 |
| 8500 Infiltrating duct carcinoma, NOS | 0 | 2 |
| 8550 Acinar cell carcinoma | 0 | 1 |
| 8560 Adenosquamous carcinoma | 2 | 2 |
| 8801 Spindle cell sarcoma | 1 | 0 |
| 8900 Rhabdomyosarcoma, NOS | 1 | 0 |
| 8936 Gastrointestinal stromal sarcoma | 1 | 0 |
| Total | 1136 | 815 |




Figure 24: Age specific incidence rates of Oesophageal cancer in Sri Lanka in 2018




Figure 25: Age standardized incidence rates of Oesophageal cancer in Sri Lanka, 2005 - 2018

Table 18: Stomach cancer incidence data in Sri Lanka, 2018

| Group | Number | % | ASR | Cum. Rate |
|--------|--------|-----|-----|-----------|
| Male | 415 | 2.8 | 3.7 | 0.5 |
| Female | 176 | 1.1 | 1.3 | 0.2 |

ASR - Age Standardized Incidence Rate per 100,000 world population

Cum.Rate -Cumulative Rate (0-74 years) per 100 population

| ICD 10 code and site | | Male | Female |
|----------------------|-------------------------------|------------|------------|
| C16.0 | Cardia, NOS | 120 | 50 |
| C16.1 | Fundus of stomach | 11 | 7 |
| C16.2 | Body of stomach | 8 | 1 |
| C16.3 | Gastric antrum | 10 | 7 |
| C16.4 | Pylorus | 25 | 19 |
| C16.5 | Lesser curvature of stomach | 14 | 4 |
| C16.6 | Greater curvature of stomach | 7 | 1 |
| C16.8 | Overlapping lesion of stomach | 15 | 9 |
| C16.9 | Stomach, NOS | 205 | 78 |
| Total | | 415 | 176 |

| ICD O code and histology | | Male | Female |
|--------------------------|--|------------|------------|
| 8000 | Neoplasm, malignant | 58 | 26 |
| 8001 | Tumor cells, malignant | 1 | 2 |
| 8004 | Malignant tumor, spindle cell | 2 | 0 |
| 8010 | Carcinoma, NOS | 32 | 13 |
| 8032 | Spindle cell carcinoma, NOS | 2 | 0 |
| 8070 | Squamous cell carcinoma, NOS | 28 | 26 |
| 8071 | Squamous cell carcinoma, keratanizing | 2 | 0 |
| 8140 | Adenocarcinoma, NOS | 222 | 75 |
| 8144 | Adenocarcinoma, intestinal typ | 15 | 4 |
| 8145 | Carcinoma, diffuse type | 9 | 6 |
| 8211 | Tubular adenocarcinoma | 4 | 0 |
| 8249 | Atypical carcinoid tumor | 1 | 0 |
| 8260 | Papillary adenocarcinoma, NOS | 0 | 1 |
| 8480 | Mucinous adenocarcinoma | 3 | 1 |
| 8490 | Signet ring cell carcinoma | 23 | 12 |
| 8500 | Infiltrating duct carcinoma, NOS | 0 | 1 |
| 8560 | Adenosquamous carcinoma | 0 | 1 |
| 8574 | Adenocarcinoma with neuroendocrine differentiation | 0 | 1 |
| 8800 | Sarcoma, NOS | 1 | 0 |
| 8890 | Leiomyosarcoma, NOS | 1 | 1 |
| 8936 | Gastrointestinal stromal sarcoma | 11 | 6 |
| Total | | 415 | 176 |




Figure 26: Age specific incidence rates of Stomach cancer in Sri Lanka in 2018




Figure 27: Age standardized incidence rates of Stomach cancer in Sri Lanka, 2005 - 2018

Table 19: Colon and rectal cancer incidence data in Sri Lanka, 2018

| Group | Number | % | ASR | Cum.Rate |
|--------|--------|-----|------|----------|
| Male | 1161 | 7.8 | 10.4 | 1.3 |
| Female | 1169 | 7.3 | 8.7 | 1.1 |

ASR - Age Standardized Incidence Rate per 100,000 world population

Cum.Rate-Cumulative Rate (0-74 years) per 100 population

| ICD 10 code & site | Male | Female |
|-----------------------------------|-------------|-------------|
| C18.0 Cecum | 42 | 48 |
| C18.1 Appendix | 22 | 26 |
| C18.2 Ascending colon | 32 | 44 |
| C18.3 Hepatic flexure of colon | 8 | 9 |
| C18.4 Transverse colon | 28 | 31 |
| C18.5 Splenic flexure of colon | 5 | 7 |
| C18.6 Descending colon | 15 | 32 |
| C18.7 Sigmoid colon | 185 | 196 |
| C18.8 Overlapping lesion of colon | 12 | 21 |
| C18.9 Colon, NOS | 181 | 176 |
| C19.9 Rectosigmoid junction | 95 | 91 |
| C20.9 Rectum, NOS | 536 | 488 |
| Total | 1161 | 1169 |

| ICD O code and histology | Male | Female |
|--|------|--------|
| 8000 Neoplasm, malignant | 122 | 102 |
| 8001 Tumor cells, malignant | 1 | 0 |
| 8004 Malignant tumor, spindle cell type | 0 | 1 |
| 8010 Carcinoma, NOS | 25 | 34 |
| 8013 Large cell neuroendocrine carcinoma | 1 | 1 |
| 8032 Spindle cell carcinoma, NOS | 1 | 1 |
| 8070 Squamous cell carcinoma, NOS | 20 | 17 |
| 8071 Squamous cell carcinoma, keratinizing | 0 | 2 |
| 8076 Squamous intraepithelial neoplasia, low grade | 3 | 0 |
| 8083 Basaloid squamous cell carcinoma | 0 | 1 |
| 8140 Adenocarcinoma, NOS | 883 | 898 |
| 8141 Scirrhus adenocarcinoma | 1 | 0 |
| 8144 Adenocarcinoma, intestinal type | 24 | 22 |
| 8210 Adenocarcinoma in adenomatous polyp | 1 | 0 |
| 8211 Tubular adenocarcinoma | 1 | 0 |
| 8240 Carcinoid tumor, NOS | 3 | 4 |
| 8243 Goblet cell carcinoid | 1 | 0 |
| 8244 Mixed adenoneuroendocrine carcinoma | 0 | 1 |
| 8246 Adenocarcinoma with neuroendocrine | 4 | 7 |
| 8249 Atypical carcinoid tumor | 5 | 2 |
| 8260 Papillary adenocarcinoma, NOS | 0 | 1 |
| 8261 Adenocarcinoma in villous adenoma | 1 | 3 |
| 8262 Villous adenocarcinoma | 3 | 4 |

Table 19 continued ...

| ICD O code and histology | | Male | Female |
|--------------------------|--|-------------|-------------|
| 8263 | Adenocarcinoma in tubulovillous adenoma | 6 | 2 |
| 8265 | Micropapillary carcinoma, NOS | 0 | 1 |
| 8470 | Mucinous cystadenocarcinoma, NOS | 0 | 1 |
| 8480 | Mucinous adenocarcinoma | 41 | 45 |
| 8481 | Mucin-producing adenocarcinoma | 1 | 2 |
| 8490 | Signet ring cell carcinoma | 12 | 8 |
| 8574 | Adenocarcinoma with neuroendocrine differentiation | 0 | 1 |
| 8720 | Malignant melanoma, NOS (except juvenile melanoma) | 0 | 1 |
| 8801 | Spindle cell sarcoma | 0 | 1 |
| 8840 | Myxosarcoma | 0 | 1 |
| 8890 | Stromal sarcoma, NOS | 0 | 1 |
| 8936 | Gastrointestinal stromal sarcoma | 1 | 4 |
| Total | | 1161 | 1169 |




Figure 28: Age specific incidence rates of Colon and Rectal cancer in Sri Lanka in 2018




Figure 29: Age standardized incidence rates of Colon and Rectal cancer in Sri Lanka, 2005 – 2018

Table 20: Laryngeal cancer incidence data in Sri Lanka, 2018

| Group | Number | % | ASR | Cum. Rate |
|--------|--------|-----|-----|-----------|
| Male | 712 | 4.9 | 6.3 | 0.8 |
| Female | 81 | 0.5 | 0.6 | 0.1 |

ASR -Age Standardized Incidence Rate per 100,000 world population

Cum.Rate-Cumulative Rate (0-74 years) per 100 population

| ICD 10 code and site | | Male | Female |
|----------------------|------------------------------|------------|-----------|
| C32.0 | Glottis | 382 | 33 |
| C32.1 | Supraglottis | 193 | 25 |
| C32.2 | Subglottis | 13 | 1 |
| C32.3 | Laryngeal cartilage | 13 | 3 |
| C32.8 | Overlapping lesion of larynx | 6 | 0 |
| C32.9 | Larynx, NOS | 105 | 19 |
| Total | | 712 | 81 |

| ICD O code and histology | | Male | Female |
|--------------------------|--|------------|-----------|
| 8000 | Neoplasm, malignant | 67 | 21 |
| 8010 | Carcinoma, NOS | 15 | 1 |
| 8033 | Pseudosarcomatous carcinoma | 1 | 0 |
| 8070 | Squamous cell carcinoma, NOS | 574 | 52 |
| 8071 | Squamous cell carcinoma, keratinizing | 24 | 2 |
| 8074 | Squamous cell carcinoma, spind | 1 | 0 |
| 8076 | Squamous cell carcinoma, microinvasive | 22 | 3 |
| 8084 | Squamous cell carcinoma, clear cell type | 2 | 0 |
| 8123 | Basaloid carcinoma | 0 | 1 |
| 8140 | Adenocarcinoma, NOS | 2 | 0 |
| 8200 | Adenoid cystic carcinoma | 1 | 1 |
| 8560 | Adenosquamous carcinoma | 1 | 0 |
| 8802 | Giant cell sarcoma | 1 | 0 |
| 8982 | Malignant myoepithelioma | 1 | 0 |
| Total | | 712 | 81 |




Figure 30: Age specific incidence rates of Laryngeal cancer in Sri Lanka, 2018




Figure 31: Age standardized incidence rates of Laryngeal cancer in Sri Lanka, 2005 - 2018

Table 21: Trachea, bronchus and lung cancer incidence data in Sri Lanka, 2018

| Group | Number | % | ASR | Cum.Rate |
|--------|--------|-----|------|----------|
| Male | 1303 | 8.9 | 11.7 | 1.6 |
| Female | 456 | 2.9 | 3.4 | 0.4 |

ASR - Age Standardized Incidence Rate per 100,000 world population

Cum.Rate-Cumulative Rate (0-74 years) per 100 population

| ICD 10 code and site | | Male | Female |
|----------------------|----------------------------|-------------|------------|
| C33.9 | Trachea | 10 | 0 |
| C34.0 | Main bronchus | 51 | 12 |
| C34.1 | Upper lobe, lung | 190 | 58 |
| C34.2 | Middle lobe, lung | 37 | 5 |
| C34.3 | Lower lobe, lung | 80 | 52 |
| C34.8 | Overlapping lesion of lung | 47 | 17 |
| C34.9 | Lung, NOS | 888 | 312 |
| Total | | 1303 | 456 |

| ICD O code and histology | | Male | Female |
|--------------------------|--|------|--------|
| 8000 | Neoplasm, malignant | 292 | 117 |
| 8001 | Tumor cells, malignant | 4 | 0 |
| 8004 | Malignant tumor, spindle cell | 1 | 1 |
| 8010 | Carcinoma, NOS | 80 | 27 |
| 8012 | Large cell carcinoma, NOS | 3 | 0 |
| 8013 | Large cell neuroendocrine carcinoma | 1 | 0 |
| 8020 | Carcinoma, undifferentiated, NOS | 0 | 1 |
| 8022 | Pleomorphic carcinoma | 1 | 1 |
| 8032 | Spindle cell carcinoma, NOS | 1 | 0 |
| 8041 | Small cell carcinoma, NOS | 72 | 10 |
| 8043 | Small cell carcinoma, fusiform cell | 2 | 0 |
| 8046 | Non-small cell carcinoma | 298 | 65 |
| 8070 | Squamous cell carcinoma, keratinizing | 184 | 33 |
| 8071 | Squamous cell carcinoma, keratinizing, NOS | 6 | 2 |
| 8072 | Squamous cell carcinoma, large | 7 | 1 |
| 8083 | Basaloid squamous cell carcinoma | 1 | 0 |
| 8140 | Adenocarcinoma, NOS | 285 | 144 |
| 8200 | Adenoid cystic carcinoma | 1 | 1 |
| 8210 | Adenocarcinoma in adenomatous polyp | 1 | 0 |
| 8230 | Solid carcinoma, NOS | 1 | 0 |
| 8240 | Carcinoid tumor, NOS | 13 | 13 |
| 8246 | Neuroendocrine carcinoma, NOS | 3 | 0 |
| 8249 | Atypical carcinoid tumor | 1 | 2 |
| 8250 | Bronchiolo-alveolar adenocarci | 1 | 1 |
| 8251 | Alveolar adenocarcinoma | 1 | 0 |
| 8253 | Bronchiolo-alveolar carcinoma, | 1 | 0 |
| 8260 | Papillary adenocarcinoma, NOS | 5 | 2 |
| 8333 | Fetal adenocarcinoma | 1 | 0 |
| 8430 | Mucoepidermoid carcinoma | 0 | 4 |
| 8470 | Mucinous cystadenocarcinoma, NOS | 0 | 1 |

Table 21 continued ..

| ICD O code and histology | | Male | Female |
|--------------------------|--------------------------------|-------------|------------|
| 8480 | Mucinous adenocarcinoma | 14 | 17 |
| 8481 | Mucin-producing adenocarcinoma | 2 | 0 |
| 8550 | Acinar cell carcinoma | 15 | 9 |
| 8551 | Acinar cell cystadenocarcinoma | 1 | 0 |
| 8560 | Adeno squamous carcinoma | 4 | 1 |
| 8800 | Sarcoma, NOS | 0 | 1 |
| 8801 | Spindle cell sarcoma | 0 | 1 |
| 9071 | Yolk sac tumor | 0 | 1 |
| Total | | 1303 | 456 |




Figure 32: Age specific incidence rates of Trachea, Bronchus and Lung cancer in Sri Lanka, 2018




Figure 33: Age standardized incidence rates of Trachea, Bronchus and Lung cancer in Sri Lanka, 2005 - 2018

Table 22: Skin cancer incidence data in Sri Lanka, 2018

| Group | Number | % | ASR | Cum. Rate |
|--------|--------|-----|-----|-----------|
| Male | 384 | 2.6 | 3.4 | 0.4 |
| Female | 310 | 1.9 | 2.3 | 0.3 |

ASR - Age Standardized Incidence Rate per 100,000 world population

Cum.Rate-Cumulative Rate (0-74 years) per 100 population

| ICD 10 code and site | | Male | Female |
|----------------------|---|------------|------------|
| C43.0 | Malignant melanoma of lip | 1 | 0 |
| C43.1 | Malignant melanoma of eyelid, including canthus | 0 | 1 |
| C43.3 | Malignant melanoma of other and unspecified parts of face | 2 | 1 |
| C43.4 | Malignant melanoma of scalp and neck | 1 | 3 |
| C43.6 | Malignant melanoma of upper limb including shoulder | 3 | 1 |
| C43.7 | Malignant melanoma of lower limb including hip | 19 | 26 |
| C43.8 | Overlapping malignant melanoma of skin | 1 | 0 |
| C43.9 | Malignant melanoma of skin, unspecified | 11 | 6 |
| C44.0 | Skin of lip, NOS | 3 | 1 |
| C44.1 | Eyelid | 11 | 16 |
| C44.2 | External ear | 10 | 19 |
| C44.3 | Skin, other & unspec parts of face | 53 | 45 |
| C44.4 | Skin of scalp and neck | 44 | 45 |
| C44.5 | Skin of trunk | 47 | 28 |
| C44.6 | Skin of upper limb and shoulder | 15 | 14 |
| C44.7 | Skin of lower limb and hip | 108 | 53 |
| C44.8 | Overlapping lesion of skin | 1 | 1 |
| C44.9 | Skin, NOS | 54 | 50 |
| Total | | 384 | 310 |

| ICD O code and histology | | Male | Female |
|--------------------------|---|------|--------|
| 8000 | Neoplasm, malignant | 9 | 11 |
| 8001 | Tumor cells, malignant | 1 | 0 |
| 8004 | Malignant tumor, spindle cell | 0 | 2 |
| 8010 | Carcinoma, NOS | 6 | 9 |
| 8022 | Pleomorphic carcinoma | 1 | 0 |
| 8032 | Spindle cell carcinoma, NOS | 7 | 6 |
| 8051 | Verrucous carcinoma, NOS | 7 | 1 |
| 8052 | Papillary squamous cell carcinoma | 0 | 1 |
| 8070 | Squamous cell carcinoma, NOS | 215 | 107 |
| 8071 | Squamous cell carcinoma, keratinizing | 9 | 0 |
| 8072 | Squamous cell carcinoma, large cell, nonkeratinizing, NOS | 1 | 0 |
| 8074 | Squamous cell carcinoma, spindle cell | 1 | 2 |
| 8076 | Squamous cell carcinoma, microinvasive | 2 | 2 |
| 8083 | Basaloid squamous cell carcinoma | 2 | 1 |
| 8090 | Basal cell carcinoma, NOS | 40 | 73 |
| 8091 | Multifocal superficial basal cell carcinoma | 1 | 0 |
| 8092 | Infiltrating basal cell carcinoma, NOS | 2 | 1 |
| 8093 | Basal cell carcinoma, fibroepithelial | 0 | 1 |
| 8094 | Basosquamous carcinoma | 4 | 1 |

Table 22 continued ...

| ICD O code and histology | | Male | Female |
|--------------------------|---|------------|------------|
| 8097 | Basal cell carcinoma, nodular | 6 | 20 |
| 8102 | Trichilemmocarcinoma | 1 | 0 |
| 8140 | Adenocarcinoma, NOS | 16 | 4 |
| 8200 | Adenoid cystic carcinoma | 0 | 1 |
| 8246 | Neuroendocrine carcinoma, NOS | 0 | 1 |
| 8247 | Merkel cell carcinoma | 0 | 1 |
| 8320 | Granular cell carcinoma | 0 | 2 |
| 8330 | Follicular adenoma | 1 | 0 |
| 8390 | Skin appendage carcinoma | 2 | 0 |
| 8401 | Apocrine adenocarcinoma | 1 | 0 |
| 8409 | Eccrine poroma, malignant | 0 | 1 |
| 8410 | Sebaceous adenocarcinoma | 6 | 12 |
| 8430 | Mucoepidermoid carcinoma | 0 | 2 |
| 8480 | Mucinous adenocarcinoma | 3 | 2 |
| 8500 | Infiltrating duct carcinoma, NOS | 0 | 2 |
| 8720 | Malignant melanoma, NOS (except) | 31 | 32 |
| 8721 | Nodular melanoma | 2 | 2 |
| 8730 | Amelanotic melanoma | 2 | 1 |
| 8742 | Lentigo maligna melanoma | 0 | 1 |
| 8744 | Acral lentiginous melanoma, malignant | 0 | 2 |
| 8745 | Desmoplastic melanoma, malignant | 1 | 0 |
| 8761 | Malignant melanoma in giant pigmented nevus | 1 | 0 |
| 8772 | Spindle cell melanoma, NOS | 1 | 0 |
| 8832 | Dermatofibrosarcoma, Nos | 2 | 5 |
| 9080 | Teratoma, malignant, NOS | 0 | 1 |
| Total | | 384 | 310 |




Figure 34: Age specific incidence rates of Skin cancer in Sri Lanka in 2018




Figure 35: Age standardized incidence rates of Skin cancer in Sri Lanka, 2005 - 2018

Table 23: Breast cancer incidence data in Sri Lanka, 2018

| Group | Number | % | ASR | Cum. Rate |
|--------|--------|------|------|-----------|
| Male | 136 | 0.9 | 1.2 | 0.1 |
| Female | 3778 | 24.1 | 28.7 | 3.4 |

ASR - Age Standardized Incidence Rate per 100,000 world population

Cum.Rate-Cumulative Rate (0-74 years) per 100 population

| ICD 10 code and site | Male | Female |
|--------------------------------------|------------|-------------|
| C50.0 Nipple | 2 | 15 |
| C50.1 Central portion of breast | 3 | 45 |
| C50.2 Upper-inner quadrant of breast | 4 | 51 |
| C50.3 Lower-inner quadrant of breast | 0 | 36 |
| C50.4 Upper-outer quadrant of breast | 4 | 167 |
| C50.5 Lower-outer quadrant of breast | 2 | 39 |
| C50.6 Axillary tail of breast | 0 | 6 |
| C50.8 Overlapping lesion of breast | 7 | 173 |
| C50.9 Breast, NOS | 114 | 3246 |
| Total | 136 | 3778 |

| ICD O code and histology | Male | Female |
|---|------|--------|
| 8000 Neoplasm, malignant | 17 | 431 |
| 8001 Tumor cells, malignant | 1 | 22 |
| 8003 Malignant tumor, giant cell type | 0 | 1 |
| 8004 Malignant tumor, spindle cell | 0 | 1 |
| 8010 Carcinoma, NOS | 28 | 552 |
| 8020 Carcinoma, undifferentiated, NOS | 0 | 3 |
| 8021 Carcinoma, anaplastic, NOS | 0 | 1 |
| 8022 Pleomorphic carcinoma | 0 | 1 |
| 8032 Spindle cell carcinoma, NOS | 0 | 2 |
| 8046 Non-small cell carcinoma | 0 | 1 |
| 8050 Papillary carcinoma, NOS | 1 | 27 |
| 8070 Squamous cell carcinoma, NOS | 4 | 6 |
| 8076 Squamous cell carcinoma, microinvasive | 0 | 1 |
| 8140 Adenocarcinoma, NOS | 1 | 87 |
| 8200 Adenoid cystic carcinoma | 1 | 1 |
| 8201 Cribriform carcinoma, NOS | 2 | 7 |
| 8211 Tubular adenocarcinoma | 2 | 4 |
| 8230 Solid carcinoma, NOS | 0 | 1 |
| 8246 Neuroendocrine carcinoma, NOS | 0 | 1 |
| 8260 Papillary adenocarcinoma, NOS | 1 | 4 |
| 8265 Micropapillary carcinoma, NOS | 0 | 1 |
| 8440 Cystadenocarcinoma, NOS | 0 | 1 |
| 8471 Papillary mucinous cystadenocarcinoma | 0 | 1 |
| 8480 Mucinous adenocarcinoma | 2 | 64 |
| 8500 Infiltrating duct carcinoma, NOS | 62 | 2081 |
| 8501 Comedocarcinoma, NOS | 0 | 1 |
| 8503 Intraductal papillary adenocarcinoma | 5 | 116 |

Table 23 continued ...

| ICD O code and histology | | Male | Female |
|--------------------------|--|------------|-------------|
| 8504 | Intracystic carcinoma, NOS | 0 | 5 |
| 8510 | Medullary carcinoma, NOS | 0 | 25 |
| 8514 | Duct carcinoma, desmoplastic type | 1 | 8 |
| 8520 | Lobular carcinoma, NOS | 5 | 118 |
| 8521 | Infiltrating ductular carcinoma | 0 | 120 |
| 8522 | Infiltrating duct and lobular | 0 | 23 |
| 8523 | Infiltrating duct mixed with other types of carcinoma | 0 | 6 |
| 8524 | Infiltrating lobular mixed with other types of carcinoma | 0 | 5 |
| 8525 | Polymorphous low grade adenocarcinoma | 0 | 1 |
| 8540 | Paget disease, mammary | 1 | 6 |
| 8541 | Paget disease and infiltrating | 0 | 6 |
| 8543 | Paget disease and intraductal carcinoma of breast | 0 | 2 |
| 8550 | Acinar cell carcinoma | 1 | 0 |
| 8560 | Adenosquamous carcinoma | 0 | 1 |
| 8575 | Metaplastic carcinoma, NOS | 1 | 10 |
| 8800 | Sarcoma, NOS | 0 | 2 |
| 8890 | Leiomyosarcoma, NOS | 0 | 1 |
| 8900 | Rhabdomyosarcoma, NOS | 0 | 2 |
| 8940 | Mixed tumor, malignant, NOS | 0 | 2 |
| 9010 | Fibroadenoma, NOS | 0 | 1 |
| 9020 | Phyllodes tumor, malignant | 0 | 14 |
| 9120 | Haemangiosarcoma | 0 | 1 |
| Total | | 136 | 3778 |




Figure 36: Age specific incidence rates of Breast cancer in Sri Lanka in 2018




Figure 37: Age standardized incidence rates of Breast cancer in Sri Lanka, 2005 - 2018

Table 24: Cervix Uteri cancer incidence data in Sri Lanka, 2018

| Group | Number | % | ASR | Cum. Rate |
|--------|--------|-----|-----|-----------|
| Female | 1073 | 6.9 | 8.0 | 1.0 |

ASR - Age Standardized Incidence Rate per 100,000 world population

Cum.Rate-Cumulative Rate (0-74 years) per 100 population

| ICD 10 code and side | No. |
|------------------------------------|-------------|
| C53.0 Endocervix | 30 |
| C53.1 Exocervix | 52 |
| C53.8 Overlapping lesion of cervix | 43 |
| C53.9 Cervix uteri | 948 |
| Total | 1073 |

| ICD O Code and histology | No. |
|---|-------------|
| 8000 Neoplasm, malignant | 116 |
| 8001 Tumor cells, malignant | 1 |
| 8003 Malignant tumor, glant cell type | 1 |
| 8010 Carcinoma, NOS | 46 |
| 8032 Spindle cell carcinoma, NOS | 3 |
| 8046 Non-small cell carcinoma | 1 |
| 8052 Papillary squamous cell carcinoma | 5 |
| 8070 Squamous cell carcinoma, NOS | 434 |
| 8071 Squamous cell carcinoma, keratanizing | 137 |
| 8072 Squamous cell carcinoma, large | 179 |
| 8073 Squamous cell carcinoma, small cell, nonkeratinizing | 24 |
| 8076 Squamous cell carcinoma, microinvasive | 30 |
| 8077 Squamous intraepithelial neoplasia, high grade | 2 |
| 8083 Basaloid squamous cell carcinoma | 4 |
| 8140 Adenocarcinoma, NOS | 58 |
| 8246 Neuroendocrine carcinoma, NOS | 1 |
| 8260 Papillary adenocarcinoma, NOS | 3 |
| 8262 Villous adenocarcinoma | 1 |
| 8310 Clear cell adenocarcinoma, NOS | 3 |
| 8380 Endometrioid adenocarcinoma, N | 7 |
| 8384 Adenocarcinoma, endocervical type | 3 |
| 8441 Serous cystadenocarcinoma, NOS | 1 |
| 8470 Mucinous cystadenocarcinoma, NOS | 1 |
| 8480 Mucinous adenocarcinoma | 4 |
| 8560 Adenosquamous carcinoma | 5 |
| 8933 Adenosarcoma | 3 |
| Total | 1073 |




Figure 38: Age specific incidence rates of Cervical cancer in Sri Lanka in 2018




Figure 39: Age standardized incidence rates of Cervical cancer in Sri Lanka, 2005 - 2018

Table 25: Uterine cancer incidence data in Sri Lanka, 2018

| Group | Number | % | ASR | Cum. Rate |
|--------|--------|-----|-----|-----------|
| Female | 1020 | 6.4 | 7.6 | 1.0 |

ASR - Age Standardized Incidence Rate per 100,000 world population
 Cum.Rate-Cumulative Rate (0-74 years) per 100 population

| ICD O code and site | No. |
|--|-------------|
| C54.0 Isthmus uteri | 4 |
| C54.1 Endometrium | 518 |
| C54.2 Myometrium | 5 |
| C54.3 Fundus uteri | 3 |
| C54.8 Overlapping lesion of corpus | 1 |
| C54.9 Corpus uteri | 14 |
| C55.0 Malignant neoplasm of uterus, part unspecified | 475 |
| Total | 1020 |

| ICD O code and histology | No. |
|---|-----|
| 8000 Neoplasm, malignant | 62 |
| 8004 Malignant tumor, spindle cell | 1 |
| 8010 Carcinoma, NOS | 44 |
| 8020 Carcinoma, undifferentiated, NOS | 1 |
| 8032 Spindle cell carcinoma, NOS | 1 |
| 8050 Papillary carcinoma, NOS | 1 |
| 8070 Squamous cell carcinoma, NOS | 33 |
| 8071 Squamous cell carcinoma, kerat | 6 |
| 8072 Squamous cell carcinoma, large | 12 |
| 8076 Squamous cell carcinoma, microinvasive | 2 |
| 8140 Adenocarcinoma, NOS | 160 |
| 8141 Scirrhous adenocarcinoma | 5 |
| 8144 Adenocarcinoma, intestinal type | 1 |
| 8260 Papillary adenocarcinoma, NOS | 8 |
| 8262 Villous adenocarcinoma | 1 |
| 8310 Clear cell adenocarcinoma, NOS | 13 |
| 8380 Endometrioid adenocarcinoma, NOS | 568 |
| 8441 Serous cystadenocarcinoma, NOS | 11 |
| 8460 Papillary serous cystadenocarcinoma | 5 |
| 8461 Serous surface papillary carcinoma | 2 |
| 8480 Mucinous adenocarcinoma | 1 |
| 8490 Signet ring cell carcinoma | 1 |
| 8560 Adenosquamous carcinoma | 1 |
| 8562 Epithelial-myoepithelial carcinoma | 1 |
| 8800 Sarcoma, NOS | 3 |
| 8806 Desmoplastic small round cell tumor | 1 |
| 8850 Liposarcoma, NOS | 1 |
| 8890 Leiomyosarcoma, NOS | 13 |
| 8896 Myxoid leiomyosarcoma | 2 |

Table 25 continued ...

| ICD O code and histology | | No. |
|--------------------------|--|-------------|
| 8930 | Endometrial stromal sarcoma, NOS | 19 |
| 8931 | Endometrial stromal sarcoma, low grade | 5 |
| 8933 | Adenosarcoma | 1 |
| 8935 | Stromal sarcoma, NOS | 4 |
| 8950 | Mullerian mixed tumor | 6 |
| 8980 | Carcinosarcoma, NOS | 21 |
| 8990 | Mesenchymoma, malignant | 1 |
| 9100 | Choriocarcinoma, NOS | 1 |
| 9120 | Haemangiosarcoma | 1 |
| Total | | 1020 |




Figure 40: Age specific incidence rates of Uterine cancer in Sri Lanka in 2018




Figure 41: Age standardized incidence rates of Uterine cancer in Sri Lanka, 2005 - 2018

Table 26: Ovary cancer incidence data in Sri Lanka, 2018

| Group | Number | % | ASR | Cum. Rate |
|--------|--------|-----|-----|-----------|
| Female | 938 | 6.0 | 7.2 | 0.8 |

ASR - Age Standardized Incidence Rate per 100,000 world population
 Cum.Rate-Cumulative Rate (0-74 years) per 100 population

| ICD 10 code and site | No. |
|----------------------|------------|
| C56.9 Ovary | 938 |
| Total | 938 |

| ICD O code and histology | No. |
|--|-----|
| 8000 Neoplasm, malignant | 121 |
| 8001 Tumor cells, malignant | 7 |
| 8005 Malignant tumor, clear cell type | 1 |
| 8010 Carcinoma, NOS | 44 |
| 8021 Carcinoma, anaplastic, NOS | 1 |
| 8050 Papillary carcinoma, NOS | 3 |
| 8070 Squamous cell carcinoma, NOS | 8 |
| 8072 Squamous cell carcinoma, large cell, nonkeratinizing, NOS | 1 |
| 8120 Transitional cell carcinoma, NOS | 1 |
| 8140 Adenocarcinoma, NOS | 84 |
| 8144 Adenocarcinoma, intestinal type | 1 |
| 8240 Carcinoid tumor, NOS | 1 |
| 8260 Papillary adenocarcinoma, NOS | 22 |
| 8310 Clear cell adenocarcinoma, NOS | 35 |
| 8320 Granular cell carcinoma | 1 |
| 8380 Endometrioid adenocarcinoma, NOS | 72 |
| 8440 Cystadenocarcinoma, NOS | 3 |
| 8441 Serous cystadenocarcinoma, NOS | 202 |
| 8442 Serous cystadenoma, borderline malignancy | 2 |
| 8450 Papillary cystadenocarcinoma, | 1 |
| 8460 Papillary serous cystadenocarcinoma | 125 |
| 8461 Serous surface papillary carcinoma | 10 |
| 8470 Mucinous cystadenocarcinoma, NOS | 55 |
| 8471 Papillary mucinous cystadenocarcinoma | 8 |
| 8472 Mucinous cystic tumor of borderline malignancy | 2 |
| 8480 Mucinous adenocarcinoma | 36 |
| 8481 Mucin-producing adenocarcinoma | 1 |
| 8482 Mucinous adenocarcinoma, endocervical type | 1 |
| 8490 Signet ring cell carcinoma | 1 |
| 8590 Sex cord-gonadal stromal tumor, NOS | 1 |
| 8620 Granulosa cell tumor, malignant | 26 |
| 8621 Granulosa cell-theca cell tumor | 1 |
| 8631 Sertoli-Leydig cell tumor, poorly differentiated | 2 |
| 8640 Sertoli cell carcinoma | 1 |
| 8810 Fibrosarcoma, NOS | 1 |

Table 26 continued ...

| ICD O code and histology | | No. |
|--------------------------|--|------------|
| 8890 | Leiomyosarcoma, NOS | 2 |
| 8950 | Mullerian mixed tumor | 3 |
| 8951 | Mesodermal mixed tumor | 1 |
| 8980 | Carcinosarcoma, NOS | 4 |
| 9000 | Brenner tumor, malignant | 3 |
| 9014 | Serous adenocarcinofibroma | 1 |
| 9060 | Dysgerminoma | 7 |
| 9064 | Germinoma | 3 |
| 9071 | Yolk sac tumor | 7 |
| 9080 | Teratoma, malignant, NOS | 13 |
| 9084 | Teratoma with malignant transformation | 1 |
| 9085 | Mixed germ cell tumor | 7 |
| 9090 | Struma ovarii, malignant | 2 |
| 9100 | Choriocarcinoma, NOS | 1 |
| 9101 | Choriocarcinoma combined with other germ cell elements | 1 |
| Total | | 938 |




Figure 42: Age specific incidence rates of Ovarian cancer in Sri Lanka in 2018




Figure 43: Age standardized incidence rates of Ovarian cancer in Sri Lanka, 2005 - 2018

Table 27: Prostate cancer incidence data in Sri Lanka, 2018

| Group | Number | % | ASR | Cum. Rate |
|-------|--------|-----|------|-----------|
| Male | 1112 | 7.6 | 10.3 | 1.3 |

ASR - Age Standardized Incidence Rate per 100,000 world population
 Cum.Rate-Cumulative Rate (0-74 years) per 100 population

| ICD 10 code and histology | | No. |
|---------------------------|----------------|-------------|
| C61.9 | Prostate gland | 1112 |
| Total | | 1112 |

| ICD O code and histology | | No. |
|--------------------------|--|-------------|
| 8000 | Neoplasm, malignant | 177 |
| 8001 | Tumor cells, malignant | 1 |
| 8010 | Carcinoma, NOS | 34 |
| 8050 | Papillary carcinoma, NOS | 2 |
| 8070 | Squamous cell carcinoma, NOS | 4 |
| 8076 | Squamous cell carcinoma, microinvasive | 1 |
| 8098 | Adenoid basal carcinoma | 1 |
| 8120 | Transitional cell carcinoma | 11 |
| 8130 | Papillary transitional cell carcinoma | 3 |
| 8140 | Adenocarcinoma, NOS | 525 |
| 8430 | Mucoepidermoid carcinoma | 1 |
| 8480 | Mucinous adenocarcinoma | 1 |
| 8500 | Infiltrating duct carcinoma, NOS | 2 |
| 8550 | Acinar cell carcinoma | 323 |
| 8551 | Acinar cell cystadenocarcinoma | 23 |
| 8562 | Epithelial-myoeithelial carcinoma | 1 |
| 8900 | Rhabdomyosarcoma, NOS | 1 |
| 8910 | Embryonal rhabdomyosarcoma, NOS | 1 |
| Total | | 1112 |




Figure 44: Age specific incidence rates of Prostate cancer in Sri Lanka in 2018




Figure 45: Age standardized incidence rates of Prostate cancer in Sri Lanka, 2005 - 2018

Table 28: Urinary bladder cancer incidence data in Sri Lanka, 2018

| Group | Number | % | ASR | Cum. Rate |
|--------|--------|-----|-----|-----------|
| Male | 573 | 3.9 | 5.2 | 0.7 |
| Female | 137 | 0.9 | 1.0 | 0.1 |

ASR - Age Standardized Incidence Rate per 100,000 world population

Cum.Rate-Cumulative Rate (0-74 years) per 100 population

| ICD 10 code and site | | Male | Female |
|----------------------|-------------------------------|------------|------------|
| C67.0 | Trigone of bladder | 1 | 0 |
| C67.1 | Dome of bladder | 1 | 0 |
| C67.2 | Lateral wall of urinary | 6 | 2 |
| C67.3 | Anterior wall of urinary | 2 | 1 |
| C67.4 | Posterior wall of urinar | 1 | 0 |
| C67.5 | Bladder neck | 3 | 0 |
| C67.6 | Ureteric orifice | 1 | 1 |
| C67.7 | Urachus | 1 | 0 |
| C67.8 | Overlapping lesion of bladder | 9 | 1 |
| C67.9 | Urinary bladder, NOS | 548 | 132 |
| Total | | 573 | 137 |

| ICD O code and histology | | Male | Female |
|--------------------------|---|------------|------------|
| 8000 | Neoplasm, malignant | 61 | 10 |
| 8001 | Tumor cells, malignant | 3 | 0 |
| 8010 | Carcinoma, NOS | 14 | 7 |
| 8050 | Papillary carcinoma, NOS | 10 | 5 |
| 8052 | Papillary squamous cell carcinoma | 1 | 0 |
| 8070 | Squamous cell carcinoma, NOS | 7 | 2 |
| 8120 | Transitional cell carcinoma, NOS | 255 | 67 |
| 8122 | Transitional cell carcinoma, spindle cell | 1 | 1 |
| 8130 | Papillary transitional cell carcinoma | 204 | 37 |
| 8131 | Transitional cell carcinoma, micropapillary | 1 | 0 |
| 8140 | Adenocarcinoma, NOS | 11 | 6 |
| 8260 | Papillary adenocarcinoma, NOS | 1 | 0 |
| 8480 | Mucinous adenocarcinoma | 3 | 1 |
| 8500 | Intraductal carcinoma, noninfiltrating, NOS | 0 | 1 |
| 8805 | Undifferentiated sarcoma | 1 | 0 |
| Total | | 573 | 137 |




Figure 46: Age specific incidence rates of Urinary Bladder cancer in Sri Lanka in 2018




Figure 47: Age standardized incidence rates of Urinary Bladder cancer in Sri Lanka, 2005 - 2018

Table 29: Thyroid gland cancer incidence data in Sri Lanka, 2018

| Group | Number | % | ASR | Cum. Rate |
|--------|--------|------|------|-----------|
| Male | 415 | 2.8 | 3.6 | 0.4 |
| Female | 1896 | 12.1 | 15.0 | 1.4 |

ASR -Age Standardized Incidence Rate per 100,000 world population

Cum.Rate-Cumulative Rate (0-74 years) per 100 population

| ICD 10 code and site | | Male | Female |
|----------------------|---------------|------------|-------------|
| C73.9 | Thyroid gland | 415 | 1896 |
| Total | | 415 | 1896 |

| ICD 0 code and histology | | Male | Female |
|--------------------------|--|------------|-------------|
| 8000 | Neoplasm, malignant | 15 | 35 |
| 8001 | Tumor cells, malignant | 1 | 1 |
| 8010 | Carcinoma, NOS | 17 | 15 |
| 8021 | Carcinoma, anaplastic, NOS | 13 | 24 |
| 8050 | Papillary carcinoma, NOS | 19 | 110 |
| 8052 | Papillary squamous cell carcinoma | 1 | 0 |
| 8070 | Squamous cell carcinoma, NOS | 4 | 2 |
| 8140 | Adenocarcinoma, NOS | 0 | 4 |
| 8200 | Adenoid cystic carcinoma | 0 | 1 |
| 8260 | Papillary adenocarcinoma, NOS | 200 | 767 |
| 8265 | Micropapillary carcinoma, NOS | 0 | 1 |
| 8290 | Oxyphilic adenocarcinoma | 8 | 24 |
| 8330 | Follicular adenocarcinoma, NOS | 35 | 229 |
| 8331 | Follicular adenocarcinoma, well differentiated | 1 | 4 |
| 8332 | Follicular adenocarcinoma, trabecular | 0 | 1 |
| 8335 | Follicular carcinoma, minimally invasive | 16 | 146 |
| 8337 | Insular carcinoma | 1 | 0 |
| 8340 | Papillary carcinoma, follicular variant | 38 | 171 |
| 8341 | Papillary microcarcinoma | 37 | 330 |
| 8343 | Papillary carcinoma, capsula | 1 | 7 |
| 8344 | Papillary carcinoma, columnar | 0 | 2 |
| 8350 | Nonencapsulated sclerosing carcinoma | 1 | 1 |
| 8500 | Intraductal carcinoma, noninfiltrating, NOS | 0 | 1 |
| 8510 | Medullary carcinoma, NOS | 6 | 16 |
| 8550 | Acinar cell carcinoma | 0 | 1 |
| 8680 | Paraganglioma, malignant | 0 | 1 |
| 8800 | Sarcoma, NOS | 0 | 1 |
| 9080 | Teratoma, malignant, NOS | 1 | 1 |
| Total | | 415 | 1896 |



Figure 48: Age specific incidence rates of Thyroid gland cancer in Sri Lanka in 2018




Figure 49: Age standardized incidence rates of Thyroid gland cancer in Sri Lanka, 2005 - 2018

Table 30: Lymphoma incidence data in Sri Lanka, 2018

| Group | Number | % | ASR | Cum. rate |
|--------|--------|-----|-----|-----------|
| Male | 551 | 3.7 | 5.0 | 0.5 |
| Female | 447 | 2.8 | 3.5 | 0.4 |

ASR - Age Standardized Incidence Rate per 100,000 world population

Cum.Rate-Cumulative Rate (0-74 years) per 100 population

| ICD 10 code and site | | Male | Female |
|----------------------|--|------------|------------|
| C81.0 | Nodular lymphocyte predominant Hodgkin lymphoma | 2 | 3 |
| C81.1 | Nodular sclerosis (classical) Hodgkin lymphoma | 28 | 21 |
| C81.2 | Mixed cellularity (classical) Hodgkin lymphoma | 21 | 8 |
| C81.3 | Lymphocyte depleted (classical) Hodgkin lymphoma | 0 | 1 |
| C81.4 | Lymphocyte-rich(classical) Hodgkin lymphoma | 1 | 1 |
| C81.9 | Hodgkin lymphoma, unspecified | 53 | 38 |
| C82.0 | Follicular lymphoma grade I | 9 | 8 |
| C82.1 | Follicular lymphoma grade II | 8 | 4 |
| C82.2 | Follicular lymphoma grade III, unspecified | 2 | 3 |
| C82.9 | Follicular lymphoma, NOS | 28 | 15 |
| C83.0 | Small cell B-cell lymphoma | 15 | 9 |
| C83.1 | Mantle cell lymphoma | 10 | 6 |
| C83.3 | Diffuse large B-cell lymphoma | 44 | 50 |
| C83.5 | Lymphoblastic (diffuse) lymphoma | 9 | 11 |
| C83.7 | Burkitt lymphoma, NOS | 3 | 1 |
| C84.0 | Mycosis fungoides | 19 | 12 |
| C84.1 | Sezary disease | 0 | 1 |
| C84.4 | Peripheral T-cell lymphoma, not elsewhere classified | 2 | 5 |
| C84.6 | Anaplastic large cell lymphoma | 1 | 3 |
| C84.8 | Cutaneous T-cell lymphoma, NOS | 1 | 0 |
| C85.7 | Other specified types of non- Hodgkin lymphoma | 3 | 10 |
| C85.9 | Non-Hodgkin lymphoma, unspecified | 289 | 235 |
| C96.6 | Unifocal Langerhans-cell histiocytosis | 3 | 2 |
| Total | | 551 | 447 |

| ICD O code & histology | | Male | Female |
|------------------------|---|------|--------|
| 9590 | Malignant lymphoma, NOS | 50 | 37 |
| 9591 | Malignant lymphoma, non-Hodgkin | 237 | 196 |
| 9596 | Composite Hodgkin and non-Hodgkin lymphoma | 3 | 10 |
| 9650 | Hodgkin lymphoma, NOS | 53 | 38 |
| 9651 | Hodgkin lymphoma, lymphocyte-rich | 1 | 1 |
| 9652 | Hodgkin lymphoma, mixed cellular | 21 | 8 |
| 9653 | Hodgkin lymphoma, lymphocyte depletion, NOS | 0 | 1 |
| 9659 | Hodgkin lymphoma, nodular lymphocyte predominance | 2 | 3 |
| 9663 | Hodgkin lymphoma, nodular sclerosis | 24 | 20 |
| 9665 | Hodgkin lymphoma, nodular sclerosis, grade 1 | 2 | 0 |
| 9667 | Hodgkin lymphoma, nodular sclerosis, grade 2 | 2 | 1 |

Table 30 continued ...

| ICD O code & histology | | Male | Female |
|------------------------|---|------------|------------|
| 9670 | Malignant lymphoma, small B lymphocytic | 9 | 4 |
| 9671 | Malignant lymphoma, lymphoplasmacytic | 5 | 4 |
| 9673 | Mantle cell lymphoma | 10 | 6 |
| 9680 | Malignant lymphoma, large B-cell | 43 | 49 |
| 9684 | Malignant lymphoma, large B-cell, diffuse, immunoblastic, NOS | 1 | 1 |
| 9687 | Burkitt lymphoma, NOS | 3 | 1 |
| 9689 | Splenic marginal zone B-cell lymphoma | 1 | 1 |
| 9690 | Follicular lymphoma, NOS | 28 | 15 |
| 9691 | Follicular lymphoma, grade 2 | 8 | 4 |
| 9695 | Follicular lymphoma, grade 1 | 9 | 8 |
| 9698 | Follicular lymphoma, grade 3 | 2 | 3 |
| 9700 | Mycosis fungoides | 19 | 12 |
| 9701 | Sezary syndrome | 0 | 1 |
| 9702 | Mature T-cell lymphoma, NOS | 2 | 5 |
| 9705 | Angioimmunoblastic T-cell lymphoma | 1 | 1 |
| 9709 | Cutaneous T-cell lymphoma, NOS | 1 | 0 |
| 9714 | Anaplastic large cell lymphoma, T cell and Null cell type | 1 | 3 |
| 9718 | Primary cutaneous CD30+ T-cell lymphoproliferative disorder | 1 | 1 |
| 9727 | Precursor cell lymphoblastic lymphoma NOS | 2 | 1 |
| 9728 | Precursor B-cell lymphoblastic lymphoma | 1 | 2 |
| 9729 | Precursor T-cell lymphoblastic lymphoma | 6 | 8 |
| 9754 | Langerhans cell histiocytosis, disseminated | 3 | 2 |
| Total | | 551 | 447 |




Figure 50: Age specific incidence rates of Lymphoma in Sri Lanka in 2018



Figure 51: Age standardized incidence rates of Lymphoma in Sri Lanka, 2011 - 2018

Table 31: Leukemia incidence data in Sri Lanka, 2018

| Group | Number | % | ASR | Cum. Rate |
|--------|--------|-----|-----|-----------|
| Male | 339 | 2.3 | 3.2 | 0.3 |
| Female | 306 | 1.9 | 2.6 | 0.2 |

ASR - Age Standardized Incidence Rate per 100,000 world population

Cum.Rate-Cumulative Rate (0-74 years) per 100 population

| ICD 10 code and site | Male | Female |
|--|------------|------------|
| C91.0 Acute lymphoblastic leukaemia | 40 | 31 |
| C91.1 Chronic lymphocytic leukaemia of B-cell type | 14 | 13 |
| C91.3 Polymphocytic leukemia of B-cell type | 1 | 3 |
| C91.4 Hairy cell leukemia | 2 | 2 |
| C91.6 Polymphocytic leukemia of T-cell type | 1 | 0 |
| C91.8 Mature B-cell leukaemia Burkitt-type | 1 | 1 |
| C91.9 Lymphoid leukaemia, unspecified | 22 | 21 |
| C92.0 Acute myeloblastic leukaemia(AML) | 97 | 110 |
| C92.1 Chronic myeloid leukemia, NOS | 53 | 44 |
| C92.2 Atypical chronic myeloid leukaemia | 1 | 0 |
| C92.3 Myeloid sarcoma | 3 | 0 |
| C92.4 Acute promyelocytic leukemia, | 6 | 4 |
| C92.5 Acute myelomonocytic leukemia | 5 | 2 |
| C92.6 Acute myeloid leukemia with 11q23-abnormality | 1 | 1 |
| C92.8 Acute myeloid leukemia with multilineage dysplasia | 1 | 0 |
| C92.9 Myeloid leukemia, NOS | 3 | 3 |
| C93.0 Acute monocytic leukemia | 3 | 7 |
| C93.1 Chronic myelomonocytic leukemia | 2 | 5 |
| C93.3 Juvenile myelomonocytic leukemia | 1 | 1 |
| C94.0 Acute erythroid leukaemia | 5 | 4 |
| C95.0 Acute leukemia of unspecified cell type | 74 | 49 |
| C95.9 Leukemia, unspecified | 4 | 5 |
| Total | 339 | 306 |

| ICD O code and histology | Male | Female |
|---|------|--------|
| 9800 Acute leukemia, NOS | 4 | 5 |
| 9801 Acute megakaryoblastic leukemia | 73 | 49 |
| 9805 Acute biphenotypic leukemia | 1 | 0 |
| 9820 Lymphoid leukaemia | 22 | 21 |
| 9823 Acute monocytic leukemia | 14 | 13 |
| 9826 Burkitt cell leukaemia | 1 | 1 |
| 9832 Polymphocytic leukemia, NOS | 0 | 3 |
| 9833 B-cell type, polymphocytic | 1 | 0 |
| 9834 Polymphocytic leukemia, T-cell type | 1 | 0 |
| 9835 Precursor cell lymphoblastic leukemia, NOS | 13 | 13 |
| 9836 Precursor B-cell lymphoblastic leukemia | 14 | 10 |
| 9837 Precursor T-cell lymphoblastic leukemia | 13 | 8 |
| 9840 Acute myeloid leukemia, NOS | 5 | 4 |
| 9860 Myeloid leukemia, NOS | 3 | 3 |
| 9861 Acute myeloid leukemia, NOS | 86 | 97 |

Table 31 continued...

| ICD O code and histology | | Male | Female |
|--------------------------|---|------------|------------|
| 9863 | Chronic myeloid leukemia, NOS | 50 | 42 |
| 9866 | Acute promyelocytic leukemia, | 6 | 4 |
| 9867 | Acute myelomonocytic leukemia | 5 | 2 |
| 9872 | Acute myeloid leukemia | 0 | 2 |
| 9873 | Acute myeloid leukemia without maturation | 3 | 1 |
| 9874 | Acute myeloid leukemia with maturation | 7 | 10 |
| 9875 | Chronic myelogenous leukemia, BCR/ABL positive | 3 | 2 |
| 9876 | Atypical chronic myeloid leukaemia | 1 | 0 |
| 9891 | Acute monocytic leukemia | 3 | 7 |
| 9895 | Acute myeloid leukaemia with multilineage dysplasia | 1 | 0 |
| 9896 | Acute myeloid leukemia, t(8;21)(q22;q22) | 1 | 0 |
| 9897 | 11q23 abnormalities, acute myeloid | 1 | 1 |
| 9930 | Myeloid sarcoma | 3 | 0 |
| 9940 | Hairy cell leukemia | 2 | 2 |
| 9945 | Chronic myelomonocytic leukemia, NOS | 2 | 5 |
| 9946 | Juvenile myelomonocytic leukemia | 0 | 1 |
| Total | | 339 | 306 |




Figure 52: Age specific incidence rates of Leukaemia in Sri Lanka in 2018



Figure 53: Age standardized incidence rates of Leukaemia in Sri Lanka, 2011 - 2018

Clinical staging at the point of diagnosis of Breast, Cervix and Lip, tongue mouth cancers in Sri Lanka, 2018

Figure 54, 55 and 56 give the clinical staging information at the point of diagnosis of Breast, Cervix and Lip, Tongue and Mouth cancers. Information on clinical staging was available for 30% of diagnosed Breast cancers, 21% of diagnosed Cervical cancers and 11% of diagnosed Lip, Tongue and Mouth cancers.

The percentages computed are out of the cancers with staging information.



Figure 54: Clinical stage at diagnosis of Breast cancers in Sri Lanka, 2018




Figure 55: Clinical stage at diagnosis of Cervical cancers in Sri Lanka, 2018



Figure 56: Clinical stage at diagnosis of Lip, Tongue and Mouth cancers in Sri Lanka, 2018

Table 32: Basis of diagnosis of cancer patients in Sri Lanka, 2018

| Basis of diagnosis | Frequency | Percentage |
|--|--------------|--------------|
| Diagnosed microscopically | | |
| Histology of primary | 26198 | 84.91 |
| Histology of metastasis | 1425 | 4.62 |
| Cytology/Haematology only | 366 | 1.19 |
| Subtotal | 27989 | 90.72 |
| Diagnosed non-microscopically | | |
| Clinical investigation including X-ray, USS, CT, etc. (imaging only) | 479 | 1.55 |
| Death certificate only | 1458 | 4.73 |
| Clinical only | 2 | 0.01 |
| Specific biochemical/immunological test only | 8 | 0.03 |
| Exploratory surgery | 10 | 0.03 |
| Subtotal | 1957 | 6.34 |
| Unknown/Not recorded | 907 | 2.94 |
| Total | 30853 | 100 |




Figure 57: Basis of diagnosis of cancers in Sri Lanka, 2018

Treatment details are available among 7188 patients (percentage) out of 30853 patients.




Figure 58: Percentage of newly detected cancer patients who received different types of treatment in Sri Lanka, 2018

Table 33: Childhood and adolescent cancer incidence data (0-19 years) in Sri Lanka, 2018 according to International Classification of Childhood Cancer third edition (ICCC-3) by sex

| ICCC-3 Site Group | ICD -O-3 Histology | Male | Female | Total |
|--|--|-----------|-----------|------------|
| I | Leukaemias, myeloproliferative diseases, and myelodysplastic diseases | | | |
| a. Lymphoid leukaemia | 9820 Lymphoid leukaemia, NOS | 15 | 14 | 29 |
| | 9833 Prolymphocytic leukemia, B-cell type | 1 | 0 | 1 |
| | 9835 Precursor cell lymphoblastic leukaemia, NOS | 5 | 6 | 11 |
| | 9836 Precursor B-cell lymphoblastic leukaemia | 12 | 5 | 17 |
| | 9837 Precursor T-cell lymphoblastic leukaemia | 3 | 7 | 10 |
| | 9940 Hairy cell leukemia | 1 | 0 | 1 |
| b. Acute myeloid leukaemia | 9840 Acute myeloid leukaemia, M6 type | 0 | 1 | 1 |
| | 9861 Acute myeloid leukaemia, NOS | 10 | 11 | 21 |
| | 9866 Acute promyelocytic leukaemia, t(15;17) (q22;q11-12) | 0 | 1 | 1 |
| | 9867 Acute myelomonocytic leukaemia | 1 | 0 | 1 |
| c. Chronic myeloproliferative diseases | 9863 Chronic myeloid leukaemia, NOS | 3 | 2 | 5 |
| | 9875 Chronic myelogenous leukemia, BCR-ABL positive | 1 | 0 | 1 |
| d. Myelodysplastic syndrome and other myeloproliferative diseases | 9946 Juvenile myelomonocytic leukaemia | 0 | 1 | 1 |
| e. Unspecified and other specified leukaemia | 9800 Leukaemia, NOS | 1 | 0 | 1 |
| | 9801 Acute leukaemia, NOS | 0 | 1 | 1 |
| | 9860 Myeloid leukemia, NOS | 34 | 22 | 56 |
| Total | | 87 | 71 | 158 |
| II | Lymphomas and reticuloendothelial neoplasms | | | |
| a. Hodgkin lymphomas | 9650 Hodgkin lymphoma, NOS | 12 | 5 | 17 |
| | 9651 Hodgkin lymphoma, lymphocyte-rich | 1 | 0 | 1 |
| | 9652 Hodgkin lymphoma, mixed cellularity, NOS | 4 | 1 | 5 |
| | 9663 Hodgkin lymphoma, nodular sclerosis, NOS | 4 | 4 | 8 |
| | 9667 Hodgkin lymphoma, nodular sclerosis, grade 2 | 1 | 0 | 1 |

Table 33 continued...

| ICCC-3 Site Group | ICD -O-3 Histology | Male | Female | Total |
|---|---|-----------|-----------|-----------|
| b. Non-Hodgkin lymphomas (except Burkitt lymphoma) | 9591 Malignant lymphoma, non-Hodgkin, NOS | 10 | 7 | 17 |
| | 9670 | 1 | 0 | 1 |
| | 9680 Malignant lymphoma, large B-cell, diffuse, NOS | 0 | 2 | 2 |
| | 9700 Mycosis fungoides | 3 | 4 | 7 |
| | 9718 Malignant lymphoma, small B lymphocytic, NOS | 0 | 1 | 1 |
| | 9727 Precursor cell lymphoblastic lymphoma, NOS | 0 | 1 | 1 |
| | 9728 Precursor B-cell lymphoblastic lymphoma | 0 | 1 | 1 |
| | 9729 Precursor T-cell lymphoblastic lymphoma | 5 | 4 | 9 |
| | 9732 Multiple myeloma | 1 | 0 | 1 |
| c. Burkitt lymphoma | 9687 Burkitt lymphoma, NOS | 2 | 0 | 2 |
| d. Miscellaneous lymphoreticular neoplasms | 9754 Langerhans cell histiocytosis, disseminated | 2 | 1 | 3 |
| e. Unspecified lymphomas | 9590 Malignant lymphoma, NOS | 5 | 3 | 8 |
| Total | | 51 | 34 | 85 |
| III CNS and miscellaneous intracranial and intraspinal neoplasms | | | | |
| a. Ependymomas and choroid plexus tumour | 9390 Choroid plexus carcinoma | 0 | 2 | 2 |
| | 9391 Ependymoma, NOS | 1 | 2 | 3 |
| | 9392 Ependymoma, anaplastic | 1 | 1 | 2 |
| b. Astrocytoma | 9380 Glioma, malignant | 1 | 0 | 1 |
| | 9400 Astrocytoma, NOS | 5 | 2 | 7 |
| | 9401 Astrocytoma, anaplastic | 2 | 0 | 2 |
| | 9424 Pleomorphic xanthoastrocytoma | 0 | 1 | 1 |
| | 9440 Glioblastoma, NOS | 0 | 3 | 3 |
| c. Intracranial and intraspinal embryonal tumours | 9470 Medulloblastoma, NOS | 5 | 1 | 6 |
| | 9471 Desmoplastic nodular medulloblastoma | 1 | 0 | 1 |
| | 9473 Primitive neuroectodermal tumor, NOS | 1 | 0 | 1 |
| | 9508 Atypical teratoid/rhabdoid tumor | 1 | 3 | 4 |
| d. Other gliomas | 9380 Glioma, malignant | 6 | 4 | 10 |
| | 9450 Oligodendroglioma, NOS | 0 | 1 | 1 |
| | 9451 Oligodendroglioma, anaplastic | 0 | 1 | 1 |
| f. Unspecified intracranial and intraspinal neoplasms | 8000 Neoplasm, malignant | 2 | 1 | 3 |
| Total | | 26 | 22 | 48 |

Table 33 continued...

| ICCC-3 Site Group | ICD -O-3 Histology | | Male | Female | Total |
|---|--------------------|---------------------------------|-----------|-----------|-----------|
| IV Neuroblastoma and other peripheral nervous cell tumours | | | | | |
| a. Neuroblastoma and ganglioneuroblastoma | 9490 | Ganglioneuroblastoma | 2 | 5 | 7 |
| | 9500 | Neuroblastoma, NOS | 15 | 5 | 20 |
| Total | | | 17 | 10 | 27 |
| V Retinoblastoma | | | | | |
| Retinoblastoma | 9510 | Retinoblastoma, NOS | 37 | 34 | 71 |
| Total | | | 37 | 34 | 71 |
| VI Renal tumours | | | | | |
| a. Nephroblastoma and other nonepithelial renal tumours | 8960 | Nephroblastoma, NOS | 12 | 17 | 29 |
| | 8964 | Clear cell sarcoma of kidney | 2 | 1 | 3 |
| b. Renal carcinomas | 8120 | Transitional cell carcinoma | 1 | 0 | 1 |
| Total | | | 15 | 18 | 33 |
| VII Hepatic tumours | | | | | |
| a. Hepatoblastoma | 8970 | Hepatoblastoma | 13 | 4 | 17 |
| b. Hepatic carcinomas | 8170 | Hepatocellular carcinoma, NOS | 2 | 0 | 2 |
| Total | | | 15 | 4 | 19 |
| VIII Malignant bone tumours | | | | | |
| a. Osteosarcomas | 9180 | Osteosarcoma, NOS | 12 | 11 | 23 |
| | 9181 | Chondroblastic osteosarcoma | 5 | 0 | 5 |
| | 9186 | Central Osteosarcoma | 1 | 0 | 1 |
| b. Chondrosarcomas | 9220 | Chondrosarcoma, NOS | 1 | 0 | 1 |
| c. Ewing tumours and related sarcomas of bone | 9260 | Ewing sarcoma | 6 | 14 | 20 |
| d. Other specified malignant bone tumours | 9261 | Adamantinoma of long bones | 1 | 0 | 1 |
| | 9270 | Odontogenic tumor, malignant | 1 | 0 | 1 |
| Total | | | 27 | 25 | 52 |
| IX Soft tissue and other extraosseous sarcoma | | | | | |
| a. Rhabdomyosarcoma | 8900 | Rhabdomyosarcoma, NOS | 5 | 9 | 14 |
| | 8910 | Embryonal rhabdomyosarcoma, NOS | 3 | 5 | 8 |

Table 33 continued...

| ICCC-3 Site Group | ICD -O-3 Histology | Male | Female | Total |
|---|--|-----------|-----------|-----------|
| b. Fibrosarcomas, peripheral nerve sheath tumours, and other fibrous neoplasms | 8811 Fibromyxosarcoma | 0 | 1 | 1 |
| | 8814 Infantile fibrosarcoma | 0 | 1 | 1 |
| d. Other specified soft tissue sarcomas | 8806 Desmoplastic small round cell tumour | 12 | 16 | 28 |
| | 8858 Dedifferentiated liposarcoma | 1 | 0 | 1 |
| | 8870 Myelolipoma | 1 | 0 | 1 |
| | 9040 Synovial sarcoma, NOS | 1 | 7 | 8 |
| | 9044 Clear cell sarcoma, NOS (except of kidney) | 0 | 1 | 1 |
| | 9133 Epithelioid hemangioendothelioma, malignant | 1 | 0 | 1 |
| e. Unspecified soft tissue sarcomas | 9260 Ewing sarcoma | 2 | 2 | 4 |
| | 8800 Sarcoma, NOS | 3 | 1 | 4 |
| Total | | 29 | 43 | 72 |
| X | Germ cell tumours, trophoblastic tumours, and neoplasms of gonads | | | |
| a. Intracranial and intraspinal germ cell tumours | 9080 Teratoma, malignant, NOS | 1 | 0 | 1 |
| | | | | |
| b. Malignant extracranial and extragonadal germ cell tumours | 9064 Germinoma | 2 | 1 | 3 |
| | 9065 Germ cell tumor, nonseminomatous | 1 | 0 | 1 |
| | 9071 Yolk sac tumour | 1 | 3 | 4 |
| | 9080 Teratoma, malignant, NOS | 0 | 5 | 5 |
| | 9085 Mixed germ cell tumour | 2 | 0 | 2 |
| | | | | |
| c. Malignant gonadal germ cell tumours | 9060 Dysgerminoma | 0 | 2 | 2 |
| | 9064 Germinoma | 1 | 2 | 3 |
| | 9071 Yolk sac tumour | 1 | 3 | 4 |
| | 9080 Teratoma, malignant, NOS | 0 | 7 | 7 |
| | 9082 Malignant teratoma, undifferentiated | 1 | 0 | 1 |
| | 9085 Mixed germ cell tumour | 1 | 0 | 1 |
| | 9100 Choriocarcinoma, NOS | 0 | 1 | 1 |
| | 9101 Choriocarcinoma combined with other germ cell elements | 0 | 1 | 1 |
| | | | | |
| | | | | |
| d. Gonadal carcinomas | 8010 Carcinoma, NOS | 0 | 1 | 1 |
| | 8441 Serous cystadenocarcinoma, NOS | 0 | 1 | 1 |
| | 8480 Mucinous adenocarcinoma | 0 | 1 | 1 |
| e. Other and unspecified malignant gonadal tumours | 8000 Neoplasm, malignant | 2 | 1 | 3 |
| | 8590 Sex cord-gonadal stromal tumor, NOS | 0 | 1 | 1 |

Table 33 continued...

| ICCC-3 Site Group | ICD -O-3 Histology | Male | Female | Total |
|--|---|-----------|-----------|------------|
| | 8620 Granulosa cell tumour, malignant | 0 | 1 | 1 |
| Total | | 13 | 31 | 44 |
| XI | Other malignant epithelial neoplasms and malignant melanomas | | | |
| a. Adrenocortical carcinomas | 8370 Adrenal cortical carcinoma | 3 | 1 | 4 |
| b. Thyroid carcinomas | 8050 Papillary carcinoma, NOS | 1 | 4 | 5 |
| | 8260 Papillary adenocarcinoma, NOS | 7 | 30 | 37 |
| | 8330 Follicular adenocarcinoma, NOS | 2 | 8 | 10 |
| | 8331 Follicular adenocarcinoma, well differentiated | 1 | 1 | 2 |
| | 8335 Follicular carcinoma, minimally invasive | 0 | 2 | 2 |
| | 8340 Papillary carcinoma, follicular variant | 1 | 6 | 7 |
| | 8341 Papillary microcarcinoma | 2 | 6 | 8 |
| | 8343 Papillary carcinoma, encapsulated | 0 | 1 | 1 |
| c. Nasopharyngeal carcinomas | 8010 Carcinoma, NOS | 1 | 2 | 3 |
| d. Malignant melanomas | 8720 Malignant melanoma, NOS (<i>except juvenile melanoma M-8770/0</i>) | 1 | 0 | 1 |
| e. Skin carcinomas | 8090 Basal cell carcinoma, NOS | 1 | 0 | 1 |
| | 8320 Granular cell carcinoma | 0 | 1 | 1 |
| f. Other and unspecified carcinomas | 8010 Carcinoma, NOS | 5 | 2 | 7 |
| | 8050 Papillary carcinoma, NOS | 1 | 0 | 1 |
| | 8051 Verrucous carcinoma, NOS | 1 | 0 | 1 |
| | 8070 Squamous cell carcinoma, NOS | 3 | 2 | 5 |
| | 8120 Transitional cell carcinoma, NOS | 1 | 0 | 1 |
| | 8140 Adenocarcinoma, NOS | 4 | 1 | 5 |
| | 8240 Carcinoid tumour, NOS | 2 | 0 | 2 |
| | 8246 Neuroendocrine carcinoma, NOS | 0 | 2 | 2 |
| | 8260 Tubulovillous adenoma, NOS | 1 | 2 | 3 |
| | 8430 Mucoepidermoid carcinoma | 2 | 5 | 7 |
| | 8480 Mucinous adenocarcinoma | 0 | 1 | 1 |
| | 8500 Infiltrating duct carcinoma, NOS | 0 | 1 | 1 |
| | 8503 Intraductal papillary adenocarcinoma with invasion | 0 | 1 | 1 |
| | 8550 Acinar cell carcinoma | 2 | 1 | 3 |
| | 8583 Thymoma, type B1, malignant | 1 | 0 | 1 |
| | 9010 Fibroadenoma, NOS | 0 | 1 | 1 |
| | 9020 Phyllodes tumor, malignant | 0 | 1 | 1 |
| | 9510 Retinoblastoma, NOS | 1 | 0 | 1 |
| Total | | 44 | 81 | 125 |

Table 33 continued ...

| ICCC-3 Site Group | | ICD -O-3 Histology | | Male | Female | Total |
|------------------------------|---|--------------------|-------------------------------------|------------|------------|------------|
| Other and unspecified | | | | | | |
| XII | malignant neoplasms | | | | | |
| | a. Other specified malignant tumours | 8936 | Gastrointestinal stromal sarcoma | 0 | 1 | 1 |
| | | 9110 | Mesonephroma, malignant | 0 | 2 | 2 |
| | b. Other unspecified malignant tumours | 8000 | Neoplasm, malignant | 19 | 6 | 25 |
| | | 8004 | Malignant tumour, spindle cell type | 1 | 4 | 5 |
| | Total | | | 20 | 13 | 33 |
| | All sites | | | 381 | 386 | 767 |

Table 34: Overall cancer incidence by province & district in Sri Lanka, 2018

| Province | District | Male | | Female | | Total | |
|----------------------|------------------|--------------|-------------|--------------|-------------|--------------|-------------|
| | | No | % | No | % | No | % |
| | Not Known | 6498 | 43.6 | 6407 | 40.2 | 12905 | 41.8 |
| Western | | 2952 | 19.8 | 3276 | 20.6 | 6228 | 20.2 |
| | Colombo | 1819 | 12.2 | 2014 | 12.6 | 3833 | 12.4 |
| | Gampaha | 677 | 4.5 | 737 | 4.6 | 1414 | 4.6 |
| | Kaluthara | 456 | 3.1 | 525 | 3.3 | 981 | 3.2 |
| Central | | 1375 | 9.2 | 1724 | 10.8 | 3099 | 10.0 |
| | Kandy | 740 | 5.0 | 914 | 5.7 | 1654 | 5.4 |
| | Matale | 341 | 2.3 | 354 | 2.2 | 695 | 2.3 |
| | Nuwara Eliya | 294 | 2.0 | 456 | 2.9 | 750 | 2.4 |
| Southern | | 737 | 4.9 | 898 | 5.6 | 1635 | 5.3 |
| | Galle | 319 | 2.1 | 386 | 2.4 | 705 | 2.3 |
| | Hambanthota | 204 | 1.4 | 223 | 1.4 | 427 | 1.4 |
| | Matara | 214 | 1.4 | 289 | 1.8 | 503 | 1.6 |
| Northern | | 415 | 2.8 | 510 | 3.2 | 925 | 3.0 |
| | Jaffna | 294 | 2.0 | 359 | 2.3 | 653 | 2.1 |
| | Killinochchi | 39 | 0.3 | 42 | 0.3 | 81 | 0.3 |
| | Mannar | 22 | 0.1 | 32 | 0.2 | 54 | 0.2 |
| | Mullativu | 27 | 0.2 | 43 | 0.3 | 70 | 0.2 |
| | Vavuniya | 33 | 0.2 | 34 | 0.2 | 67 | 0.2 |
| Eastern | | 334 | 2.2 | 414 | 2.6 | 748 | 2.4 |
| | Ampara | 137 | 0.9 | 164 | 1.0 | 301 | 1.0 |
| | Batticaloa | 147 | 1.0 | 157 | 1.0 | 304 | 1.0 |
| | Trincomalee | 50 | 0.3 | 93 | 0.6 | 143 | 0.5 |
| North Western | | 1186 | 8.0 | 1230 | 7.7 | 2416 | 7.8 |
| | Kurunegala | 947 | 6.3 | 944 | 5.9 | 1891 | 6.1 |
| | Puttalam | 239 | 1.6 | 286 | 1.8 | 525 | 1.7 |
| North Central | | 207 | 1.4 | 257 | 1.6 | 464 | 1.5 |
| | Anuradhapura | 105 | 0.7 | 156 | 1.0 | 261 | 0.8 |
| | Polonnaruwa | 102 | 0.7 | 101 | 0.6 | 203 | 0.7 |
| Uva | | 365 | 2.4 | 388 | 2.4 | 753 | 2.4 |
| | Badulla | 243 | 1.6 | 256 | 1.6 | 499 | 1.6 |
| | Monaragala | 122 | 0.8 | 132 | 0.8 | 254 | 0.8 |
| Sabaragamuwa | | 848 | 5.7 | 832 | 5.2 | 1680 | 5.4 |
| | Rathnapura | 485 | 3.3 | 489 | 3.1 | 974 | 3.2 |
| | Kegalle | 363 | 2.4 | 343 | 2.2 | 706 | 2.3 |
| Total | | 14917 | 100 | 15936 | 100 | 30853 | 100 |

Table 35: Leading cancer incidence data by district in Sri Lanka, 2018

Western province

Colombo

| Rank | ICD code & site | Cases | CR | % |
|------------------|-----------------------------------|-------------|--------------|------------|
| 1 | C50 Breast | 546 | 22.4 | 14.2 |
| 2 | C33-C34 Trachea, broncus and lung | 294 | 12.1 | 7.7 |
| 3 | C18-C20 Colon and rectum | 289 | 11.9 | 7.5 |
| 4 | C00-C06 Lip, tongue & mouth | 225 | 9.2 | 5.9 |
| 5 | C61 Prostate | 172 | 7.1 | 4.5 |
| 6 | C73 Thyroid | 165 | 6.8 | 4.3 |
| 7 | C54-C55 Uterus | 154 | 6.3 | 4 |
| 8 | C22 Liver | 150 | 6.2 | 3.9 |
| 8 | C56 Ovary | 150 | 6.2 | 3.9 |
| 10 | C15 Oesophagus | 133 | 5.5 | 3.5 |
| All sites | | 3833 | 157.2 | 100 |

Gampaha

| Rank | ICD code & site | Cases | CR | % |
|------------------|-----------------------------------|-------------|-------------|------------|
| 1 | C50 Breast | 230 | 9.5 | 16.3 |
| 2 | C00-C06 Lip, tongue & mouth | 174 | 7.2 | 12.3 |
| 3 | C73 Thyroid | 96 | 4.0 | 6.8 |
| 4 | C18-C20 Colon and rectum | 95 | 3.9 | 6.7 |
| 5 | C33-C34 Trachea, broncus and lung | 81 | 3.4 | 5.7 |
| 6 | C81-85 & C96 Lymphoma | 64 | 2.7 | 4.5 |
| 7 | C15 Oesophagus | 63 | 2.6 | 4.5 |
| 8 | C54-C55 Uterus | 60 | 2.5 | 4.2 |
| 9 | C56 Ovary | 59 | 2.4 | 4.2 |
| 10 | C61 Prostate | 57 | 2.4 | 4 |
| All sites | | 1414 | 58.7 | 100 |

Kaluthara

| Rank | ICD code & site | Cases | CR | % |
|------------------|-----------------------------------|------------|-------------|------------|
| 1 | C50 Breast | 134 | 10.5 | 13.7 |
| 2 | C00-C06 Lip, tongue & mouth | 132 | 10.3 | 13.5 |
| 3 | C18-C20 Colon and rectum | 85 | 6.6 | 8.7 |
| 4 | C73 Thyroid | 62 | 4.8 | 6.3 |
| 5 | C33-C34 Trachea, broncus and lung | 57 | 4.5 | 5.8 |
| 6 | C15 Oesophagus | 55 | 4.3 | 5.6 |
| 7 | C53 Cervix | 41 | 3.2 | 4.2 |
| 8 | C56 Ovary | 37 | 2.9 | 3.8 |
| 9 | C91-C95 Leukemia | 32 | 2.5 | 3.3 |
| 10 | C61 Prostate | 30 | 2.3 | 3.1 |
| All sites | | 981 | 76.6 | 100 |

Central Province

Kandy

| Rank | ICD code & site | Cases | CR | % |
|------------------|-----------------------------------|-------------|--------------|------------|
| 1 | C50 Breast | 237 | 16.1 | 14.3 |
| 2 | C18-C20 Colon and rectum | 149 | 10.1 | 9 |
| 3 | C15 Oesophagus | 124 | 8.4 | 7.5 |
| 4 | C33-C34 Trachea, broncus and lung | 122 | 8.3 | 7.4 |
| 5 | C73 Thyroid | 118 | 8.0 | 7.1 |
| 6 | C00-C06 Lip, tongue & mouth | 97 | 6.6 | 5.9 |
| 7 | C81-85 & C96 Lymphoma | 80 | 5.4 | 4.8 |
| 8 | C56 Ovary | 65 | 4.4 | 3.9 |
| 9 | C91-C95 Leukemia | 53 | 3.6 | 3.2 |
| 10 | C61 Prostate | 50 | 3.4 | 3 |
| All sites | | 1654 | 112.7 | 100 |

Matale

| Rank | ICD code & site | Cases | CR | % |
|------------------|-----------------------------------|------------|--------------|------------|
| 1 | C00-C06 Lip, tongue & mouth | 91 | 17.5 | 13.1 |
| 2 | C50 Breast | 77 | 14.8 | 11.1 |
| 3 | C73 Thyroid | 67 | 12.9 | 9.6 |
| 4 | C15 Oesophagus | 62 | 11.9 | 8.9 |
| 5 | C18-C20 Colon and rectum | 47 | 9.0 | 6.8 |
| 6 | C33-C34 Trachea, broncus and lung | 38 | 7.3 | 5.5 |
| 7 | C81-85 & C96 Lymphoma | 30 | 5.8 | 4.3 |
| 8 | C32 Larynx | 28 | 5.4 | 4 |
| 9 | C09-C14 Pharynx | 27 | 5.2 | 3.9 |
| 10 | C56 Ovary | 25 | 4.8 | 3.6 |
| All sites | | 695 | 133.8 | 100 |

Nuwara Eliya

| Rank | ICD code & site | Cases | CR | % |
|------------------|-----------------------------------|------------|-------------|------------|
| 1 | C15 Oesophagus | 110 | 14.4 | 14.7 |
| 2 | C50 Breast | 104 | 13.6 | 13.9 |
| 3 | C00-C06 Lip, tongue & mouth | 65 | 8.5 | 8.7 |
| 4 | C73 Thyroid | 51 | 6.7 | 6.8 |
| 5 | C53 Cervix | 41 | 5.4 | 5.5 |
| 6 | C33-C34 Trachea, broncus and lung | 35 | 4.6 | 4.7 |
| 7 | C18-C20 Colon and rectum | 30 | 3.9 | 4 |
| 8 | C81-85 & C96 Lymphoma | 29 | 3.8 | 3.9 |
| 9 | C91-C95 Leukemia | 26 | 3.4 | 3.5 |
| 10 | C16 Stomach | 24 | 3.1 | 3.2 |
| All sites | | 750 | 98.3 | 100 |

Southern Province

Galle

| Rank | ICD code & site | Cases | CR | % |
|------------------|-----------------------------------|------------|-------------|------------|
| 1 | C73 Thyroid | 88 | 7.8 | 12.5 |
| 2 | C50 Breast | 78 | 6.9 | 11.1 |
| 3 | C18-C20 Colon and rectum | 50 | 4.4 | 7.1 |
| 4 | C00-C06 Lip, tongue & mouth | 49 | 4.4 | 7 |
| 5 | C15 Oesophagus | 43 | 3.8 | 6.1 |
| 6 | C33-C34 Trachea, broncus and lung | 41 | 3.6 | 5.8 |
| 7 | C56 Ovary | 34 | 3.0 | 4.8 |
| 8 | C81-85 & C96 Lymphoma | 33 | 2.9 | 4.7 |
| 9 | C53 Cervix | 24 | 2.1 | 3.4 |
| 9 | C54-C55 Uterus | 24 | 2.1 | 3.4 |
| All sites | | 705 | 62.7 | 100 |

Hambantota

| Rank | ICD code & site | Cases | CR | % |
|------------------|-----------------------------------|------------|-------------|------------|
| 1 | C73 Thyroid | 82 | 12.5 | 19.2 |
| 2 | C00-C06 Lip, tongue & mouth | 52 | 7.9 | 12.2 |
| 3 | C50 Breast | 45 | 6.9 | 10.5 |
| 4 | C18-C20 Colon and rectum | 43 | 6.6 | 10.1 |
| 5 | C81-85 & C96 Lymphoma | 19 | 2.9 | 4.4 |
| 6 | C32 Larynx | 16 | 2.4 | 3.7 |
| 7 | C53 Cervix | 14 | 2.1 | 3.3 |
| 7 | C61 Prostate | 14 | 2.1 | 3.3 |
| 9 | C15 Oesophagus | 12 | 1.8 | 2.8 |
| 9 | C33-C34 Trachea, broncus and lung | 12 | 1.8 | 2.8 |
| All sites | | 427 | 65.2 | 100 |

Matara

| Rank | ICD code & site | Cases | CR | % |
|------------------|--|------------|-------------|------------|
| 1 | C73 Breast | 66 | 7.7 | 13.1 |
| 2 | C00-C06 Thyroid | 59 | 6.9 | 11.7 |
| 3 | C50 Colon and rectum | 49 | 5.7 | 9.7 |
| 4 | C18-C20 Lip, tongue & mouth | 39 | 4.5 | 7.8 |
| 5 | C81-85 & C96 Trachea, broncus and lung | 34 | 4.0 | 6.8 |
| 6 | C32 Lymphoma | 27 | 3.1 | 5.4 |
| 7 | C53 Prostate | 25 | 2.9 | 5 |
| 8 | C61 Cervix | 22 | 2.6 | 4.4 |
| 9 | C15 Ovary | 20 | 2.3 | 4 |
| 10 | C33-C34 Oesophagus | 19 | 2.2 | 3.8 |
| All sites | | 503 | 58.6 | 100 |

Northern Province

Jaffna

| Rank | ICD code & site | | Cases | CR | % |
|------------------|-----------------|---------------------|------------|--------------|------------|
| 1 | C50 | Breast | 100 | 16.3 | 15.3 |
| 2 | C15 | Oesophagus | 57 | 9.3 | 8.7 |
| 3 | C73 | Thyroid | 54 | 8.8 | 8.3 |
| 4 | C00-C06 | Lip, tongue & mouth | 52 | 8.5 | 8 |
| 5 | C09-C14 | Pharynx | 45 | 7.3 | 6.9 |
| 6 | C61 | Prostate | 34 | 5.5 | 5.2 |
| 7 | C81-85 & C96 | Lymphoma | 32 | 5.2 | 4.9 |
| 8 | C53 | Cervix | 27 | 4.4 | 4.1 |
| 9 | C32 | Larynx | 25 | 4.1 | 3.8 |
| 10 | C56 | Ovary | 24 | 3.9 | 3.7 |
| All sites | | | 653 | 106.5 | 100 |

Killinochchi

| Rank | ICD code & site | | Cases | CR | % |
|------------------|-----------------|---------------------|-----------|-------------|------------|
| 1 | C00-C06 | Lip, tongue & mouth | 8 | 6.3 | 9.9 |
| 2 | C15 | Oesophagus | 7 | 5.5 | 8.6 |
| 2 | C50 | Breast | 7 | 5.5 | 8.6 |
| 2 | C91-95 | Leukemia | 7 | 5.5 | 8.6 |
| 5 | C53 | Cervix | 6 | 4.7 | 7.4 |
| 6 | C09-C14 | Pharynx | 5 | 4.0 | 6.2 |
| 7 | C18-C20 | Colon and rectum | 4 | 3.2 | 4.9 |
| 7 | C73 | Thyroid | 4 | 3.2 | 4.9 |
| 9 | C16 | Stomach | 3 | 2.4 | 3.7 |
| 9 | C64 | Kidney | 3 | 2.4 | 3.7 |
| All sites | | | 81 | 64.1 | 100 |

Mannar

| Rank | ICD code & site | | Cases | CR | % |
|------------------|-----------------|---------------------|-----------|-------------|------------|
| 1 | C00-C06 | Lip, tongue & mouth | 7 | 6.4 | 13 |
| 1 | C50 | Breast | 7 | 6.4 | 13 |
| 1 | C54-55 | Uterus | 7 | 6.4 | 13 |
| 4 | C09-14 | Pharynx | 6 | 5.5 | 11.1 |
| 5 | C73 | Thyroid | 5 | 4.6 | 9.3 |
| 6 | C56 | Ovary | 4 | 3.7 | 7.4 |
| 7 | C15 | Oesophagus | 2 | 1.8 | 3.7 |
| 7 | C16 | Stomach | 2 | 1.8 | 3.7 |
| 7 | C22 | Liver | 2 | 1.8 | 3.7 |
| 7 | C91-C95 | Leukemia | 2 | 1.8 | 3.7 |
| All sites | | | 54 | 49.4 | 100 |

Mullativu

| Rank | ICD code & site | Cases | CR | % |
|------------------|-----------------------------|-----------|-------------|------------|
| 1 | C15 Oesophagus | 10 | 10.4 | 14.3 |
| 2 | C53 Cervix | 8 | 8.3 | 11.4 |
| 2 | C73 Thyroid | 8 | 8.3 | 11.4 |
| 4 | C50 Breast | 6 | 6.2 | 8.6 |
| 5 | C09-C14 Pharynx | 5 | 5.2 | 7.1 |
| 6 | C00-C06 Lip, tongue & mouth | 4 | 4.1 | 5.7 |
| 6 | C54-C55 Uterus | 4 | 4.1 | 5.7 |
| 6 | C91-C95 Leukemia | 4 | 4.1 | 5.7 |
| 9 | C16 Stomach | 3 | 3.1 | 4.3 |
| 10 | C18-C20 Colon and rectum | 2 | 2.1 | 2.9 |
| All sites | | 70 | 72.6 | 100 |

Vavuniya

| Rank | ICD code & site | Cases | CR | % |
|------------------|-----------------------------|-----------|-------------|------------|
| 1 | C53 Cervix | 10 | 5.3 | 14.9 |
| 2 | C00-C06 Lip, tongue & mouth | 7 | 3.7 | 10.4 |
| 3 | C73 Thyroid | 6 | 3.2 | 9 |
| 4 | C50 Breast | 5 | 2.7 | 7.5 |
| 4 | C81-C85 & C96 Lymphoma | 5 | 2.7 | 7.5 |
| 6 | C15 Oesophagus | 3 | 1.6 | 4.5 |
| 6 | C40-C41 Bone | 3 | 1.6 | 4.5 |
| 6 | C60 Penis | 3 | 1.6 | 4.5 |
| 9 | C09-C14 Pharynx | 2 | 1.1 | 3 |
| 9 | C16 Stomach | 2 | 1.1 | 3 |
| All sites | | 67 | 35.8 | 100 |

Eastern Province

Ampara

| Rank | ICD code & site | Cases | CR | % |
|------------------|-----------------------------------|------------|-------------|------------|
| 1 | C50 Breast | 45 | 6.3 | 15 |
| 2 | C73 Thyroid | 34 | 4.7 | 11.3 |
| 3 | C00-C06 Lip, tongue & mouth | 28 | 3.9 | 9.3 |
| 4 | C33-C34 Trachea, broncus and lung | 24 | 3.3 | 8 |
| 5 | C15 Oesophagus | 17 | 2.4 | 5.6 |
| 6 | C53 Cervix | 14 | 1.9 | 4.7 |
| 7 | C32 Larynx | 12 | 1.7 | 4 |
| 7 | C81-C85 & C96 Lymphoma | 12 | 1.7 | 4 |
| 9 | C18-C20 Colon and rectum | 10 | 1.4 | 3.3 |
| 9 | C61 Prostate | 10 | 1.4 | 3.3 |
| All sites | | 301 | 41.8 | 100 |

Trincomalee

| Rank | ICD code & site | Cases | CR | % |
|------------------|-----------------------------|------------|-----------|------------|
| 1 | C73 Thyroid | 26 | 6.2 | 18.2 |
| 2 | C50 Breast | 18 | 4.3 | 12.6 |
| 3 | C00-C06 Lip, tongue & mouth | 16 | 3.8 | 11.2 |
| 4 | C53 Cervix | 13 | 3.1 | 9.1 |
| 5 | C15 Oesophagus | 8 | 1.9 | 5.6 |
| 6 | C18-C20 Colon and rectum | 7 | 1.7 | 4.9 |
| 7 | C54-C55 Uterus | 5 | 1.2 | 3.5 |
| 8 | C09-C14 Pharynx | 4 | 1.0 | 2.8 |
| 8 | C56 Ovary | 4 | 1.0 | 2.8 |
| 8 | C67 Bladder | 4 | 1.0 | 2.8 |
| All sites | | 143 | 34 | 100 |

Batticaloa

| Rank | ICD code & site | Cases | CR | % |
|------------------|-----------------------------------|------------|-------------|------------|
| 1 | C50 Breast | 49 | 8.6 | 16.1 |
| 2 | C33-C34 Trachea, broncus and lung | 29 | 5.1 | 9.5 |
| 3 | C09-C14 Pharynx | 20 | 3.5 | 6.6 |
| 4 | C00-C06 Lip, tongue & mouth | 19 | 3.3 | 6.3 |
| 5 | C53 Cervix | 14 | 2.5 | 4.6 |
| 5 | C67 Bladder | 14 | 2.5 | 4.6 |
| 5 | C73 Thyroid | 14 | 2.5 | 4.6 |
| 8 | C18-C20 Colon and rectum | 13 | 2.3 | 4.3 |
| 9 | C15 Oesophagus | 12 | 2.1 | 3.9 |
| 10 | C81-C85 & C96 Lymphoma | 10 | 1.8 | 3.3 |
| All sites | | 304 | 53.4 | 100 |

North Western province

Kurunegala

| Rank | ICD code & site | Cases | CR | % |
|------------------|-----------------------------------|-------------|--------------|------------|
| 1 | C50 Breast | 282 | 16.5 | 14.9 |
| 2 | C00-C06 Lip, tongue & mouth | 228 | 13.3 | 12.1 |
| 3 | C15 Oesophagus | 140 | 8.2 | 7.4 |
| 4 | C18-20 Colon and rectum | 128 | 7.5 | 6.8 |
| 5 | C73 Thyroid | 118 | 6.9 | 6.2 |
| 6 | C33-34 Trachea, bronchus and lung | 94 | 5.5 | 5 |
| 7 | C91-95 Leukemia | 79 | 4.6 | 4.2 |
| 8 | C09-C14 Pharynx | 76 | 4.4 | 4 |
| 9 | C53 Cervix | 73 | 4.3 | 3.9 |
| 10 | C81-C85 & C96 Lymphoma | 67 | 3.9 | 3.5 |
| All sites | | 1891 | 110.6 | 100 |

Puttalam

| Rank | ICD code & site | Cases | CR | % |
|------------------|-----------------------------|------------|-------------|------------|
| 1 | C50 Breast | 70 | 8.5 | 13.3 |
| 2 | C00-C06 Lip, tongue & mouth | 57 | 6.9 | 10.9 |
| 3 | C73 Thyroid | 47 | 5.7 | 9 |
| 4 | C91-C95 Leukemia | 44 | 5.3 | 8.4 |
| 5 | C18-C20 Colon and rectum | 32 | 3.9 | 6.1 |
| 6 | C54-C55 Uterus | 26 | 3.2 | 5 |
| 7 | C15 Oesophagus | 23 | 2.8 | 4.4 |
| 7 | C53 Cervix | 23 | 2.8 | 4.4 |
| 9 | C56 Ovary | 21 | 2.5 | 4 |
| 10 | C09-C14 Pharynx | 15 | 1.8 | 2.9 |
| All sites | | 525 | 63.6 | 100 |

North Central Province

Annuradhapura

| Rank | ICD code & site | Cases | CR | % |
|------------------|-----------------------------------|------------|-------------|------------|
| 1 | C73 Thyroid | 53 | 5.7 | 20.3 |
| 2 | C00-C06 Lip, tongue & mouth | 38 | 4.1 | 14.6 |
| 3 | C53 Cervix | 27 | 2.9 | 10.3 |
| 4 | C33-C34 Trachea, broncus and lung | 16 | 1.7 | 6.1 |
| 5 | C91-C95 Leukemia | 13 | 1.4 | 5 |
| 6 | C15 Oesophagus | 12 | 1.3 | 4.6 |
| 7 | C18-C20 Colon and rectum | 11 | 1.2 | 4.2 |
| 7 | C50 Breast | 11 | 1.2 | 4.2 |
| 7 | C56 Ovary | 11 | 1.2 | 4.2 |
| 7 | C09-C14 Lymphoma | 11 | 1.2 | 4.2 |
| All sites | | 261 | 28.1 | 100 |

Polonnaruwa

| Rank | ICD code & site | Cases | CR | % |
|------------------|-----------------------------------|------------|-------------|------------|
| 1 | C73 Thyroid | 44 | 10.1 | 21.7 |
| 2 | C00-C06 Lip, tongue & mouth | 42 | 9.6 | 20.7 |
| 3 | C50 Breast | 19 | 4.4 | 9.4 |
| 4 | C09-C14 Pharynx | 11 | 2.5 | 5.4 |
| 5 | C33-C34 Trachea, broncus and lung | 8 | 1.8 | 3.9 |
| 6 | C15 Oesophagus | 7 | 1.6 | 3.4 |
| 7 | C54-C55 Uterus | 6 | 1.4 | 3 |
| 7 | C61 Prostate | 6 | 1.4 | 3 |
| 7 | C70-C72 Brain & nervous system | 6 | 1.4 | 3 |
| 7 | C81-C85 & C96 Lymphoma | 6 | 1.4 | 3 |
| All sites | | 203 | 46.5 | 100 |

Uva Province

Badulla

| Rank | ICD code & site | Cases | CR | % |
|------------------|-----------------------------------|------------|-------------|------------|
| 1 | C50 Breast | 64 | 7.3 | 12.8 |
| 2 | C15 Oesophagus | 46 | 5.3 | 9.2 |
| 3 | C00-C06 Lip, tongue & mouth | 44 | 5.0 | 8.8 |
| 4 | C33-C34 Trachea, broncus and lung | 37 | 4.2 | 7.4 |
| 5 | C73 Thyroid | 36 | 4.1 | 7.2 |
| 6 | C18-C20 Colon and rectum | 32 | 3.7 | 6.4 |
| 7 | C56 Ovary | 26 | 3.0 | 5.2 |
| 8 | C53 Cervix | 25 | 2.9 | 5 |
| 9 | C81-C85 & C96 Lymphoma | 18 | 2.1 | 3.6 |
| 10 | C16 Stomach | 16 | 1.8 | 3.2 |
| All sites | | 499 | 57.2 | 100 |

Moneragala

| Rank | ICD code & site | Cases | CR | % |
|------------------|-----------------------------------|------------|-------------|------------|
| 1 | C00-C06 Lip, tongue & mouth | 39 | 7.9 | 15.4 |
| 2 | C50 Breast | 34 | 6.9 | 13.4 |
| 3 | C73 Thyroid | 33 | 6.7 | 13 |
| 4 | C33-C34 Trachea, broncus and lung | 19 | 3.9 | 7.5 |
| 5 | C18-C20 Colon and rectum | 17 | 3.5 | 6.7 |
| 6 | C15 Oesophagus | 9 | 1.8 | 3.5 |
| 6 | C81-C85 & C96 Lymphoma | 9 | 1.8 | 3.5 |
| 8 | C56 Ovary | 8 | 1.6 | 3.1 |
| 8 | C91-C95 Leukemia | 8 | 1.6 | 3.1 |
| 10 | C53 Cervix | 7 | 1.4 | 2.8 |
| All sites | | 254 | 51.7 | 100 |

Sabaragamuwa Province


Kegalle



| Rank | ICD code & site | Cases | CR | % |
|------------------|----------------------------------|------------|-------------|------------|
| 1 | C50 Breast | 98 | 11.1 | 13.9 |
| 2 | C00-C06 Lip, tongue & mouth | 86 | 9.7 | 12.2 |
| 3 | C15 Oesophagus | 59 | 6.7 | 8.4 |
| 4 | C18-C20 Colon and rectum | 56 | 6.3 | 7.9 |
| 5 | C73 Thyroid | 52 | 5.9 | 7.4 |
| 6 | C33-34 Trachea, broncus and lung | 39 | 4.4 | 5.5 |
| 7 | C09-C14 Pharynx | 35 | 4.0 | 5 |
| 8 | C81-C85 & C96 Lymphoma | 27 | 3.1 | 3.8 |
| 9 | C56 Ovary | 26 | 2.9 | 3.7 |
| 10 | C53 Cervix | 23 | 2.6 | 3.3 |
| All sites | | 706 | 79.9 | 100 |



Rathnapura

| Rank | ICD code & site | Cases | CR | % |
|------------------|----------------------------------|------------|-------------|------------|
| 1 | C00-C06 Lip, tongue & mouth | 189 | 16.3 | 19.4 |
| 2 | C50 Breast | 93 | 8.0 | 9.5 |
| 3 | C73 Thyroid | 85 | 7.3 | 8.7 |
| 4 | C18-C20 Colon and rectum | 79 | 6.8 | 8.1 |
| 5 | C15 Oesophagus | 59 | 5.1 | 6.1 |
| 6 | C81-C85 & C96 Lymphoma | 46 | 4.0 | 4.7 |
| 7 | C53 Cervix | 40 | 3.4 | 4.1 |
| 8 | C33-34 Trachea, broncus and lung | 33 | 2.8 | 3.4 |
| 9 | C56 Ovary | 31 | 2.7 | 3.2 |
| 10 | C91-95 Leukemia | 30 | 2.6 | 3.1 |
| All sites | | 974 | 83.8 | 100 |

Figure 59: Cancer incidence data by districts among males in Sri Lanka, 2018




















Figure 60: Cancer incidence data by districts among females in Sri Lanka, 2018











Cancer Mortality Data of Sri Lanka

Mortality data due to cancers were obtained through Annual Health Bulletin of Ministry of Health based on Indoor Morbidity Mortality Return (IMMR).

Cause of death data reported to vital registration system of Sri Lanka for year 2018 is not published by the Registrar General Department or Department of Census and Statistics yet. Therefore, total number of cancer deaths or number of cancer deaths according to ICD-10 site is not available currently.

Table 36: Deaths due to cancers among males & females in hospitals in Sri Lanka, 2012-2018

| Year | No. of hospital deaths due to cancers | | |
|------|---------------------------------------|--------|-------|
| | Male | Female | Total |
| 2005 | - | - | 2753 |
| 2006 | - | - | 3241 |
| 2007 | - | - | 3498 |
| 2008 | - | - | 3485 |
| 2009 | - | - | 3774 |
| 2010 | - | - | 4449 |
| 2011 | - | - | 4631 |
| 2012 | 2538 | 1931 | 4519 |
| 2013 | 2559 | 1980 | 4539 |
| 2014 | 2867 | 2128 | 4995 |
| 2015 | 2657 | 2141 | 4798 |
| 2016 | 2878 | 2270 | 5148 |
| 2017 | 2720 | 2218 | 4938 |
| 2018 | 3223 | 2566 | 5789 |

Sources: Annual Health Bulletin 2005 to 2018

Table 37: Deaths due to cancers in hospitals, crude hospital annual death rates due to cancers and proportionate mortality ratio for cancers out of all hospital deaths in Sri Lanka, 2005-2018

| Year | No. of hospital deaths due to cancers | Crude hospital annual death rate due to cancers per 100,000 population | Proportionate Mortality Ratio (PMR) out of all hospital deaths |
|------|---------------------------------------|--|--|
| 2005 | 2753 | 14.0 | 8.3 |
| 2006 | 3241 | 16.3 | 9.9 |
| 2007 | 3498 | 17.5 | 10.1 |
| 2008 | 3485 | 17.2 | 9.8 |
| 2009 | 3774 | 18.5 | 10.0 |
| 2010 | 4449 | 21.5 | 11.1 |
| 2011 | 4631 | 22.2 | 11.8 |
| 2012 | 4519 | 22.2 | 11.6 |
| 2013 | 4539 | 22.2 | 11.2 |
| 2014 | 4995 | 24.0 | 11.7 |
| 2015 | 4798 | 22.9 | 11.0 |
| 2016 | 5148 | 24.3 | 12.0 |
| 2017 | 4938 | 23.0 | 10.5 |
| 2018 | 5789 | 26.7 | 11.7 |

Sources: Annual Health Bulletin 2005 to 2018

Table 38: Hospitalizations, hospital deaths and case fatality rate due to cancers in year 2018 by RDHS divisions in Sri Lanka

| *RDHS Area | Hospital Admissions due to cancers | | | **Case fatality rate |
|------------------|------------------------------------|--------------------------|---------------------|----------------------|
| | Total hospital admissions | Live hospital discharges | No. hospital deaths | |
| Colombo | 69807 | 67408 | 2399 | 3.44 |
| Gampaha | 4432 | 4189 | 243 | 5.48 |
| Kalutara | 2319 | 2257 | 62 | 2.67 |
| Kandy | 20201 | 19604 | 597 | 2.96 |
| Matale | 1001 | 956 | 45 | 4.50 |
| Nuwara Eliya | 1177 | 1122 | 55 | 4.67 |
| Galle | 14814 | 14356 | 458 | 3.09 |
| Matara | 1001 | 935 | 66 | 6.59 |
| Hambanthota | 681 | 638 | 43 | 6.31 |
| Jaffna | 5316 | 5161 | 155 | 2.92 |
| Kilinochchi | 456 | 455 | 1 | 0.22 |
| Mullaitivu | 64 | 62 | 2 | 3.13 |
| Vavuniya | 310 | 295 | 15 | 4.84 |
| Mannar | 171 | 162 | 9 | 5.26 |
| Batticaloa | 6254 | 6176 | 78 | 1.25 |
| Ampara | 219 | 197 | 22 | 10.05 |
| Kalmunai | 386 | 374 | 12 | 3.11 |
| Trincomalee | 1251 | 1228 | 23 | 1.84 |
| Kurunegala | 5989 | 5498 | 491 | 8.20 |
| Puttalam | 520 | 486 | 34 | 6.54 |
| Anuradhapura | 6389 | 6102 | 287 | 4.49 |
| Polonnaruwa | 989 | 838 | 151 | 15.27 |
| Badulla | 6382 | 6126 | 256 | 4.01 |
| Moneragala | 1018 | 968 | 50 | 4.91 |
| Ratnapura | 5684 | 5510 | 174 | 3.06 |
| Kegalle | 1227 | 1166 | 61 | 4.97 |
| Sri Lanka | 158058 | 152269 | 5789 | 3.66 |

RDHS divisions – Regional Director of health Services divisions

**Case Fatality rate = $\frac{\text{No. of hospital deaths due to cancers}}{\text{Total number of hospital admissions due to cancers}} \times 100$

Annex

Summary details of previous publications of 'Cancer Incidence Data Sri Lanka'

| Year of cancer incidence data | Data generating centres | | | | | | Publication | |
|-------------------------------|--------------------------|------------------------|-----------|----------------------|------------------|----------------------|-------------|----------------|
| | Cancer Treatment Centres | Pathology laboratories | OMF units | Medical Record Rooms | Death Registrars | Total no. of centres | Volume | Year published |
| 1985 | 3 | - | - | - | - | 3 | 1 | 1990 |
| 1986 | 3 | - | - | - | - | 3 | 2 | 1991 |
| 1987 | 3 | - | - | - | - | 3 | 3 | 1993 |
| 1990 | 3 | - | - | - | - | 3 | 4 | 1996 |
| 1995 | 3 | - | - | - | - | 3 | 5 | 2002 |
| 2000 | 4 | - | - | - | - | 4 | 6 | 2006 |
| 2001-2005 | 5 | - | - | - | - | 5 | 7 | 2009 |
| 2006 | 6 | - | 4 | - | - | 10 | 8 | 2012 |
| 2007 | 6 | - | 4 | - | - | 10 | 9 | 2013 |
| 2008 | 7 | 16 | 17 | - | - | 40 | 10 | 2014 |
| 2009 | 9 | 15 | 17 | - | - | 41 | 11 | 2015 |
| 2010 | 9 | 13 | 17 | - | - | 39 | 12 | 2016 |
| 2011 | 9 | 13 | 12 | - | - | 34 | 13 | 2018 |
| 2012 | 9 | 37 | 15 | 9 | - | 70 | 14 | 2020 |
| 2013 | 9 | 45 | 15 | 25 | - | 94 | 15 | 2020 |
| 2014 | 9 | 51 | 15 | 24 | 40 | 139 | 16 | 2020 |
| 2015 | 9 | 58 | 15 | 24 | 40 | 146 | 17 | 2021 |
| 2016 | 14 | 53 | 22 | 22 | 40 | 151 | 18 | 2021 |
| 2017 | 19 | 61 | 23 | 21 | 40 | 164 | 19 | 2021 |

Statistical Terminology

Population at risk

The population at risk includes all individuals susceptible to a specific cancer. It is defined on the basis of demographic variables, such as place of residence, sex, age group. Years of risk duration are counted in person-years.

Incidence

Incidence quantifies the number of new cases that develop in a population of individuals at risk during a specified time interval. Usually it is given as per 100,000 population per year.

Mortality

Mortality is the number of deaths occurring in a given period in a specified population. It can be expressed as an absolute number of deaths per year or as a rate per 100,000 persons per year.

Crude rate

Data on incidence or mortality are often presented as rates. For a specific tumour and population, a crude rate is calculated simply by dividing the number of cancer deaths observed during a given time period by the corresponding number of person years in the population at risk. For cancer, the result is usually expressed as an annual rate per 100,000 persons at risk.

$$\text{Crude incidence rate} = \frac{\text{Total number of cases in the year}}{\text{Total midyear population at risk}} \times 100,000$$

$$\text{Crude death rate} = \frac{\text{Total number of deaths in the year}}{\text{Total midyear population at risk}} \times 100,000$$

Age-specific rate

The age-specific rate is calculated simply by dividing the number of new cancers or cancer deaths observed in a given age category during a given time period by the corresponding number of person years in the population at risk in the same age category and time period.

The result is usually expressed as an annual rate per 100,000 person-years. In this publication, five- year age categories are used

$$\text{Age-specific incidence rate} = \frac{\text{Number of cases in the five-year age group}}{\text{Population at risk in the corresponding age group}} \times 100,000$$

$$\text{Age-specific death rate} = \frac{\text{Number of deaths in the five-year age group} \times 100,000}{\text{Population at risk in the corresponding age group}}$$

ASR (Age standardized rate)

An age-standardised rate (ASR) is a summary measure of the rate that a population would have if it had a standard age structure. Standardization is necessary when comparing several populations that differ with respect to age because age has a powerful influence on the risk of dying from cancer. The ASR is a weighted mean of the age-specific rates; the weights are taken from population distribution of the *standard population*. The most frequently used standard population is the *World Standard Population*. The calculated mortality rate is then called age-standardised mortality rate (world). The world standard population used within the application is as proposed by Segi (1960) and modified by Doll and *al.* (1966). The ASR is also expressed per 100,000.

| Age distribution of the world standard population | |
|---|----------------|
| Age group | w _i |
| 0-4 | 12000 |
| 5-9 | 10000 |
| 10-14 | 9000 |
| 15-19 | 9000 |
| 20-24 | 8000 |
| 25-29 | 8000 |
| 30-34 | 6000 |
| 35-39 | 6000 |
| 40-44 | 6000 |
| 45-49 | 6000 |
| 50-54 | 5000 |
| 55-59 | 4000 |
| 60-64 | 4000 |
| 65-69 | 3000 |
| 70-74 | 2000 |
| 75-79 | 1000 |
| 80-84 | 500 |
| 85+ | 500 |
| Total | 100000 |

Life time risk (Cumulative Risk)

Cumulative incidence/mortality is the probability or risk of individuals getting/dying from the disease within a specified age interval within a time period.

(The cumulative risk is the risk which an individual would have of developing the cancer under study during a certain age span if no other causes of death were in operation)

List of References

1. Department of Census and Statistics. (2021). Retrieved 27 September 2021, from <http://www.statistics.gov.lk/Population/StaticInformation/VitalStatistics>
2. World Health Organization. (2013). International classification of diseases for oncology (ICD-O) – 3(1). World Health Organization. [https:// apps.who.int/iris /handle/10665/96612](https://apps.who.int/iris/handle/10665/96612)
3. International Association of Research on Cancer. (2010). *Glossary of terms*. Retrieved 27 September 2021, from <https://www-dep.iarc.fr/WHOdb/glossary.htm>.
4. World Health Organization. (2016). International statistical classification of diseases and related health problems: ICD 10 – 5(1). World Health Organization. Retrieved from: <https://icd.who.int/browse10/Content/statichtml/ICD10Volume2en2016.pdf>
5. International Association of Research on Cancer. (2021). International Association of Cancer Registries. Retrieved 27 September 2021, from <http://www.iacr.com.fr/index.php>
6. Steliarova-Foucher, E., Stiller, C., Lacour, B., & Kaatsch, P. (2005). International classification of childhood cancer. *Cancer*, 103(7), 1457-1467.
7. Ministry of Health, Nutrition and Indigenous Medicine Sri Lanka. (2016). Annual Health Bulletin 2018. Retrieved 27th September 2021, from <http://www.health.gov.lk/mohfinal/english/public/elfinder/files/publications/AHB/2017/AHB2016.pdf>



National Cancer Control Programme
Ministry of Health
555/5, Public Health Complex
Elvitigala Mawatha, Narahenpita,
Colombo 05, Sri Lanka
+94 11236 8627
www.nccp.health.gov.lk



PSG Printers 811240722